

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/40000 A2(51) International Patent Classification⁷: A61K 31/00

(21) International Application Number: PCT/US01/47324

(22) International Filing Date:
13 November 2001 (13.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/249,077 15 November 2000 (15.11.2000) US

(71) Applicant: WYETH [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventors: DUKART, Gary; 1714 Benjamin Drive, Ambler, PA 19002 (US). GIBBONS, James, Joseph, Jr.; 33 Terrace Drive, Westwood, NJ 07675 (US). SPEICHER, Lisa, Anne; 509 Covington Road, Havertown, PA 19083 (US). FROST, Philip; 4 Emerson Court, Morris Township, NJ 07960 (US). DISCAFANI-MARRO, Carolyn, Mary; 8 Brookside Avenue, Cortlandt Manor, NY 10567 (US).

(74) Agents: MILOWSKY, Arnold, S.; Wyeth, Patent Law Department, Five Giralda Farms, Madison, NJ 07940-0874 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF CCI-779 AS AN ANTINEOPLASTIC AGENT

(57) Abstract: This invention provides the use of CCI-779 in the treatment of neoplasms.

WO 02/40000 A2

USE OF CCI-779 AS AN ANTINEOPLASTIC AGENT

This invention relates to the use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) as an antineoplastic agent.

5

Rapamycin is a macrocyclic triene antibiotic produced by Streptomyces hygroscopicus, which was found to have antifungal activity, particularly against Candida albicans, both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721 (1975); S.N. Sehgal et al., J. Antibiot. 28, 727 (1975); H. A. Baker et al., J. Antibiot. 31, 539 (1978); U.S. Patent 3,929,992; and U.S. Patent 3,993,749]. Additionally, rapamycin alone (U.S. Patent 4,885,171) or in combination with picibanil (U.S. Patent 4,401,653) has been shown to have antitumor activity.

The immunosuppressive effects of rapamycin have been disclosed in FASEB 3, 3411 (1989). Cyclosporin A and FK-506, other macrocyclic molecules, also have been shown to be effective as immunosuppressive agents, therefore useful in preventing transplant rejection [FASEB 3, 3411 (1989); FASEB 3, 5256 (1989); R. Y. Calne et al., Lancet 1183 (1978); and U.S. Patent 5,100,899]. R. Martel et al. [Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed that rapamycin is effective in the experimental allergic encephalomyelitis model, a model for multiple sclerosis; in the adjuvant arthritis model, a model for rheumatoid arthritis; and effectively inhibited the formation of IgE-like antibodies.

Rapamycin is also useful in preventing or treating systemic lupus erythematosus [U.S. Patent 5,078,999], pulmonary inflammation [U.S. Patent 5,080,899], insulin dependent diabetes mellitus [U.S. Patent 5,321,009], skin disorders, such as psoriasis [U.S. Patent 5,286,730], bowel disorders [U.S. Patent 5,286,731], smooth muscle cell proliferation and intimal thickening following vascular injury [U.S. Patents 5,288,711 and 5,516,781], adult T-cell leukemia/lymphoma [European Patent Application 525,960 A1], ocular inflammation [U.S. Patent 5,387,589], malignant carcinomas [U.S. Patent 5,206,018], cardiac inflammatory disease [U.S. Patent 5,496,832], and anemia [U.S. Patent 5,561,138].

The preparation and use of hydroxyesters of rapamycin, including CCI-779, are disclosed in U.S. Patent 5,362,718.

DESCRIPTION OF THE INVENTION

5 This invention provides the use of CCI-779 as an antineoplastic agent, and particularly for neoplasms which are refractory to standard therapy, or for whom standard therapy is not appropriate. In particular CCI-779 is useful in the treatment of renal cancer, soft tissue cancer, breast cancer, neuroendocrine tumor of the lung, cervical cancer, uterine cancer, head and neck cancer, glioblastoma, non-small lung
10 cell cancer, prostate cancer, pancreatic cancer, lymphoma, melanoma, small cell lung cancer, ovarian cancer, colon cancer.

As used in accordance with this invention, the term "treatment" means treating a mammal having a neoplastic disease by providing said mammal an effective amount
15 of CCI-779 with the purpose of inhibiting growth of the neoplasm in such mammal, eradication of the neoplasm, or palliation of the neoplasm.

As used in accordance with this invention, the term "providing," with respect to providing CCI-779, means either directly administering CCI-779, or administering
20 a prodrug, derivative, or analog which will form an effective amount of CCI-779 within the body.

As used in accordance with this invention, the term "refractory neoplasm" refers to neoplasms in patients which typically had progressed following treatment
25 with standard chemotherapy that was appropriate for that given neoplasm.

The preparation of CCI-779 is described in U.S. Patent 5,362,718, which is hereby incorporated by reference.

30 The antineoplastic activity of CCI-779 was confirmed in a preclinical *in vitro* and *in vivo* standard pharmacological test procedure which measured the ability of

CCI-779 to treat human renal cell cancer (a rapidly progressive disease with very limited treatment options), as well as in two Phase I human clinical trials. The procedures used and results obtained are briefly described below.

5 Preclinical Test Procedures

10 In vitro test procedure: Renal tumor lines HTB-44 and CRL-1161 were obtained from the American Tissue Culture Collection (ATCC), Bethesda, MD. SN12-C line was obtained from Dr. J. Fidler, M.D. Anderson Hospital, Houston, TX. Cells were plated in MEM (Gibco) supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 5 ml penicillin-streptomycin solution, 1 mM non-essential amino acid solution, 10% fetal bovine solution. Cells (5×10^3) were plated in 96 well plates with a final volume of 200 ml and incubated for 24 hours at 37°C. Log dilutions of CCI-779 beginning at 100 µg/ml were then added to the cultures for 48 hours. Over the last 5 hours, cells were pulsed with 1 µci ^3H -thymidine (New England Nuclear, 15 6.7 ci/m Mol). Cells were then harvested and the degree of thymidine uptake determined by liquid scintillation spectrometry. The IC_{50} was determined as the concentration that produced 50% of the maximum uptake of thymidine in control untreated cells.

20 In vivo test procedure: Female Balb/c nu/nu mice were obtained from Charles River Labs, Wilmington, DE, at 6-8 weeks of age. Mice (n=10/group) were injected sc with 5×10^6 cells resuspended in a 50% solution of Matrigel (BD Biosciences) and tumors allowed to develop. When tumor size reached 100 mg, mice were treated orally with CCI-779 at 25 mg/kg. CCI-779 was dosed for 5 consecutive days with 25 repeated 14 day cycles throughout the duration of the experiment. The formulation used for CCI-779 was a 50% ethanol, 49% phosal, 1% tween 80 vehicle for resuspending CCI-779, where the stock was resuspended into a 1:10 dilution of the vehicle prior to dosing. Tumor growth was evaluated using a vernier caliper and volume ($l \times w \times h$) was converted to mass using the formula: $l \times w^2 / 2$.

30

Results:

Human renal cell tumors were cultured *in vitro* in the presence or absence of CCI-779 for 3 days and the effect on growth determined by ³H-thymidine incorporation of control versus treated cells. Table 1 shows that IC₅₀ (50% growth inhibitory concentration) for all 3 lines tested was in the low nM range.

Table 1 The effect of CCI-779 on the growth of human renal tumor cells *in vitro*

<u>Renal Tumor Line</u>	<u>CCI-779 IC₅₀ (nM)</u>
HTB-44	5.0
CRL-1161	2.0
SN12-C	5.5

10

The effect of CCI-779 in two human renal lines (HTB-44 and CRL-1161) were was evaluated *in vivo* by engrafting tumor cells on the flanks of nude mice. Once tumors were established at a size of about 100 mg, mice were treated with CCI-779 or a vehicle control. Treatment with CCI-779 at 25 mg/kg resulted in significant inhibition of tumor cell growth in the mice (Table 2).

15

Table 2 Effect of CCI-779 on the growth of human renal tumor cells in nude mouse xenografts

Cell Line	Drug Treatment	Tumor Mass (mg)					
		Days					
		0	7	21	35	49	55
HTB-44	Control	288±21	219±18	616±55	1095±44	2033±247	2412±342
	CCI	290±15	156±13*	252±48*	453±85*	980±155*	1050±183*
	% T/C	101	71	41	41	48	44
CRL-1161	Control	273±18	355±36	413±60	480±127	546±170	507±156
	CCI	272±14	219±16*	226±17*	200±21*	229±28*	268±30
	% T/C	100	62	60	42	42	53

20

* p value - < .05

% T/C - Treated/Control x 100

25

Clinical Trial:

Two single agent (CCI-779) Phase I clinical trials have been conducted. In the first study, CCI-779 was administered as a 30 minute i.v. infusion daily for 5 days, every two to three weeks. In the second study, CCI-779 was administered as a 30 minute i.v. infusion, once weekly. Both trials were open label, ascending dose, single-arm, multicenter studies. Patients were allowed to continue treatment as long as the CCI-779 was tolerated and there was no evidence of obvious disease progression. The following eligibility criteria were used:

Inclusion Criteria

1. Patients with a histologic diagnosis of advanced cancer (solid tumors and, in the first study, lymphomas) who are refractory to standard therapy or for whom standard therapy is not appropriate.
2. Measurable or evaluable disease.
3. At least 3 weeks since prior chemotherapy and/or radiation therapy (6 weeks since nitrosoureas or mitomycin C).
4. At least 4 weeks since any other investigational agent.
5. Age at least 18 years old.
6. Adequate bone marrow, renal, and hepatic function.
7. Serum cholesterol \leq 350 mg/dL and triglycerides \leq 300 mg/dL.
8. ECOG performance status 0-2.
9. Life expectancy of at least 3 months.
10. Signed, dated, witnessed written informed consent.

A total of 63 patients and 24 patients were enrolled in first and second studies, respectively. Dose levels ranged from 0.75-24 mg/m² and 7.5-220 mg/m², with the daily x 5 every 2 weeks and weekly schedules, respectively.

The following summarizes the results that were obtained:

In patients having renal cancer on the weekly schedule, 1 partial response (\geq 50% reduction in tumor size) and 2 minor responses (\geq 25% but $<$ 50% reduction in

tumor size) were observed. In renal cancer patients on the daily x 5 schedule, 1 minor response, 1 unconfirmed minor response, and 1 stable disease (< 25% increase to < 25% reduction in tumor size) lasting approximately 5 months were observed. In patients having soft tissue sarcoma on the daily x 5 dosage schedule, 1 possible partial response, 2 minor responses, and 1 stable disease lasting approximately 5½ months were observed. In patients with breast cancer on the weekly dosage schedule, one partial response was observed. In patients with neuroendocrine tumor of the lung on the weekly dosage schedule, one partial response was observed. In patients having cervical cancer on the daily x 5 dosage schedule, one minor response was observed. In patients having uterine cancer receiving the daily x 5 dosage schedule, one unconfirmed minor response was observed. In patients having head and neck cancer receiving the daily x 5 dosage schedule, 1 stable disease for approximately 8½ months was observed. In patients having non-small cell lung cancer receiving the daily x 5 dosage schedule, one partial response was observed. These results are particularly surprising, considering that the patients in these studies had advanced cancers that were generally refractory to standard treatment, and also considering that these were Phase I clinical trials, in which efficacy is often limited, as the primary objective of a Phase I trial is to determine the safety and tolerability of the drug being evaluated.

Based on the results of the preclinical and clinical test procedures, CCI-779 is useful in treating neoplasms, in particular, refractory neoplasms. More particularly, CCI-779 is useful in treating treatment of renal carcinoma, soft tissue carcinoma, breast cancer, neuroendocrine tumor of the lung, cervical cancer, uterine cancer, head and neck cancer, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, lymphoma, melanoma, small cell lung cancer, ovarian cancer, and colon cancer.

As typical with chemotherapy, dosage regimens are closely monitored by the treating physician, based on numerous factors including the severity of the disease, response to the disease, any treatment related toxicities, age, and health of the patient.

Based on the results obtained with CCI-779, it is projected that initial i.v. infusion dosages will be between about 0.1 and 100 mg/m² when administered on a daily dosage regimen, and between about 1 and 1000 mg/m² when administered on a weekly dosage regimen. Other dosage regimens and variations are foreseeable, and will be determined through physician guidance. It is preferred that CCI-779 is administered by i.v. infusion or orally, preferably in the form of tablets or capsules. Other routes of administration are also feasible, such as via implants, parenterally (besides i.v., such as intraperitoneal and subcutaneous injections), rectally, intranasally, vaginally, and transdermally.

Dosage regimens are expected to vary according to the route of administration. For example, dosages for oral administration are often up to tenfold greater than for i.v. administration. It is anticipated that CCI-779 may be administered as the sole active chemotherapeutic agent, or may be part of a chemotherapeutic regimen containing more than one antineoplastic agent. The use of concomitant chemotherapeutic agents often allows for dosage reduction of each particular agent, thereby increasing the safety margin of the particular agents.

Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc. Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium

phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar. Preferred surface modifying agents include nonionic and anionic surface modifying agents. Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine. Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s). The oral formulation may also consist of administering the active ingredient in water or a fruit juice, containing appropriate solubilizers or emulsifiers as needed.

In some cases it may be desirable to administer the compounds directly to the airways in the form of an aerosol.

The compounds of this invention may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparation contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

For the purposes of this disclosure, transdermal administrations are understood to include all administrations across the surface of the body and the inner

linings of bodily passages including epithelial and mucosal tissues. Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).

- 5 Transdermal administration may be accomplished through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin. The carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices.
- 10 The creams and ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety of occlusive devices may be used to release the active ingredient into the blood stream such as a semi-permeable membrane covering a reservoir
- 15 containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature.

- Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water soluble suppository bases, such as polyethylene glycols of
- 20 various molecular weights, may also be used.

CLAIMS

1. A method of treating a neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of CCI-779.

5

2. A method of treating a refractory neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of CCI-779.

3. The method according to claim 1, wherein the neoplasm is renal cancer.

10

4. The method according to claim 1, wherein the neoplasm is soft tissue sarcoma.

5. The method according to claim 1, wherein the neoplasm is breast cancer.

15

6. The method according to claim 1, wherein the neoplasm is a neuroendocrine tumor of the lung.

7. The method according to claim 1, wherein the neoplasm is cervical cancer.

20

8. The method according to claim 1, wherein the neoplasm is uterine cancer.

25

9. The method according to claim 1, wherein the neoplasm is a head and neck cancer.

10. The method according to claim 1, wherein the neoplasm is glioblastoma.

30

11. The method according to claim 1, wherein the neoplasm is non-small cell lung cancer.
- 5 12. The method according to claim 1, wherein the neoplasm is prostate cancer.
13. The method according to claim 1, wherein the neoplasm is pancreatic cancer.
- 10 14. The method according to claim 1, wherein the neoplasm is lymphoma.
15. The method according to claim 1, wherein the neoplasm is melanoma.
- 15 16. The method according to claim 1, wherein the neoplasm is small cell lung cancer.
17. The method according to claim 1, wherein the neoplasm is ovarian cancer.
- 20 18. The method according to claim 1, wherein the neoplasm is colon cancer.
- 25 19. Use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) in the preparation of a medicament for the treatment of a neoplasm in a mammal.
- 30 20. Use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) in the preparation of a medicament for the treatment of a refractory neoplasm in a mammal.

21. Use according to claim 19 wherein the neoplasm is renal cancer, soft tissue sarcoma, breast cancer, neuroendocrine tumor of the lung, cervical cancer, uterine cancer, head and neck cancer, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, lymphoma, melanoma, small cell lung cancer, ovarian cancer or colon cancer.

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/040000 A3

(51) International Patent Classification⁷: **A61K 31/436**,
A61P 35/00, A61K 31/435

(21) International Application Number: PCT/US01/47324

(22) International Filing Date:
13 November 2001 (13.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/249,077 15 November 2000 (15.11.2000) US

(71) Applicant: **WYETH** [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventors: **DUKART, Gary**; 1714 Benjamin Drive, Ambler, PA 19002 (US). **GIBBONS, James, Joseph, Jr.**; 33 Terrace Drive, Westwood, NJ 07675 (US). **SPEICHER, Lisa, Anne**; 509 Covington Road, Havertown, PA 19083 (US). **FROST, Philip**; 4 Emerson Court, Morris Township, NJ 07960 (US). **DISCAFANI-MARRO, Carolyn, Mary**; 8 Brookside Avenue, Cortlandt Manor, NY 10567 (US).

(74) Agents: **MILOWSKY, Arnold, S.**; Wyeth, Patent Law Department, Five Giralda Farms, Madison, NJ 07940-0874 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
6 September 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF CCI-779 AS AN ANTINEOPLASTIC AGENT

(57) Abstract: This invention provides the use of CCI-779 in the treatment of neoplasms.

WO 02/040000 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/47324

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/436 A61P35/00 A61K31/435

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, BIOSIS, EMBASE, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	GEOERGER BIRGIT ET AL: "Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy." CANCER RESEARCH, vol. 61, no. 4, 15 February 2001 (2001-02-15), pages 1527-1532, XP001079526 ISSN: 0008-5472 the whole document --- -/-	1-21

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

27 June 2002

Date of mailing of the international search report

04/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Brück, M

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 1-18

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 01/47324

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GEOERGER, B KERR, K. JANSS, A.J. SUTTON LN. PHILLIPS PC.: "rapamycin analog cci 779 inhibits growth of human medulloblastoma xenografts" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03), XP001080186 the whole document	1-21
X	ALEXANDRE, JEROME ET AL.: "Phase I study of CCI-779, a novel rapamycin analog: preliminary results" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 41, March 1999 (1999-03), page 613 XP001071217 page 613	1-21
X	GIBBONS J J ET AL: "The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03), page 301 XP001071222 90th Annual Meeting of the American Association for Cancer Research; Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999 ISSN: 0197-016X page 301	1-21
X	ALEXANDRE, JEROME, RAYMOND, ERIC, ARMAND, JEAN-PIERRE: "La rapamycine et le CCI-779" BULLETIN DU CANCER, vol. 86, no. 10, October 1999 (1999-10), pages 808-811, XP001078856 page 810	1-21
X	SCHWARTSMANN, GILBERTO: "Marine organisms and other novel natural sources of new cancer drugs" ANNALS OF ONCOLOGY, vol. 11, no. 3, 13 October 2000 (2000-10-13), pages 235-243, XP001070989 page 239	1-21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/47324

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-18
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12Q 1/68	A2	(11) International Publication Number: WO 00/40749
		(43) International Publication Date: 13 July 2000 (13.07.00)

(21) International Application Number: PCT/CA00/00005

(22) International Filing Date: 5 January 2000 (05.01.00)

(30) Priority Data:

60/115,125	6 January 1999 (06.01.99)	US
09/477,148	4 January 2000 (04.01.00)	US

(71)(72) Applicant and Inventor: LIEW, Choong-Chin [CA/CA];
81 Millersgrove Drive, Willowdale, Ontario M2R 3S1 (CA).(74) Agent: DEETH WILLIAMS WALL; National Bank Building,
Suite 400, 150 York Street, Toronto, Ontario M5H 3S5
(CA).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).



Published

Without international search report and to be republished upon receipt of that report.

(54) Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF

(57) Abstract

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**METHOD FOR THE DETECTION OF GENE TRANSCRIPTS
IN BLOOD AND USES THEREOF**

5

BACKGROUND OF THE INVENTION

Cross-Reference to Related Application

This application claims the benefit of priority of provisional patent application U.S. Serial Number 60/115,125, filed January 6, 1999 and of a U.S. application
10 entitled "Method for the Detection of Gene Transcripts in Blood and uses Thereof" filed on January 4, 2000 (application number not yet assigned).

Field of the Invention

The present invention relates generally to the molecular biology of
15 human diseases. More specifically, the present invention relates to a process using the genetic information contained in human peripheral whole blood for the diagnosis, prognosis and monitoring of genetic and infectious disease in the human body.

Description of the Related Art

20 The blood is a vital part of the human circulatory system for the human body. Numerous cell types make up the blood tissue including monocytes, leukocytes, lymphocytes and erythrocytes. Although many blood cell types have been described, there are likely many as yet undiscovered cell types in the human blood. Some of these undiscovered cells may exist transiently, such as those derived from
25 tissues and organs that are constantly interacting with the circulating blood in health and disease. Thus, the blood can provide an immediate picture of what is happening in the human body at any given time.

The turnover of cells in the hematopoietic system is enormous. It was reported that over one trillion cells, including 200 billion erythrocytes and 70 billion neutrophilic leukocytes, turn over each day in the human body (Ogawa 1993). As a consequence of continuous interactions between the blood and the body, genetic changes that occur within the cells or tissues of the body will trigger specific changes in gene expression within blood. It is the goal of the present invention that these genetic alterations be harnessed for diagnostic and prognostic purposes, which may lead to the development of therapeutics for ameliorating disease.

The complete profile of gene expression in the circulating blood remains totally unexplored. It is hypothesized that gene expression in the blood is reflective of body state and, as such, the resultant disruption of homeostasis under conditions of disease can be detected through analysis of transcripts differentially expressed in the blood alone. Thus, the identification of several key transcripts or genetic markers in blood will provide information about the genetic state of the cells, tissues, organs and systems of the human body in health and disease.

The prior art is deficient in non-invasive methods of screening for tissue-specific diseases. The present invention fulfills this long-standing need and desire in the art.

SUMMARY OF THE INVENTION

This present invention discloses a process of using the genetic information contained in human peripheral whole blood in the diagnosis, prognosis and monitoring of genetic and infectious disease in the human body. The process described herein requires a simple blood sample and is, therefore, non-invasive compared to conventional practices used to detect tissue specific disease, such as biopsies.

One object of the present invention is to provide a non-invasive method for the diagnosis, prognosis and monitoring of genetic and infectious disease in humans and animals.

5 In one embodiment of the present invention, there is provided a method for detecting expression of a gene in blood from a subject, comprising the steps of: a) quantifying RNA from a subject blood sample; and b) detecting expression of the gene in the quantified RNA, wherein the expression of the gene in quantified RNA indicates the expression of the gene in the subject blood.

10 In another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; and e) detecting expression of the genes in the ESTs, wherein the expression of the genes in the ESTs indicates the expression of
15 the genes in the subject blood. Preferably, the genes are tissue-specific genes.

In still another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting DNA fragments from the blood sample; c) amplifying the DNA fragments; and d) detecting
20 expression of the genes in the amplified DNA product, wherein the expression of the genes in the amplified DNA product indicates the expression of the genes in the subject blood.

In yet another embodiment of the present invention, there is provided a method for monitoring a course of a therapeutic treatment in an individual,
25 comprising the steps of: a) obtaining a blood sample from the individual; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; e) detecting expression of genes in the ESTs, wherein the expression of the genes is associated with the effect of

the therapeutic treatment: and f) repeating steps a)-e), wherein the course of the therapeutic treatment is monitored by detecting the change of expression of the genes in the ESTs. Such a method may also be used for monitoring the onset of overt symptoms of a disease, wherein the expression of the genes is associated with the onset of the symptoms.

In still yet another embodiment of the present invention, there is provided a method for diagnosing a disease in a test subject, comprising the steps of: a) generating a cDNA library for the disease from a whole blood sample from a normal subject; b) generating expressed sequence tag (EST) profile from the normal subject cDNA library; c) generating a cDNA library for the disease from a whole blood sample from a test subject; d) generating EST profile from the test subject cDNA library; and e) comparing the test subject EST profile to the normal subject EST profile, wherein if the test subject EST profile differs from the normal subject EST profile, the test subject might be diagnosed with the disease.

In still yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) gene-specific primers; wherein the primers are designed in such a way that their sequences contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and b) a carrier, wherein the carrier immobilizes the primer(s). Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease.

In yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) probes derived from a whole blood sample for a specific disease; and b) a carrier, wherein the carrier immobilizes the probes. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease.

Furthermore, the present invention provides a cDNA library specific for a disease, wherein the cDNA library is generated from whole blood samples.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.

5

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope. not be considered to limit the scope of the invention.

Figure 1 shows the following RNA samples prepared from human blood; **Figure 1A**: Lane 1, Molecular weight marker; Lane 2, RT-PCR on APP gene; Lane 3, PCR on APP gene; Lane 4, RT-PCR on APC gene; Lane 5, PCR on APC gene; **Figure 1B**: Lanes 1 and 2, RT-PCR and PCR of β MyHC, respectively; Lanes 3 and 4, RT-PCR of β MyHC from RNA prepared from human fetal and human adult heart, respectively; Lane 5, Molecular weight marker.

Figure 2 shows quantitative RT-PCR analysis performed on RNA samples extracted from a drop of blood. Forward primer (5'-GCCCTCTGGGGACCTGAC-3', SEQ ID No. 1) of exon 1 and reverse primer (5'-CCCACCTGCAGGTCCTCT-3', SEQ ID No. 2) of exons 1 and 2 of insulin gene. Blood samples of 4 normal subjects were assayed. Lanes 1, 3, 5 and 7 represent overnight "fasting" blood sample and lanes 2, 4, 6 and 8 represent "non-fasting" samples.

Figure 3 shows quantitative RT-PCR analysis performed on RNA samples extracted from a drop of blood. Lanes 1 and 2 represent normal healthy person and lane 3 represents late-onset diabetes (Type II) and lane 4 represents asymptomatic diabetes.

5 **Figure 4** shows multiple RT-PCR assay in a drop of blood. Primers were derived from insulin gene (INS), zinc-finger protein gene (ZFP) and house-keeping gene (GADH). Lane 1 represents normal person. Lane 2 represents late-onset diabetes and lane 3 represents asymptomatic diabetes.

Figure 5 shows standardized levels of insulin gene (**Figure 5A**) and
10 ZFP gene (**Figure 5B**) expressed in a drop of blood. The first three subjects were normal, second two subjects showed normal glucose tolerance, and the last subject had late onset diabetes type II. **Figure 5C** shows standardized levels of insulin gene expressed in each fractionated cell from whole blood.

Figure 6 shows the differential screening of human blood cell cDNA
15 library with different cDNA probes of heart and brain tissue. **Figure 6A** shows blood cell cDNA probes vs. adult heart cDNA probes. **Figure 6B** shows blood cell cDNA probes vs. human brain cDNA probes.

Figure 7 graphically shows the 1,800 unique genes in human blood and in the human fetal heart grouped into seven cellular functions.

20

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there may be employed
conventional molecular biology, microbiology, and recombinant DNA techniques
25 within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid

Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription and Translation" [B.D. Hames & S.J. Higgins eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984). Therefore, if appearing
5 herein, the following terms shall have the definitions set out below.

A "cDNA" is defined as copy-DNA or complementary-DNA, and is a product of a reverse transcription reaction from an mRNA transcript. "RT-PCR" refers to reverse transcription polymerase chain reaction and results in production of cDNAs that are complementary to the mRNA template(s).

10 The term "oligonucleotide" is defined as a molecule comprised of two or more deoxyribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide. The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced
15 synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be
20 sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and the method used. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides,
25 although it may contain fewer nucleotides. The factors involved in determining the appropriate length of primer are readily known to one of ordinary skill in the art.

As used herein, random sequence primers refer to a composition of primers of random sequence, i.e. not directed towards a specific sequence. These

sequences possess sufficient complementary to hybridize with a polynucleotide and the primer sequence need not reflect the exact sequence of the template.

“Restriction fragment length polymorphism” refers to variations in DNA sequence detected by variations in the length of DNA fragments generated by restriction endonuclease digestion.

A standard Northern blot assay can be used to ascertain the relative amounts of mRNA in a cell or tissue obtained from plant or other tissue, in accordance with conventional Northern hybridization techniques known to those persons of ordinary skill in the art. The Northern blot uses a hybridization probe, e.g. radiolabelled cDNA, either containing the full-length, single stranded DNA or a fragment of that DNA sequence at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100 consecutive nucleotides in length). The DNA hybridization probe can be labelled by any of the many different methods known to those skilled in this art. The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. Proteins can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from ^3H , ^{14}C , ^{32}P , ^{35}S , ^{36}Cl , ^{51}Cr , ^{57}Co , ^{58}Co , ^{59}Fe , ^{90}Y , ^{125}I , ^{131}I , and ^{186}Re . Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized.

The preferred are peroxidase, β -glucuronidase, β -D-glucosidase, β -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.

5 As used herein, "individual" refers to human subjects as well as non-human subjects. The examples herein are not meant to limit the methodology of the present invention to human subjects only, as the instant methodology is useful in the fields of veterinary medicine, animal sciences and such.

10 In one embodiment of the present invention, there is provided a method for detecting expression of a gene in blood from a subject, comprising the steps of: a) quantifying RNA from a subject blood sample; and b) detecting expression of the gene in the quantified RNA, wherein the expression of the gene in quantified RNA indicates the expression of the gene in the subject blood. An example of the quantifying method is by mass spectrometry.

15 In another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; and e) detecting expression of the genes in
20 the ESTs, wherein the expression of the genes in the ESTs indicates the expression of the genes in the subject blood. Preferably, the subject is a fetus, an embryo, a child, an adult or a non-human animal. The genes are non-cancer-associated and tissue-specific genes. Still preferably, the amplification is performed by RT-PCR using random sequence primers or gene-specific primers.

25 In still another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting DNA fragments from the blood sample; c) amplifying the DNA fragments; and d) detecting

expression of the genes in the amplified DNA product, wherein the expression of the genes in the amplified DNA product indicates the expression of the genes in the subject blood.

In yet another embodiment of the present invention, there is provided a method for monitoring a course of a therapeutic treatment in an individual, comprising the steps of: a) obtaining a blood sample from the individual; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; e) detecting expression of genes in the ESTs, wherein the expression of the genes is associated with the effect of the therapeutic treatment; and f) repeating steps a)-e), wherein the course of the therapeutic treatment is monitored by detecting the change of expression of the genes in the ESTs. Such a method may also be used for monitoring the onset of overt symptoms of a disease, wherein the expression of the genes is associated with the onset of the symptoms. Preferably, the amplification is performed by RT-PCR, and the change of the expression of the genes in the ESTs is monitored by sequencing the ESTs and comparing the resulting sequences at various time points; or by performing single nucleotide polymorphism analysis and detecting the variation of a single nucleotide in the ESTs at various time points.

In still yet another embodiment of the present invention, there is provided a method for diagnosing a disease in a test subject, comprising the steps of: a) generating a cDNA library for the disease from a whole blood sample from a normal subject; b) generating expressed sequence tag (EST) profile from the normal subject cDNA library; c) generating a cDNA library for the disease from a whole blood sample from a test subject; d) generating EST profile from the test subject cDNA library; and e) comparing the test subject EST profile to the normal subject EST profile, wherein if the test subject EST profile differs from the normal subject EST profile, the test subject might be diagnosed with the disease.

In still yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) gene-specific primers; wherein the primers are designed in such a way that their sequences contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and b) a carrier, wherein the carrier immobilizes the primer(s). Preferably, the gene-specific primers are selected from the group consisting of insulin-specific primers, atrial natriuretic factor-specific primers, zinc finger protein gene-specific primers, beta-myosin heavy chain gene-specific primers, amyloid precursor protein gene-specific primers, and adenomatous polyposis-coli protein gene-specific primers. Further preferably, the gene-specific primers are selected from the group consisting of SEQ ID Nos. 1 and 2; and SEQ ID Nos. 5 and 6. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease by detecting the quantitative expression levels of specific genes associated with the disease in the test subject and then comparing to the levels of same genes expressed in a normal subject. Such a kit may also be used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of a disease.

In yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) probes derived from a whole blood sample for a specific disease; and b) a carrier, wherein the carrier immobilizes the probes. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease by detecting the quantitative expression levels of specific genes associated with the disease in the test subject and then comparing to the levels of same genes expressed in a normal subject. Such a kit may also be used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of a disease.

Furthermore, the present invention provides a cDNA library specific for a disease, wherein the cDNA library is generated from whole blood samples.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

5

EXAMPLE 1

Construction of a cDNA library

RNA extracted from human tissues (including fetal heart, adult heart, liver, brain, prostate gland and whole blood) were used to construct unidirectional cDNA libraries. The first mammalian heart cDNA library was constructed as early as 1982. Since then, the methodology has been revised and optimal conditions have been developed for construction of human heart and hematopoietic progenitor cDNA libraries (Liew *et al.*, 1984; Liew 1993, Claudio *et al.*, 1998). Most of the novel genes which were identified by sequence annotation can now be obtained as full length transcripts.

15

EXAMPLE 2

Catalogue of blood cell ESTs

20

Random partial sequencing of expressed sequence tags (ESTs) of cDNA clones from the blood cell library was carried out to establish an EST database of blood. The known genes as derived from the ESTs were categorized into seven major cellular functions (Hwang, Dempsey *et al.*, 1997).

EXAMPLE 3

Differential screening of cDNA library

5 cDNA probes generated from transcripts of each tissue were used to hybridize the blood cell cDNA clones (Liew *et al.*, 1997). The "positive" signals which were hybridized with ³²P-labelled cDNA probes were defined as genes which shared identity with blood and respective tissues. The "negative" spots which were not exposed to ³²P-labelled cDNA probes were considered to be blood-cell-enriched or
10 low frequency transcripts.

EXAMPLE 4

Reverse transcriptase-polymerase chain reaction (RT-PCR) assay

15 RNA extracted from samples of human tissue was used for RT-PCR analysis (Jin *et al.* 1990). Three pairs of forward and reverse primers were designed for human cardiac beta-myosin heavy chain gene (β MyHC), amyloid precursor protein (APP) gene and adenomatous polyposis-coli protein (APC) gene. The PCR products were also subjected to automated DNA sequencing to verify the sequences as
20 derived from the specific transcripts of blood.

EXAMPLE 5

Detection of tissue specific gene expression in human blood using RT-PCR

25 The beta-myosin heavy chain gene (β MyHC) transcript (mRNA) is known to be highly expressed in ventricles of the human heart. This sarcomeric protein is important for heart muscle contraction and its presence would not be expected in other non-muscle tissues and blood. In 1990, the gene for human cardiac

β MyHC was completely sequenced (Liew *et al.* 1990) and was comprised of 4 exons and 42 introns.

The method of reverse transcription polymerase chain reaction (RT-PCR) was used to determine whether this cardiac specific mRNA is also present in human blood. A pair of primers was designed; the forward primer (SEQ ID No. 3) was on the boundary of exons 21 and 22, and the reverse primer (SEQ ID No. 4) was on the boundary of exons 24 and 25. This region of mRNA is only present in β MyHC and is not found in the alpha-myosin heavy chain gene (α MyHC).

A blood sample was first treated with lysing buffer and then undergone centrifuge. The resulting pellets were further processed with RT-PCR. RT-PCR was performed using the total blood cell RNA as a template. A nested PCR product was generated and used for sequencing. The sequencing results were subjected to BLAST and the identity of exons 21 to 25 was confirmed to be from β MyHC (Figure 1A).

Using the same method just described, two other tissue specific genes - amyloid precursor protein (APP, forward primer, SEQ ID No. 7; reverse primer, SEQ ID No. 8) found in the brain and associated with Alzheimer's disease, and adenomatous polyposis coli protein (APC) found in the colon and rectum and associated with colorectal cancer (Grodén *et al.* 1991; Santoro and Grodén 1997) - were also detected in the RNA extracted from human blood (Figure 1B).

EXAMPLE 6

Multiple RT-PCR analysis on a drop of blood from a normal/diseased individual

A drop of blood was extracted to obtain RNA to carry out quantitative RT-PCR analysis. Specific primers for the insulin gene were designed: forward primer (5'-GCCCTCTGGGGACCTGAC-3', SEQ ID No. 1) of exon 1 and reverse primer (5'-CCCACCTGCAGGTCCTCT-3'', SEQ ID No. 2) of exons 1 and 2 of insulin gene. Such reverse primer was obtained by deleting the intron between the

exons 1 and 2. Blood samples of 4 normal subjects were assayed. It was found that the insulin gene is expressed in the blood and the quantitative expression of the insulin gene in a drop of blood is influenced by fasting and non-fasting states of normal healthy subjects (Figure 2). This very low level of expression of the insulin gene reflects the phenotypic status of a person and strongly suggests that there is a physiological and pathological role for its expression, contrary to the basal or illegitimate theory of transcription suggested by Chelly *et al.* (1989) and Kimoto (1998).

Same quantitative RT-PCR analysis was performed using insulin specific primers on RNA samples extracted from a drop of blood from a normal healthy person, a person having late-onset diabetes (Type II) and a person having asymptomatic diabetes. It was found that the insulin gene is expressed differentially amongst subjects that are healthy, diagnosed as type II diabetic, and also in an asymptomatic preclinical patient (Figure 3).

Similarly, specific primers for the atrial natriuretic factor (ANF) gene were designed (forward primer, SEQ ID No. 5; reverse primer, SEQ ID No. 6) and RT-PCR analysis was performed on a drop of blood. ANF is known to be highly expressed in heart tissue biopsies and in the plasma of heart failure patients. However, atrial natriuretic factor was observed to be expressed in the blood and the expression of the atrial natriuretic factor gene is significantly higher in the blood of patients with heart failure as compared to the blood of a normal control patient.

Specific primers for the zinc finger protein gene (ZFP, forward primer, SEQ ID No. 9; reverse primer, SEQ ID No. 10) were also designed and RT-PCR analysis was performed on a drop of blood. ZFP is known to be high in heart tissue biopsies of cardiac hypertrophy and heart failure patients. In the present study, the expression of ZFP was observed in the blood as well as differential expression levels of ZFP amongst the normal, diabetic and asymptomatic preclinical subjects (Figure 4); although neither of the non-normal subjects has been specifically diagnosed as

suffering from cardiac hypertrophy and/or heart failure, the higher expression levels of the ZFP gene in their blood may indicate that these subjects are headed in that general direction.

5 It was hypothesized that a housekeeping gene such as glyceraldehyde dehydrogenase (GADH) which is required and highly expressed in all cells would not be differentially expressed in the blood of normal vs. disease subjects. This hypothesis was confirmed by RT-PCR using GADH specific primers (Figure 4). Thus, GADH is useful as an internal control.

10 Standardized levels of insulin gene or ZFP gene expressed in a drop of blood were estimated using a housekeeping gene as an internal control relative to insulin or ZFP expressed (Figures 5A & 5B). The levels of insulin gene expressed in each fractionated cell from whole blood were also standardized and shown in Figure 5C.

15

EXAMPLE 7

Human blood cell cDNA library

20 In order to further substantiate the present invention, differential screening of the human blood cell cDNA library was conducted. cDNA probes derived from human blood, adult heart or brain were respectively hybridized to the human blood cDNA library clones. As shown in Figure 7, more than 95% of the "positively" identified clones are identical between the blood and other tissue samples.

25 DNA sequencing of randomly selected clones from the human whole blood cell cDNA library was also performed. This allowed information regarding the cellular function of blood to be obtained concurrently with gene identification. More than 20,000 expressed sequence tags (ESTs) have been generated and characterized to date, 17.6% of which did not result in a statistically significant match to entries in the

GenBank databases and thus were designated as "Novel" ESTs. These results are summarized in Figure 7 together with the seven cellular functions related to percent distribution of known genes in blood and in the fetal heart.

From 20,000 ESTs, 1,800 have been identified as known genes which may not all appear in the hemapoietic system. For example, the insulin gene and the atrial natriuretic factor gene have not been detected in these 20,000 ESTs but their transcripts were detected in a drop of blood, strongly suggesting that all transcripts of the human genome can be detected by performing RT-PCR analysis on a drop of blood.

In addition, approximately 400 novel genes have been identified from the 20,000 ESTs characterized to date, and these will be subjected to full length sequencing and open reading frame alignment to reduce the actual number of novel ESTs prior to screening for disease markers.

Analysis of the approximately 6,283 ESTs which have known matches in the GenBank databases revealed that this dataset represents over 1,800 unique genes. These genes have been catalogued into seven cellular functions. Comparisons of this set of unique genes with ESTs derived from human brain, heart, lung and kidney demonstrated a greater than 50% overlap in expression (Table 1).

TABLE 1

Overlap of Genes Expressed in Blood *

<u>Tissues</u>	<u>ESTs**</u>	<u>Overlap in Blood</u>
brain	134,000	60%
heart	65,000	59%
lung	60,200	58%
kidney	32,300	54%

* Estimated from limited known genes of about 1,800 as derived from the database of 6,297 ESTs from human blood cell library.

** Obtained from the National Centre of Biotechnology Information (NCBI), U.S.A.

5

EXAMPLE 8

Blood cell ESTs

The results from the differential screening clearly indicate that the
10 transcripts expressed in the whole blood are reflective of genes expressed in all cells
and tissues of the body. More than 95% of detectable spots were identical from two
different tissues. The remaining 5% of spots may represent cell- or tissue-specific
transcripts; however, results obtained from partial sequencing to generate ESTs of
these clones revealed most of them not to be cell- or tissue-specific transcripts.
15 Therefore, the negative spots are postulated to be reflective of low abundance
transcripts in the tissue from which the cDNA probes were derived.

An alternative approach that was employed to identify transcripts
expressed at low levels is the large-scale generation of expressed sequence tags
(ESTs). There is substantial evidence regarding the efficiency of this technology to
20 detect previously characterized (known) and uncharacterized (unknown or novel)
genes expressed in the cardiovascular system (Hwang & Dempsey *et al.*, 1997). In
the present invention, 20,000 ESTs have been produced from a human blood cell
cDNA library and resulted in the identification of approximately 1,800 unique known
genes (Table 2)

25 In the most recent GenBank release, analysis of more than 300,000
ESTs in the database (dbESTs) generated more than 48,000 gene clusters which are
thought to represent approximately 50% of the genes in the human genome. Only
4,800 of the dbESTs are blood-derived. In the present invention, 20,000 ESTs have

been obtained to date from a human blood cDNA library, which provides the world's most informative database with respect to blood cell transcripts. From the limited amount of information generated so far (i.e. 1,800 unique genes), it has already been determined that more than 50% of the transcripts are found in other cells or tissues of the human body (Table 2). Thus, it is expected that by increasing the number of ESTs generated, more genes will be identified that have an overlap in expression between the blood and other tissues. Furthermore, the transcripts for several genes which are known to have tissue-restricted patterns of expression (i.e. β MyHC, APP, APC, ANF, ZFP) have also been demonstrated to be present in blood.

Most recently, a cDNA library of human hematopoietic progenitor stem cells has also been constructed. From the limited set of 1,000 ESTs, there are at least 200 known genes that are shared with other tissue related genes (Claudio *et al.* 1998).

Table 2 demonstrates the expression of known genes of specific tissues in blood cells. Previously, only the presence of "housekeeping" genes would have been expected. Additionally, the presence of at least 25 of the currently known 500 genes corresponding to molecular drug targets was detected. These molecular drug targets are used in the treatment of a variety of diseases which involve inflammation, renal and cardiovascular function, neoplastic disease, immunomodulation and viral infection (Drews & Ryser, 1997). It is expected that additional novel ESTs will represent future molecular drug targets.

TABLE 2

Comparison of 1,800 Unique Genes Identified in the Blood Cell cDNA Library to
Genes Previously Identified in Specific Tissues

5

Gene Identification	No. of ESTs	Accession No.	Tissue Distribution						
			Bl	Br	H	K	L	Lu	
100 kDa coactivator	2	U22055		+				+	
10kD protein (BC10)	2	AF053470		+	+		+	+	
14-3-3 epsilon	2	U54778		+	+			+	
14-3-3 protein	11	U28964		+	+		+		
15 kDa selenoprotein (SEP15)	1	AF051894		+	+			+	
1-phosphatidylinositol-4-phosphate 5-kinase isoform C	1	S78798							
23 kD highly basic protein	21	X56932	+	+	+	+	+	+	
2-5A-dependent RNase	1	L10381							
2'-5' oligoadenylate synthetase 2 (OAS2)	4	M87284	B						
26S proteasome subunit 11	1	AF086708							
36 kDa phosphotyrosine protein	2	AJ223280	T		+				
3-7 gene product (non-exact 86%aa)	1	D64159							
3-phosphoglycerate dehydrogenase (PGAD)	1	AF006043	T	+	+			+	
3-prime-phosphoadenosine 5-prime-phosphosulfate synthase 1 (PAPSS1)	2	U53447	+	+	+	+		+	
46kd mannose 6-phosphate receptor (MPR46) (low match)	1	X56257							
5-aminoimidazole-4-carboxamide ribonucleotide transformylase	1	D89976							
5'-nucleotidase	3	D38524	T	+			+		
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4)	1	D49818		+					
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PF2K)	1	AF041829							
71 kd heat shock cognate protein hsc70	23	Y00371							
76 kDa membrane protein (P76)	2	U81006		+	+	+	+	+	
8-oxoguanine DNA glycosylase (OGG1)	1	U96710	B				+	+	
a disintegrin and metalloprotease domain 10 (ADAM10)	1	AF009615	T				+		
a disintegrin and metalloprotease domain 8 (ADAM8)	1	D26579	B	+					
A kinase anchor protein 95 (AKAP95)	2	Y11997	B, T activated		+			+	
A kinase anchor protein, 149kd (AKAP149)	2	X97335		+	+	+		+	

A4 differentiation-dependent protein (A4), triple LIM domain protein (LMO6), and synaptophysin (SYP); calcium channel alpha-1 subunit (CACNA1F)	1	U93305								
ABL and putative M8604 Met protein	1	U07561								
Absent in melanoma 1 (AIM1)	1	U83115	+	+					+	
accessory proteins BAP31/BAP29 (DXS1357E)	2	Z31696		+	+					
acetyl-Coenzyme A acyltransferase (peroxisomal 3-oxoacyl-Coenzyme A thiolase) (ACAA)	2	X12966	+	+	+	+	+	+		
acetyl-Coenzyme A transporter (ACATN)	1	D88152	T lymphoma	+	+					
acidic 82 kDa protein	4	U15552								
acidic protein rich in leucines (SSP29)	1	Y07969	B	+	+			+	+	
Aconitase 2, mitochondrial (ACO2)	1	U80040	+	+	+	+			+	
actin binding protein MAYVEN	1	AF059569								
actin, beta (ACTB)	158	X04098	T, B	+	+			+		
actin, beta (ACTB) (non-exact, low match 73%)	1	M10277								
actin, gamma (low score)	1	K00791								
actin, gamma 1 (ACTG1)	4	X04098	+	+	+	+	+	+		high in many libraries
actin-binding LIM protein (ABLIM)	4	D31883		+	+	+			+	
Actinin, alpha 1 (ACTN1)	8	M95178		+	+	+			+	
actinin, alpha 4 (ACTN4)	1	D89980		+	+			+		
activated p21cdc42Hs kinase (ACK)	1	L13738	B	+					+	
activated RNA polymerase II transcription cofactor 4 (PC4)	1	X79805	+	+	+	+			+	
activating transcription factor 1 (ATF1)	1	X55544			+					
activating transcription factor 2 (ATF2)	1	X15875		+	+			+		
activating transcription factor 4 (tax-responsive enhancer element B67) (ATF4)	2	M86842						+	+	
active BCR-related gene (ABR)	1	U01147	+	+	+	+			+	
acyl-CoA oxidase (AOX)	1	U03254								
acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain (ACADM)	2	M16827								
acyl-Coenzyme A dehydrogenase, very long chain (ACADVL)	3	D43682	+	+	+	+	+	+		
acyloxyacyl hydrolase (neutrophil) (AOAH)	3	M62840	T		+			+	+	
adaptin, delta (ADTD)	2	U91930		+	+			+		
adaptin, delta (ADTD) (non-exact 59%)	1	AC005328								
adaptin, gamma (ADTG)	1	Y12226		+	+	+			+	
adaptor complex sigma3B (AP3S3)	2	X99459		+		+			+	
adaptor protein p150	1	Y08991								
adducin 1 (alpha) (ADD1)	2	L07261		+	+			+		

adducin 1 (alpha) (add1)	3	L29296	+	+	+	+	+	+
adducin 3 (gamma) (ADD3)	3	U37122	B, W	+	+	+	+	+
adenine nucleotide translocator 2 (fibroblast) (ANT2)	2	M57424		+	+	+	+	+
adenine nucleotide translocator 2 (fibroblast) (ANT2) (non-exact 81%)	1	J02683						
adenine nucleotide translocator 2 (fibroblast) (ANT2) (non-exact, 79%)	1	J02683						
adenine nucleotide translocator 2 (fibroblast) (ANT2) (non-exact, 86%)	1	J02683						
adenine nucleotide translocator 3 (liver) (ANT3)	3	J03592		+	+	+	+	+
adenosine deaminase, RNA-specific (ADAR)	6	U18121		+	+	+	+	+
adenylate cyclase 3 (ADCY3)	2	AF033861		+	+	+	+	+
adenylate cyclase 7 (ADCY7)	1	D25538						
adenylate kinase 2 (AK2)	2	U39945		+	+	+	+	+
adenylate kinase 3 (AK3) (non-exact, 67%)	1	X60673						
adenylyl cyclase-associated protein (CAP)	28	M98474	I		+	+	+	+
adipose differentiation-related protein; adipophilin (ADFP)	1	X97324			+	+	+	+
ADP-ribosylation factor 1 (ARF1)	13	M84326		+	+	+	+	+
ADP-ribosylation factor 3 (ARF3)	2	M33384		+	+	+	+	+
ADP-ribosylation factor 4 (ARF4)	1	M36341	T lymphoma	+	+	+	+	+
ADP-ribosylation factor 5 (ARF5)	1	M57567			+	+	+	+
ADP-ribosylation factor domain protein 1, 64kD (ARFD1)	1	L04510		+				
ADP-ribosyltransferase (NAD ⁺ ; poly (ADP-ribose) polymerase) (ADPRT)	4	M32721	+	+	+	+	+	+
adrenergic, beta, receptor kinase 1 (ADRBK1)	2	X61157	B	+			+	
adrenoleukodystrophy-like 1 (ALDL1)	1	AJ000327						
AE-binding protein 1 (AEBP1) (non-exact, 62%)	1	D86479						
AF-17	1	U07932						
A-gamma-globin	1	V00514						
A-gamma-globin (chromosome 11 allele)	1	J00176						
agammaglobulinaemia tyrosine kinase (ATK)	1	U78027						
AHNAK nucleoprotein (desmoyokin) (AHNAK)	4	M80899	+	+	+	+	+	+
alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150) (ANPEP)	1	X13276			+		+	
alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5)	1	M29872						
aldehyde dehydrogenase 1, soluble (ALDH1)	1	AF003341		+			+	+

aldehyde dehydrogenase 10 (fatty aldehyde dehydrogenase) (ALDH10)	2	U75286								
aldehyde reductase 1 (low Km aldose reductase) (ALDR1)	3	J04795	B	+	+	+	+			
aldo-keto reductase family 1, member A1 (aldehyde reductase) (AKR1A1)	2	J04794	B	+	+		+			
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) (AKR1C3)	1	D17793		+	+	+			+	
aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) (AKR7A2)	1	Y16675		+	+			+	+	
aldolase A, fructose-bisphosphate (ALDOA)	7	X12447		+	+			+		
aldolase C, fructose-bisphosphate (ALDOC)	2	X05196		+	+			+		
alkaline phosphatase, liver/bone/kidney (ALPL)	1	4502062								
ALL-1 (=L04731;L04284 HRX)	4	Z69780								
alpha mannosidase II isozyme	1	D55649		+					+	
alpha thalassemia/mental retardation syndrome X-linked (ATRX)	3	U75653	+	+	+	+			+	
alpha-2 macroglobulin	1	Z11711								
alpha-2-globin	2	V00516								
alpha-2-macroglobulin receptor/lipoprotein receptor protein (A2MR/LRP)	1	U06985								
alpha-polypeptide of N-acetyl-alpha-glucosaminidase (HEXA)	1	M13520								
alpha-spectrin	1	X86901								
alpha-subunit of Gi2 a (GTP-binding signal transduction protein)	1	X07854								
aminin receptor 1 (67kD); Ribosomal protein SA (LAMR1)	2	J03799	T	+	+			+	+	
aminolevulinate, delta-, dehydratase (ALAD)	1	X64467		+						
amino-terminal enhancer of split (AES)	2	X73358	+	+	+	+			+	
amino-terminal enhancer of split (AES)	3	U04241	B	+	+			+	+	
AMP deaminase isoform L (AMPD2)	8	M91029		+					+	
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) (AMPH)	1	U07616	B	+					+	
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) (AMPH)(non-exact, 68%)	1	U07616								
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) (AMPH)(non-exact, 68%)	1	U07616								
amphiphysin II	4	U87558		+	+			+		
amphiphysin II (67%aa amphiphysin?)	1	AF068915								
amphiphysin II (non-exact 69% aa)	1	AF001383								

amphiphysin-like (AMPHL)	1	U68485		+	+					
amphiphysin-like (AMPHL) (low match)	1	AF068918								
AMY-1	1	D50692	B, T					+		
amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) (APBB1)	1	L77864		+	+	+			+	
amyloid beta (A4) precursor-like protein 2 (APLP2)	6	L27631	T lymphoma	+	+			+	+	
ankyrin 3, node of Ranvier (ankyrin G) (ANK) (non- exact, 50%)	1	U43965								
annexin I (lipocortin I) (ANX1)	1	X05908		+	+	+			+	
annexin II	1	D28364								
annexin II (lipocortin II; calpactin I, heavy polypeptide) (ANX2)	7	D00017	+	+	+	+	+	+	+	high in many libraries
annexin IV (placental anticoagulant protein II) (ANX4)	1	M19383		+	+	+	+	+	+	
annexin V (endonexin II) (ANX5)	2	M21731		+	+	+			+	
annexin V (endonexin II) (ANXV)	1	M19384		+	+	+			+	
annexin VI (p68) (ANX6)	6	Y00097		+	+	+			+	
annexin VII (synexin) (ANX7)	1	J04543		+	+	+			+	
antigen identified by monoclonal antibodies 12E7, F21 and O13 (MIC2)	2	M16279		+	+	+			+	
antigen identified by monoclonal antibodies 4F2, TRA1.10, TROP4, and T43 (MDU1)	3	J02939		+	+	+	+	+	+	
antigen TQ1	1									
anti-oxidant protein 2 (non- selenium glutathione peroxidase, acidic calcium- independent phospholipase A2) (KIAA0106)	1	D14662		+	+	+	+	+	+	
APEX nuclease (multifunctional DNA repair enzyme) (APEX)	5	X66133		+	+			+	+	
Apolipoprotein L (APOL) (59%aa)	1	Z82215								
apoptosis inhibitor 1 (API1)	1	L49431		+	+	+	+	+	+	
apoptosis inhibitor 4 (survivin) (API4)	1	U75285	B, W	+	+			+		
apoptosis inhibitor 5 (API5)	1	U83857	T lymphoma	+				+		
apoptosis specific protein (ASP)	1	Y11588	B	+				+	+	
apoptotic protease activating factor (APAF1)	1	AF013263	B	+	+			+		
aquaporin 3 (AQP3)	1	AB001325	T					+		
aquaporin 9 (AQP9)	7	AB008775	T activated					+		
arachidonate 12- lipoxygenase (ALOX12)	1	M58704	T					+	+	
arachidonate 5- lipoxygenase-activating protein (ALOX5AP)	3	X52195	+	+		+			+	
ariadne homolog (ARI)	1	AJ009771	+	+	+	+			+	
ariadne-2 (D. melanogaster) homolog (all-trans retinoic acid inducible RING finger) (ARI2)	1	AF099149	+	+	+	+			+	

ARP1 (actin-related protein 1, yeast) homolog A (centractin alpha) (ACTR1A)	1	X82206		+				+		
ARP2 (actin-related protein 2, yeast) homolog (ACTR2)	9	AF006082		+	+			+	+	
ARP2/3 protein complex subunit 34 (ARC34)	5	AF006085	T activated, W	+	+			+		
Arp2/3 protein complex subunit p41 (ARC41)	6	AF006084	monocyte stimulated	+	+			+		
Arp2/3 protein complex subunit p41 (ARC41)) (low match)	1	AF006084								
Arp2/3 protein complex subunit p16 (ARC16)	20	AF017807		+	+			+	+	
Arp2/3 protein complex subunit p20 (ARC20)	2	AF006087		+	+			+	+	
Arp2/3 protein complex subunit p21 (ARC21)	3	AF006086	W					+	+	
ARP3 (actin-related protein 3, yeast) homolog (ACTR3)	11	AF006083	W		+			+	+	
arrestin, beta 2 (ARRB2)	1	AF106941	B, T, W	+	+			+		
arsA (bacterial) arsenite transporter, ATP-binding, homolog 1 (ASNA1)	1	AF047469	B, T	+				+		
aryl hydrocarbon receptor nuclear translocator-like (ARNTL)	2	AF044288	B	+	+			+		
aryl hydrocarbon receptor-interacting protein (AIP)	1	U31913	+	+	+	+			+	
arylsulfatase A (ARSA)	1	X52151	T activated	+				+		
asialoglycoprotein receptor 2 (ASGR2)	1	M11025						+	+	
asparaginyl-tRNA synthetase (NARS)	3	D84273		+	+			+		
aspartyl-tRNA synthetase (DARS)	1	J05032	B	+	+			+		
ataxia telangiectasia mutated (includes complementation groups A, C and D) (ATM)	1	U82828	B, T		+			+		
ataxin-2-like protein A2LP (A2LG)	1	AF034373	B, T activated	+	+				+	
ATF6	1	AF005887		+				+		
ATP binding cassette transporter (ABCR) (non-exact 80%)	1	U88667								
ATP synthase (F1-ATPase) alpha subunit, mitochondrial	1	X59066								
ATP synthase beta subunit gene	1	M19482								
ATP synthase, H ⁺ transporting, mitochondrial F0 complex, subunit b, isoform 1 (ATP5F1)	1	X60221	+	+	+	+			+	
ATP synthase, H ⁺ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 (ATP5G1)	1	X69907	T activated	+	+			+	+	
ATP synthase, H ⁺ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1)	3	D14710								
ATP synthase, H ⁺ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1) (low match)	1	D14710								

ATP synthase, H ⁺ transporting, mitochondrial F1 complex, beta polypeptide (ATP5B)	2	M27132									
ATP synthase, H ⁺ transporting, mitochondrial F1 complex, gamma polypeptide 1 (ATP5C1)	1	D16563	W	+	+	+	+				
ATP synthase, H ⁺ transporting, mitochondrial F1F0, subunit g (ATP5JG)	1	AF092124	+	+	+	+	+	+			
ATP/GTP-binding protein (HEAB)	2	U73524	+	+	+	+			+		
ATPase, Ca ⁺⁺ transporting, ubiquitous (ATP2A3)	5	Z69881		+							
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump) 21kD (ATP6F)	2	D89052	+	+	+	+				+	
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump) 31kD (ATP6E)	1	X76228		+	+	+				+	
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump) 42kD; Vacuolar proton-ATPase, subunit C; V-ATPase, subunit C (ATP6D)	5	X69151		+	+	+				+	
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump), alpha polypeptide, 70kD, isoform 1 (ATP6A1)	3	L09235		+		+					
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump), beta polypeptide, 56/58kD, isoform 2 (ATP6B2)	6	X62949	+	+	+	+				+	
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump), member J (ATP6J)	2	AF038954	+	+	+	+				+	high in testis
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump), subunit 1 (ATP6S1)	1	D16469		+	+	+				+	
ATP-binding cassette 50 (TNF-alpha stimulated) (ABC50)	1	AF027302	+	+	+	+				+	
ATP-binding cassette protein M-ABC1 (mitochondrial)	1	AF047690									
ATP-dependent RNA helicase	1	AJ010840	T lymphoma		+			+			
autoantigen (Hs.75528)	2	L05425	T activated		+						
autoantigen (Hs.75528) (non-exact 84%)	1	L05425									
autoantigen (Hs.75682)	1	U17474	B	+							
autoantigen La/SS-B	1	Z35127								+	
axin (AXIN1)	1	AF009674	T	+							
axonemal dynein heavy chain (DNAH17)	1	AJ000522								+	
BAI1-associated protein 3 (BAIAP3) (non-exact 54%)	1	AB017111									
basement membrane-induced gene (ICB1)	1	AF044896									
basic leucine zipper nuclear factor 1 (JEM-1) (BLZF1)	2	U79751									
basic transcription factor 3 (BTF3)	5	X74070	+	+	+	+	+	+	+		
basigin (BSG)	1	L10240		+					+		
BC-2	1	AF042384	B		+	+	+				

B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6)	1	U00115		+	+					
B-cell translocation gene 1, anti-proliferative (BTG)	1	X61123			+				+	
BCL2/adenovirus E1B 19kD-interacting protein 2 (BNIP2)	1	U15173	B	+				+	+	
BCL2/adenovirus E1B 19kD-interacting protein 3-like (BNIP3L)	2	AF067396		+	+	+			+	
beclin 1 (coiled-coil, myosin-like BCL2-interacting protein) (BECN1)	1	AF077301	B	+	+			+		
beta-1,2-N-acetylglucosaminyltransferase II (MGAT2)	2	U15128								
beta-2-microglobulin (B2M)	63	S82297	+	+	+	+	+	+		high in invasive prostate tumor
beta-hexosaminidase alpha chain (HEXA)	1	M16411								
beta-tubulin	7	V00599	+	+	+	+	+	+		high in many libraries
beta-tubulin (non-exact, 76%)	1	AF070561								
beta-tubulin, pseudogene	1	J00315								
BING4	1	Z97184								
biotinidase (BTD) (non-exact 62%)	1	U03274								
biotinidase (BTD) (non-exact 70%)	1	U03274								
biotinidase (BTD) (non-exact, 56%)	1	U03274								
BIOTINIDASE PRECURSOR	1	P43251								
biphenyl hydrolase-like (serine hydrolase) (BPHL)	1	X81372		+				+		
bone marrow stromal cell antigen 1 (BST1)	1	D21878						+		
box-dependent myc-interacting protein isoform BIN1-10 (BIN1)	1	AF043900								
box-dependent myc-interacting protein isoform BIN1-10 (BIN1) (non-exact, 64%)	1	AF043900								
brain my047 protein	1	AF063605	+	+	+			+		
branched chain keto acid dehydrogenase E1, alpha polypeptide (maple syrup urine disease) (BCKDHA)	3	Z14093	+	+	+			+		
BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) (BAP1)	1	D87462	+	+	+	+				
BRCA1, Rho7 and vaf1 genes, and ipf35	1	L78833								
breakpoint cluster region protein, uterine leiomyoma, 1; barrier to autointegration factor (BCRP1)	2	AF044773		+	+					
breakpoint cluster region protein, uterine leiomyoma, 2 (BCRP2)	2	AF044774		+	+			+	+	
breast cancer anti-estrogen resistance 3 (BCAR3) (non-exact 73%)	1	U92715								
bromodomain-containing protein, 140kD (peregrin) (BR140)	2	M91585		+						
Bruton's agammaglobulinemia tyrosine kinase (Btk)	1	U13424								

Bruton's tyrosine kinase (BTK)	1	U78027								
Bruton's tyrosine kinase (BTK), alpha-D-galactosidase A (GLA), L44-like ribosomal protein (L44L) and FTP3 (FTP3)	1	U78027								
BS4	1	AF108083								
BTG2 (BTG2)	6	Y09943	+	+	+	+			+	
BTK region clone ftp	1	U78027	+	+	+	+			+	
BTK region clone ftp-3	1	U01923		+	+			+		
BUB3 (budding uninhibited by benzimidazoles 3, yeast) homolog (BUB3)	4	AF053304	+	+	+	+			+	
butyrate response factor 1 (EGF-response factor 1) (BRF1)	4	X79067	+	+	+	+			+	
butyrophilin (BTF1)	7	U90543		+	+			+		
butyrophilin like receptor	1	AB020625.1								
CAG repeat containing (CTG4A)	2	U80744		+	+					
CAGH32	2	U80743		+	+			+		
calcium channel, voltage-dependent, L type, alpha 1D subunit (CACNA1D) (low match)	1	M83566								
calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma (CAMK2G)	1	AF069765		+	+	+			+	
calcium/calmodulin-dependent protein kinase kinase (KIAA0787)	1	AF101264	B	+	+			+		
calmodulin (=M19311)	7	D45887								
calmodulin 1 (phosphorylase kinase, delta) (CALM1)	6	M27319	B	+	+			+	+	
calnexin (CANX)	3	M94859	T	+				+	+	
calpain, large polypeptide L1 (CAPN1)	5	X04366		+	+			+	+	
calpain, large polypeptide L2 (CAPN2)	5	M23254		+	+					
calpain, small polypeptide (CAPN4)	1	X04106		+	+			+	+	
calpastatin (CAST)	3	D16217						+		
Calponin 2	2	D83735		+			+		+	
calponin 2 (CNN2)	1	D83735	B, T	+				+		
calponin 2 (CNN2) (low score)	1	D83735								
calumenin (CALU)	3	AF013759	B		+			+	+	
cAMP response element-binding protein CRE-Bpa (H GS165L15.1)	4	L05912								
cAMP-dependent protein kinase type II (Ht31)	1	M90360								
canicular multispecific organic anion transporter (CMOAT2)	1	AF009670					+	+	+	
capping protein (actin filament) muscle Z-line, alpha 1 (CAPZA1)	6	U56637	B, T		+				+	
capping protein (actin filament) muscle Z-line, alpha 2 (CAPZA2)	2	U03269	B	+	+					
capping protein (actin filament) muscle Z-line, beta (CAPZB)	1	U03271	+	+	+	+			+	

capping protein (actin filament), gelsolin-like (CAPG)	8	M94345	+	+		+		+	
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD)	1	D78586	+	+	+	+		+	
carbonic anhydrase V, mitochondrial (CA5)	1	L19297		+				+	
carboxypeptidase D (CPD)	3	U65090	B	+	+				
camitine/acylcarnitine translocase (CACT)	1	Y10319		+	+			+	
Cas-Br-M (munne) ecotropic retroviral transforming sequence (cbl)	2	X57110						+	
casein kinase 1, alpha 1 (CSNK1A1)	1	L37042	+	+	+	+		+	
casein kinase 2, alpha 1 polypeptide (CSNK2A1)	2	M55265	B	+				+	+
casein kinase I gamma 3L (CSNK1G3L)	1	AF049090.1							
casein kinase II alpha subunit(=S72393)	1	X69951							
CASP8 and FADD-like apoptosis regulator (CFLAR)	4	AF015450		+	+	+	+	+	
caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) (CASP1)	7	U13697	+				+		
caspase 10, apoptosis-related cysteine protease (CASP10)	1	U60519	B, T activated, T lymphoma					+	
caspase 3, apoptosis-related cysteine protease (CASP3)	3	U13737	B, T	+	+	+	+		
caspase 4, apoptosis-related cysteine protease (CASP4)	6	U25804	+	+	+	+		+	
caspase 5, apoptosis-related cysteine protease (CASP5)	1	U28015			+				
caspase 8, apoptosis-related cysteine protease (CASP8)	2	X98173		+		+		+	
caspase 9, apoptosis-related cysteine protease (CASP9)	1	U56390	B				+	+	
catalase (CAT)	5	X04076	B	+	+			+	
catechol-O-methyltransferase (COMT)	1	M65213		+	+			+	
catenin (cadherin-associated protein), alpha 1 (102kD) (CTNNA1)	6	D14705		+	+				
cathelicidin antimicrobial peptide (CAMP)	1	X89658	B						
cathepsin B (CTSB)	4	L16510			+			+	+
cathepsin C (CTSC)	3	U79415		+	+	+			+
cathepsin D (lysosomal aspartyl protease) (CTSD)	4	M11233		+	+			+	
cathepsin E (CTSE)	1	J05036						+	
cathepsin G (CTSG)	1	M16117	T, W		+				
cathepsin S (CTSS)	34	M86553	B, Monocyte stimulated, T lymphoma					+	+
cathepsin W (lymphopain) (CTSW)	4	AF013611						+	
CBF1 interacting corepressor CIR (=U03644 recepin)	1	AF098297							

CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA)	3	X87248		+	+	+	+	+	
CCAAT/enhancer binding protein (C/EBP), delta (CEBPB)	1	S63168			+		+	+	
CCAAT-box-binding transcription factor (CBF2)	2	M37197	T lymphoma			+	+		
CCR5 receptor (CCR5) (non-exact?)	1	AF011504							
CD14 antigen (CD14)	11	M86511	+	+	+	+		+	
CD18 (=M95293)	4	X64071							
CD1C antigen, c polypeptide (CD1C)	2	M28827						+	
CD2 antigen (cytoplasmic tail)-binding protein 2 (CD2BP2)	1	AF104222							
CD2 antigen (p50), sheep red blood cell receptor (CD2)	4	M14362	+		+	+		+	
CD2 cytoplasmic tail-binding protein 1 (CD2BP1)	2	AF038602					+		
CD20 antigen (CD20)	1	X12530							
CD20 receptor (S7)	1	X07203							
CD22 antigen (CD22)	1	U62631	B						
CD24 signal transducer	1	M58664							
CD33 antigen (gp67) (CD33)	1	M23197					+		
CD33 antigen-like 2: OB binding protein-2 (CD33L2) (non-exact, 68%)	1	U71383							
CD33L2 (61% aa)	1	D86359							
CD36 antigen (collagen type I receptor, thrombospondin receptor) (CD36)	7	M98398	T lymphoma		+		+	+	
CD37 antigen (CD37)	5	X14046	+	+		+		+	
CD38 alt	1	D84277							
CD39 antigen (CD39)	1	U87967	B	+			+	+	
CD3D antigen, delta polypeptide (TIT3 complex) (CD3D)	1	X03934			+	+		+	
CD3E antigen, epsilon polypeptide (TIT3 complex) (CD3E)	1	X03884	+			+			
CD3G antigen, gamma polypeptide (TIT3 complex) (CD3G)	2	X06026	W				+		
CD3Z antigen, zeta polypeptide (TIT3 complex) (CD3Z)	2	J04132	+			+			
CD3-zeta (clone pBS NK1)	1	X55510							
CD4 (low match)	1	S68043							
CD4 antigen (p55) (CD4)	4	M12807		+	+		+		
CD44 antigen (homing function and Indian blood group system) (CD44)	6	X56794	W				+	+	
CD48 antigen (B-cell membrane protein) (CD48)	3	X06341	+	+	+	+		+	
CD53 antigen (CD53)	10	L11670	+	+		+		+	
CD53 antigen (CD53) (low match)	1	M60871							
CD63 antigen (melanoma 1 antigen) (CD63)	3	M59907							
CD68 antigen (CD68)	2	S57235		+	+		+	+	

CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) (CD74)	72	K01144	+	+	+	+	+	+	high in many libraries
CD79A antigen (immunoglobulin-associated alpha) (CD79A)	2	M80462			+				
CD79B antigen (immunoglobulin-associated beta) (CD79B)	2	M89957	+						
CD8 antigen, alpha polypeptide (p32) (CD8A)	2	M27161	+			+		+	
CD8 antigen, beta polypeptide 1 (p37) (CD8B1)	1	X13445	W						
CD81 antigen (target of antiproliferative antibody 1) (CD81)	1	M33680		+	+			+	
CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) (CD83)	1	Q01151	B	+	+			+	
CD84 antigen (leukocyte antigen) (CD84)	1	U82988		+	+			+	
CD86 antigen	1	L25259		+					
CD9 antigen (p24) (CD9)	2	M38690			+		+	+	
CD97 antigen (CD97)	12	X84700	+	+		+			
CD97 antigen (CD97) (non-exact 59%)	1	P48960							
CD97 antigen (CD97) (non-exact 62%)	1	X94630	+	+		+			
CDC23 (cell division cycle 23, yeast, homolog) (CDC23)	1	AF053977		+			+	+	
CDC37 homolog	1	U63131	B	+	+		+	+	
Cdc42 effector protein 3 (CEP3)	2	AF104857	B	+	+		+		
CDC-like kinase (CLK)	1	L29219		+	+	+		+	
CDC-like kinase 2 (CLK2)	1	AF023268	B	+	+				
CDW52 antigen (CAMPATH-1 antigen) (CDW52)	13	X15183	activated	+	+		+		
cell cycle progression restoration 8 protein(CPR8)	1	AF011794							
cell division cycle 10 (homologous to CDC10 of S. cerevisiae) (CDC10)	4	S72008	+	+	+	+		+	
cell division cycle 20, S.cerevisiae homolog (CDC20)	1	U05340		+	+	+			
cell division cycle 25B (CDC25B)	6	Z68092	+	+	+	+		+	
cell division cycle 2-like 1 (PITSLRE proteins) (CDC2L1) (non-exact 42%)	1	AF067514							
cell division cycle 42 (GTP-binding protein, 25kD) (CDC42)	5	M35543	+	+	+	+		+	
cell division protein (non-exact 68%)	1	AF063015							
CELL-CYCLE NUCLEAR AUTOANTIGEN SG2NA (S/G2 NUCLEAR ANTIGEN)	1	Q13033							
centromere protein B (80kD) (CENPB)	1	X55039		+			+		
cep250 centrosome associated protein	3	AF022655	B	+			+		

ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease) (CLN2)	7	AF017456	+	+	+	+	+	+	+	high in bone
c-fgr (=M63877 nonreceptor protein-tyrosine kinase (fgr))	6	X52206								
CGI-19 protein	3	AF132953.1								
chaperonin containing TCP1, subunit 3 (gamma) (CCT3)	1	X74801		+	+				+	
chaperonin containing TCP1, subunit 4 (delta) (CCT4)	1	AF026291		+	+			+	+	
chaperonin containing TCP1, subunit 6A (zeta 1) (CCT6A)	4	L27706	B	+	+					
chaperonin containing TCP1, subunit 7 (eta) (CCT7)	4	AF026292	B	+					+	
Chediak-Higashi syndrome 1 (CHS1)	1	U67615	B, T lymphoma	+	+			+		
Chediak-Higashi syndrome 1 (CHS1) (low score)	1	U67615								
chemokine (C-C motif) receptor 2 (CCR2)	4	U03905								
chemokine (C-C motif) receptor 4 (CCR4) (low match) (may contain repeat)	1	X85740								
chemokine (C-C motif) receptor 7 (CCR7)	6	L31581								
chemokine (C-X3-C) receptor 1 (CX3CR1)	5	U20350		+						
chemokine (C-X-C motif), receptor 4 (fusin) (CXCR4)	5	M99293	+	+	+	+			+	
chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1)	2	M80927		+		+			+	
chitinase 3-like 2 (CHI3L2)	2	U49835		+		+			+	
chloride channel 1, skeletal muscle (CLCN1)	1	G18280								
chloride channel 6 (CLCN6)	1	D28475		+	+					
chloride intracellular channel 1 (CLIC1)	1	U93205	+	+	+	+			+	
chondroitin sulfate proteoglycan 2 (versican) (CSPG2)	5	X15998			+					
chondroitin sulfate proteoglycan core protein	2	J02814			+				+	
chromatin assembly factor 1 p48 subunit (CAF-1 P48 subunit) (retinoblastoma binding protein p48) (retinoblastoma-binding protein 4) (MSI1 protein homolog)	1	Q09028								
chromodomain helicase DNA binding protein 1 (CHD1)	2	AF006513								
chromodomain helicase DNA binding protein 1-like (CHD1L)	1	AF054177								
chromodomain helicase DNA binding protein 2 (CHD2)	1	AF006514	B	+	+			+		
chromodomain helicase DNA binding protein 3 (CHD3)	1	AF006515								
chromodomain helicase DNA binding protein 4 (CHD4)	5	X86691	+	+	+	+			+	

chromosome 1 open reading frame 7 (C1ORF7)	1	AF054176								
chromosome 1 specific transcript KIAA0493	1	AB007962								
chromosome 17 open reading frame 1B (C17ORF1B)	1	AJ008112	T	+						
chromosome 4 open reading frame 1 (C4ORF1)	1	AF006621		+	+	+			+	
chromosome condensation 1-like (CHC1L)	2	AF060219		+	+	+			+	
chromosome X open reading frame 5 (CXORF5)	1	Y15164	B	+	+			+		
chromosome-associated polypeptide C(CAP-C)	2	AF092564	B	+	+			+	+	
cig42	1	AF026944								
cig5	3	AF026941								
citrate synthase (CS)	2	AF047042	B	+	+			+	+	
class I major histocompatibility antigen (HLA-Cw3)	2	U31372								
class I major histocompatibility antigen (HLA-Cw3) (low match)	1	U31372								
clathrin assembly protein lymphoid myeloid leukemia (CALM)	3	U45976	B	+	+				+	
clathrin heavy chain	1	X55878								
clathrin, heavy polypeptide-like 2 (CLTCL2)	1	D21260								
clathrin, light polypeptide (Lca) (CLTA) (low match)	1	M20472								
clathrin-associated/assembly/adapt or protein, medium 1 (CLAPM1)	3	D63475		+	+	+	+	+	+	
cleavage stimulation factor, 3' pre-RNA, subunit 2 64kD (CSTF2) (non-exact 82%)	1	M85085								
cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kD (CSTF3)	1	U15782	B	+	+			+		
clk3	1	L29220	B	+	+					
clone 23815 (Hs.82845)	1	U90916		+	+				+	
clone 24592 mRNA sequence	1	D88378	+	+	+	+			+	
Clq/MBL/SPA receptor C1qR(p) ()	1	U94333								
clustenn (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J) (CLU)	1	M64722	+	+	+	+	+	+	+	
CMP-sialic acid transporter (CMPST)	1	D87969	B	+	+					
CMRF35	3	X66171								
c-myc oncogene containing coxiii	1	X54629								
coagulation factor II (thrombin) receptor (F2R)	1	M62424		+	+				+	
coagulation factor V (proaccelerin, labile factor) (F5)	1	M14335		+		+	+			
coagulation factor XIII a subunit	3	M21998								
coagulation factor XIII, A1 polypeptide (F13A1)	6	M14354		+	+	+			+	
coated vesicle membrane protein (RNP24)	1	X92098	+	+	+	+	+	+	+	

coatomer protein complex, subunit alpha (COPA)	5	U24105	I	+				+		
Cofilin 1 (non-muscle) (CFL1)	13	X95404	+	+	+	+	+	+	+	high in fetal brain
cold inducible RNA-binding protein (CIRBP)	7	D78134		+	+				+	
cold shock domain protein A (CSDA)	3	X95325		+	+					
collagen, type IX, alpha 2 (COL9A2)	3	AF019406	B							
colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog (CSF1R)	3	X03663		+				+	+	
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB)	5	M59941								
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB) (low match)	1	M59941								
colony stimulating factor 3 receptor (granulocyte) (CSF3R)	16	X55720		+						
complement component 5 receptor 1 (C5a ligand) (C5R1)	1	M62505	L							
conserved gene amplified in osteosarcoma (OS4)	2	AF000152		+	+	+			+	
COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 3 (COPS3)	2	AF031647		+	+				+	
COP9 homolog (HCOP9)	2	U51205	B	+	+	+	+	+	+	
COP11 protein, homolog of s. cerevisiae SEC23p (SEC23A)	4	X97064		+	+					
copine I (CPNE1)	2	U83246	B	+	+			+		
copine I (CPNE1) (low score)	1	U83246								
coproporphyrinogen oxidase (coproporphyrin, harderoporphyrin) (CPO)	1	D16611			+			+	+	
core-binding factor, beta subunit (CBFB)	1	L20298		+						
coronin	22	X89109	T, W	+	+			+		
coronin (low match)	1	U34690								
coronin (non-exact, 71%)	1	X89109								
cot (cancer Osaka thyroid) oncogene (COT)	1	D14497	+	+	+	+			+	
cryptochrome 1 (photolyase-like) (CRY1)	1	D84657		+	+				+	
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 (CTDP1)	1	AF081287		+	+	+			+	
C-terminal binding protein 1 (CTBP1)	1	U37408	B	+	+			+		
C-terminal binding protein 2 (CTBP2)	2	AF016507		+	+			+		
CUG triplet repeat, RNA-binding protein 1 (CUGBP1)	3	U63289		+	+	+			+	
cullin 1 (CUL1)	3	U58087		+	+	+			+	
cullin 3 (CUL3)	2	U58089		+	+	+			+	
cut (Drosophila)-like 1 (CCAAT displacement protein) (CUTL1)	1	M74099	B	+						

cyclin D2 (CCND2)	2	D13639		+	+	+	+	+	
cyclin D3 (CCND3)	5	M92287	B, T lymphoma		+			+	
cyclin G1 (CNNG1)	1	D78341	B	+	+				+
cyclin I	3	D50310	B	+				+	
cyclin T2 (CNN12)	1	AF048732	B, T lymphoma	B					
cyclin-dependent kinase 2 (CDK2)	1	X62071							
cyclin-dependent kinase inhibitor (p27Kip1)	1	S76986							
cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A)	2	S67388	+	+	+	+	+	+	
CYP2D7-CYP2D6 intergenic region (partial)	1	X90926							
cystatin B (stein B) (CSTB)	1	L03558			+			+	+
cysteine and glycine-rich protein 3 (cardiac LIM protein) (CSRP3)	5	L54057			+				
cytidine deaminase (CDA)	2	L27943						+	
cytochrome b	1	AF042500							
cytochrome b (CYTB) (isolate Aus5)	1	AF042518							
cytochrome b(-245) beta chain N-terminal region (X-linked granulomatous disease gene)	2	X05895							
cytochrome b-245, beta polypeptide (chronic granulomatous disease) (CYBB)	2	X04011	+				+		+
cytochrome C	1	P00001							
cytochrome c oxidase subunit IV (COX4)	1	U90915	I	+	+			+	+
cytochrome c oxidase subunit Vb (COX5B)	2	M59250						+	
cytochrome c oxidase subunit VII-related protein (COX7RP)	6	AB007618	+	+	+	+			+
cytokine suppressive anti-inflammatory drug binding protein 1 (p38 MAP kinase) (CSBP1)	1	L35263	lymphocyte	+	+			+	
Cytoplasmic antiproteinase=38 kda intracellular serine proteinase inhibitor	1	S69272			+				
cytotoxic granule-associated RNA-binding protein p40-TIA-1	1	S70114							
DT23 (DT23)	1	D14878	+	+			+		+
D2-2	1	AF019226							
D38	1	X74802							
damage-specific DNA binding protein 1 (127kD) (DDB1)	2	AJ002955	+	+	+	+	+	+	
DCHT (low match)	1	AF017635							
DEAD/H (Asp-Glu-Ala-Asp/His) box binding protein 1 (DDXBP1)	1	U78524		+	+	+	+	+	
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide (72KD) (P72)	2	U59321	I	+	+			+	+
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1 (DDX1)	1	X70649		+	+				+

			PCT/CA00/00005									
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 15 (DDX15)	2	AB001636										
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 16 (DDX16)	2	AB011149	+	+	+	+			+			
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3 (DDX3)	3	U50553	+	+	+	+				+		
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA helicase, 68kD) (DDX5)	37	X15729	+	+	+	+				+		
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA helicase, 68kD) (DDX5) (low match)	1	AF015812										
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 6 (RNA helicase, 54kD) (DDX6)	2	D17532	+	+								
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 8 (RNA helicase, 54kD) (DDX8)	1	D50487		+	+	+				+		
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 9 (RNA helicase A, nuclear DNA helicase II; leukophysin) (DDX9)	3	L13848	+	+	+	+				+		
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide, Y chromosome (DBY)	1	AF000985		+	+				+			
Death associated protein 3 (DAP3)	2	X83544	+	+	+	+	+	+	+			
death effector domain-containing protein (DEDD)	1	AF083236		+	+	+				+		
death-associated protein 6 (DAXX)	2	AF039136		+	+	+				+		
dedicator of cyto-kinesis 2 (DOCK2)	4	D86964	+	+		+				+		
defender against cell death 1 (DAD1)	1	D15057			+				+	+		
Defensin, alpha 1, myeloid-related sequence (DEFA1)	4	L12690					+	+	+			
DEK gene (D6S231E)	1	X64229	B		+				+			
delta sleep inducing peptide, immunoreactor (DSIP)	4	Z50781	+	+	+	+				+		
dendritic cell protein (GA17)	3	AF064603	+	+	+	+				+		
deoxycytidine kinase (DCK)	1	M60527										
deoxyribonuclease II, lysosomal (DNASE2)	3	AB004574										
DGS-I	2	L77566		+								
diacylglycerol kinase	3	D16440										
diacylglycerol kinase alpha (DAGK1) (clone 24)	3	AF064771		+								
diacylglycerol kinase alpha (DAGK1) (clone 24) (low match)	1	AF064771										
diaphanous (Drosophila, homolog) 1 (DIAPH1)	1	AF051782	B, monocyte stimulated	+	+				+	+		
diaphorase (NADH) (cytochrome b-5 reductase) (DIA1)	1	Y09501	+	+	+	+	+	+	+	+		
differentiated Embryo Chondrocyte expressed gene 1 (DEC1)	1	AB004066		+					+	+		

differentiated Embryo Chondrocyte expressed gene 1 (DEC1) (low match)	1	AB004066								
differentiation antigen CD20	1	L23415								
DiGeorge syndrome critical region gene 2 (DGCR2)	1	X84076		+	+				+	
dihydrolipoamide dehydrogenase (E3 component of pyruvate dehydrogenase complex, 2-oxo-glutarate complex, branched chain keto acid dehydrogenase complex) (DLD)	2	J03620		+				+	+	
dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex) (DLAT)	1	Y00978	B	+				+		
dihydropyrimidinase-like 2 (DPYSL2)	1	D78013		+	+			+	+	
dinG gene	1	Y10571								
diphtheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2 (DPH2L2)	3	AF053003	B	+	+			+	+	
disintegrin-protease (non-exact 72%)	1	Y13323								
DJ-1 protein	2	AF021819	+	+	+	+			+	
Dmx-like 1 (DMXL1)	1	AJ005821	+		+	+				
DNA (cytosine-5)-methyltransferase 1 (DNMT1)	3	X63692	T activated, lymphoma	+				+	+	
DNA fragmentation factor, 40 kD, beta subunit (DFFB)	1	AF064019								
DNA fragmentation factor, 45 kD, alpha subunit (DFFA)	2	U91985	T	+	+				+	
DNA mismatch repair protein (hMLH1)	1	U17840								
DNA segment on chromosome X (unique) 648 expressed sequence	3	M64241	+	+	+	+	+	+	+	high in many libraries
DNA segment, single copy probe LNS-CAI/LNS-CAII (deleted in polyposis) (D5S346)	3	M73547		+	+	+			+	
DNA-damage-inducible transcript 1 (DDIT1) (low match)	1	L24498								
DnaJ protein	1	AJ001309								
DnaJ protein	1	AJ001309								
docking protein 2, 56kD (DOK2)	1	AF034970								
dolichyl-diphosphooligosaccharide-protein glycosyltransferase (DDOST)	1	D89060	+	+	+	+	+	+	+	activated T cell
dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit (DPM1)	1	D86198	T activated	+	+			+		
down-regulated by activation (immunoglobulin superfamily) (DORA)	1	AJ223183						+		
down-regulated in adenoma DRA (low match)	1	P40879								
D-type cyclin-interacting protein 1 (DIP1)	1	AF082569	B					+	+	

dual specificity phosphatase 1 (DUSP1)	4	X68277	+	+	+	+	+	+	
dual specificity phosphatase 11 (RNA/RNP complex 1-interacting) (dusp11)	1	AF023917	+	+	+	+		+	
dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related) (DUSP3)	1	L05147		+	+		+	+	
dual specificity phosphatase 6 (DUSP6)	6	X93920	+	+	+	+	+	+	
dynactin 1 (p150, Glued (Drosophila) homolog) (DYTN1)	3	X98801							
dynactin 1 (p150, Glued (Drosophila) homolog) (DYTN1) (low match)	1	X98801	B	+	+				
dynamitin 2 (DNM2)	1	L36983							
dynamitin (dynactin complex 50 kD subunit) (DCTN-50) (non-exact 88%)	1	U50733							
dynein, axonemal, heavy polypeptide 17-like (non-exact, 57%aa)	1	X99947							
dynein, cytoplasmic, light intermediate polypeptide 2 (DNCL12)	1	AF035812	B	+	+			+	
dynein, cytoplasmic, light intermediate polypeptide 2 (DNCL12) (non-exact, 69%)	1	AF035812							
dyskeratosis congenita 1, dyskerin (DKC1)	1	U59151	B	+			+	+	
dystonia 1, torsion (autosomal dominant) (DYT1)	1	AF007871		+	+	+		+	
dystrobrevin, beta (DTNB)	1	AF022728		+					
dystrophia myotonica-containing WD repeat motif (DMWD)	1	L19267		+	+		+	+	
dystrophia myotonica-protein kinase (DMPK)	1	L08835	+	+	+			+	
dystrophin (muscular dystrophy, Duchenne and Becker types) (DMD) (low match, 59%aa)	1	X14298							
E1B-55kDa-associated protein	1	AJ007509	W	+	+		+	+	
E2F transcription factor 3 (E2F3)	2	D38550		+	+	+	+	+	
E2F transcription factor 4, p107/p130-binding (E2F4)	1	X86096	B	+			+		
E2F transcription factor 5, p130-binding (E2F5)	2	U15642	+	+		+		+	
E74-like factor 1 (ets domain transcription factor) (ELF1)	1	M82882	B		+		+	+	
E74-like factor 4 (ets domain transcription factor) (ELF4)	3	U32645		+	+			+	
E74-like factor 4 (ets domain transcription factor) (ELF4) (non-exact, 71%)	1	U32645							
early development regulator 2 (homolog of polyhomeotic 2) (EDR2)	4	U89278	+	+	+	+		+	
EBV induced G-protein coupled receptor (EBI2)	1	L08177	W						
ecotropic viral integration site 2B (EVI2B)	3	M60830		+		+			

ectin, galactoside-binding, soluble, 1 (galectin 1) (LGALS1)	1	J04456								+	
EGF-like-domain, multiple 4 (EGFL4)	1	AB011541									
eIF-2-associated p67 homolog	3	U13261	B	+						+	
elastin (supravalvular aortic stenosis, Williams-Beuren syndrome) (ELN) (low match)	1	M24782		+	+						
elav-type RNA-binding protein (ETR-3)	3	U69546									
electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II) (ETFA)	2	J04058		+							
ELK3, ETS-domain protein (SRF accessory protein 2) (ELK3)	2	Z36715			+					+	
elongation factor 1-beta	1	L26404									
elongation factor 1s (mitochondrial protein)	1	AF110399									
elongation factor Tu-nuclear encoded mitochondrial	1	X84694									
eMDC II protein	1	AJ242015.1									
ems1 sequence (mammary tumor and squamous cell carcinoma-associated (p80/85 src substrate) (EMS1)	1	M98343		+	+			+	+		
endogenous retroviral element HC2	1	Z70664									
endosulfine alpha (ENSA)	1	X99906	T	+							
endothelial differentiation, sphingolipid G-protein-coupled receptor, 1 (EDG1)	2	M31210		+	+	+				+	
endothelial differentiation, sphingolipid G-protein-coupled receptor, 1 (EDG1) (low match 66%)	1	M31210									
endothelial monocyte-activating polypeptide (EMAPII)	1	U10117	+	+	+	+				+	
enolase 1, (alpha) (ENO1)	12	M14328	+	+	+	+	+	+	+		
enolase 2, (gamma, neuronal) (ENO2)	1	X51956		+							
enolase-alpha	1	D28437									
enoyl Coenzyme A hydratase 1, peroxisomal (ECH1)	2	U16660									
enoyl Coenzyme A hydratase, short chain, 1, mitochondrial (ECHS1)	1	D13900	+	+	+	+	+	+	+		
ENOYL-COA HYDRATASE, MITOCHONDRIAL PRECURSOR (SHORT CHAIN ENOYL-COA HYDRATASE) (SCEH) (ENOYL-COA HYDRATASE 1) (low match, non-exact 56%)	1	P30084									
epidermal growth factor receptor pathway substrate 15 (EPS15)	2	U07707		+		+				+	

EPIDIDYMAL SECRETORY PROTEIN E1 PRECURSOR (EPI-1) (HE1) (EPIDIDYMAL SECRETORY PROTEIN 14.6) (ESP14.6)	2	Q15668									
epithelial membrane protein 3 (EMIP3)	1	U87947	+	+	+	+			+		
Epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1)	1	L29766									+ only
ERCC2 (=L47234)	1	X52221									
ERF-2	3	U07802	+	+	+	+			+		high in gall bladder
ERp28 protein	1	X94910	+	+	+	+					
erythrocyte membrane protein	2	M81635									
erythroleukemic cells K562	2	L25343									
EST (Hs.189509)	2	U24166									
estrogen receptor-related protein (hERRa1)	1	L38487									
ESTs, Highly similar to ADENYLOSUCCINATE SYNTHETASE	1	X66503	B, T	+	+						
ESTs, Moderately similar to cysteine-rich fibroblast growth factor receptor	1	U28811	+	+	+	+			+		
ET binding factor 1 (SBF1)	1	U93181	+	+							
ets domain protein ERF	1	U15655	+	+	+	+					
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)	326	X03558	T	+	+				+		
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) (low match)	1	X03558									
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) (low match)	1	X03558									
eukaryotic translation elongation factor 1 beta 2 (EEF1B2)	5	X60489	+	+	+	+			+		
eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) (EEF1D)	1	Z21507	+	+	+	+	+	+			
eukaryotic translation elongation factor 1 gamma (EEF1G)	31	Z11531									
eukaryotic translation elongation factor 2 (EEF2)	2	X51466		+					+		
eukaryotic translation initiation factor 2, subunit 1 (alpha, 35kD) (EIF2S1)	1	J02645									
eukaryotic translation initiation factor 2, subunit 2 (beta, 38kD) (EIF2S2)	1	M29536									
eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD) (EIF2S3)	3	L19161		+	+						
eukaryotic translation initiation factor 3, subunit 10 (theta, 150/170kD) (EIF3S10)	2	U78311									
eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD) (EIF3S2)	3	U36764	+	+	+	+	+	+			high in white blood cells
eukaryotic translation initiation factor 3, subunit 3 (gamma, 40kD) (EIF3S3)	6	U54559	+	+	+	+			+		high in spleen
eukaryotic translation initiation factor 3, subunit 4 (delta, 44kD) (EIF3S4)	9	AF020833		+	+	+			+		

eukaryotic translation initiation factor 3, subunit 6 (48kD) (EIF3S6)	4	U94175	+	+	+	+		+	high in bladder
eukaryotic translation initiation factor 3, subunit 6 (EIF3S6)	1	U62962		+	+	+		+	Highly represented (1.4833 pct) in library 36 human gall bladder
eukaryotic translation initiation factor 3, subunit 7 (zeta, 66/67kD) (EIF3S7)	3	U54558	+	+	+	+		+	
eukaryotic translation initiation factor 3, subunit 8, 110kD (EIF3S8)	5	U46025	+	+	+	+	+	+	high in testis
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G)	1	AF012088							
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G) (low match)	1	AF012088							
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G1)	2	D12686							
eukaryotic translation initiation factor 4 gamma, 2 (EIF4G2)	6	U73824	+	+	+	+	+	+	
eukaryotic translation initiation factor 4 gamma, 2 (EIFG2)	2	U76111	+	+	+	+	+	+	
eukaryotic translation initiation factor 4A, isoform 1 (EIF4A1)	29	D13748							
eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2)	11	D30655	+	+	+	+	+	+	
eukaryotic translation initiation factor 4B (EIF4B)	18	X55733	+	+	+	+		+	
eukaryotic translation initiation factor 4E (EIF4E)	1	P06730							
Eukaryotic translation initiation factor 4E binding protein 2 (EIF4EBP2)	3	L36056	I, B	+				+	
eukaryotic translation initiation factor 4H (EIF4H)	2	Q15056							
eukaryotic translation initiation factor 5 (EIF5)	2	U49436	+	+	+	+	+	+	
eukaryotic translation termination factor 1 (ETF1)	2	U90176	+	+	+	+		+	
EV12 protein	1	M55266		+					
Ewing sarcoma breakpoint region 1 (EWSR1)	1	X66899	+	+	+	+		+	
EWS/FLI1 activated transcript 2 homolog (EAT-2)	2	AF020264							
EWS-E1A-F chimenc protein	1	U35622							
excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) (ERCC1)	1	M28650	+	+	+	+		+	
excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome)) (ERCC5)	1	X69978		+	+	+		+	
exostoses (multiple)-like 3 (EXTL3)	1	AF001690		+	+	+		+	
F11	1	X77744				+			

42

fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome) syndrome, Pfeiffer syndrome, Jackson-Weiss) (FGFR2)	1	M35718	+	+	+	+	+	+	
ficolin (collagen/fibrinogen domain-containing) 1 (FCN1)	19	D83920				+		+	
filamin A, alpha (actin-binding protein-280) (FLNA)	2	X53416							
filamin B, beta (actin-binding protein-278) (FLNB)	1	AF043045		+	+		+		
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived); ribosomal protein S30 (FAU)	2	X65923	+	+	+	+	+	+	Highly represented in intraepithelial neoplasia and invasive prostate tumor
FK-506 binding protein	1	M80199	+	+	+	+		+	
FK506-binding protein 1A (12kD) (FKBP1A)	2	M34539							
FK506-binding protein 1B (12.6 kD) (FKBP1B)	1	M92423		+		+		+	
FK506-binding protein 5 (FKBP5)	4	U71321		+	+	+		+	
Flightless I (Drosophila) homolog (FLII)	3	U80184		+					
Flightless I (Drosophila) homolog (FLII) (low match)	1	U80184							
FLN29 (FLN29)	2	AB007447		+		+		+	
flotillin 2 (FLOT2)	5	M60922	+	+	+	+	+	+	
folate receptor 2 (fetal) (FOLR2)	1	AF000380		+	+	+		+	
forkhead (Drosophila) homolog (rhabdomyosarcoma) like 1 (FKHRL1)	1	AF032886	+	+		+		+	
Formyl peptide receptor 1 (FPR1)	9	M60627	+	+	+	+		+	
formyl peptide receptor-like 1 (FPRL1)	1	M84562							Found only in libraries from placenta
formyl peptide receptor-like 1 (FPRL1) (low score)	1	M84562							
fragile X mental retardation 1 (FMR1)	1	L29074	+	+		+		+	
fragile X mental retardation, autosomal homolog 1 (FXR1)	1	U25165	+	+	+	+			
Friend leukemia virus integration 1 (FLI1)	3	M93255	+	+					
fructose-bisphosphatase 1 (FBP1)	1	D26054				+		+	
FSHD-associated repeat DNA, proximal region	1	U85056							
fucose-1-phosphate guanylyltransferase (FPGT)	1	AF017445		+	+	+			
full length insert cDNA clone ZA78A09	1	AF086122							
full length insert cDNA YP07G10	1	AF075061							
fumarate hydratase (FH)	1	U59309		+	+	+		+	
FUS (low match)	1	X99006							
FYN-binding protein (FYB-120/130) (FYB)	16	U93049		+		+			

44

GLE1 (yeast homolog)-like, RNA export mediator (GLE1L)	1	AF058922		+	+					
glia maturation factor, beta (GMFB)	1	AB001106	+	+		+			+	
glioma-associated oncogene homolog (zinc finger protein) (GLI)	1	X07384								
glioma-associated oncogene homolog (zinc finger protein) (GLI) (low score)	1	X07384								
globin, alpha 2	1	V00516								
glucocorticoid receptor (=M69104)	1	M32284								
glucocorticoid receptor (GRL)	2	U80947	+	+	+	+			+	
glucosyl phosphate isomerase (CONTAINS LARGE REPEAT)	1	L09105								
glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) (GNS)	1	Z12173	+							
glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) (GNS) (non-exact 56%)	1	Z12173								
glucose transporter-like protein-III (GLUT3)	1	M20681		+	+	+	+	+		
glucose transporter-like protein-III (GLUT3) (low match)	1	M20681								
glucosidase, alpha; acid (Pompe disease, glycogen storage disease type II) (GAA)	1	Y00839	+	+		+			+	
glucosidase, beta; acid (includes glucosylceramidase) (GBA)	1	K02920	+	+	+	+			+	
glutamate dehydrogenase 1 (GLUD1)	1	M20867		+	+	+	+	+		
glutamate-ammonia ligase (glutamine synthase) (GLUL)	12	X59834	+	+	+	+			+	
glutamate-ammonia ligase (glutamine synthase) (GLUL) (low score)	1	Y00387								
glutamate-cysteine ligase (gamma-glutamylcysteine synthetase), catalytic (72.8kD) (GLCLC)	1	M90656				+				
glutamine cyclotransferase	1	X71125		+	+					
glutamine-fructose-6-phosphate transaminase 1 (GFPT1)	1	M90516		+		+				
glutamyl-tRNA synthetase	1	X72396								
glutamyl-tRNA synthetase (QARS)	6	X76013	+	+	+	+			+	
glutamyl-prolyl-tRNA synthetase (EPRS)	1	X54326								
glutathione peroxidase 1 (GPX1)	2	M21304	+	+	+	+	+	+		
glutathione peroxidase 4 (phospholipid hydroperoxidase) (GPX4)	1	X71973	+	+	+	+			+	
glutathione S-transferase pi (GSTP1)	1	U30897		+	+	+	+	+		
glutathione S-transferase subunit 13 homolog	1	AF070657								
glyceraldehyde-3-phosphate dehydrogenase (GAPD)	12	J02642					+			

glycogenin (GYG)	1	U31525		+	+	+		+	
glycophorin C (Gerbich blood group) (GYPC)	1	X12496		+	+	+		+	
glycoprotein M6B (GPM6B)	1	U45955		+	+				
glycyl-tRNA synthetase (GARS)	1	U09587		+	+	+		+	
glyoxalase I (lactoyl glutathione lyase) (GLYI)	1	L07837	+	+	+	+		+	
golgi autoantigen, golgin subfamily a, 1 (GOLGA1)	1	U51587		+		+			
golgi autoantigen, golgin subfamily a, 2 (GOLGA2) (non-exact, 70%)	1	L06147							
golgi autoantigen, golgin subfamily a, 4 (GOLGA4)	1	U31906							
golgi autoantigen, golgin subfamily b, macrogolgin (with transmembrane signal), 1 (GOLGB1)	1	X75304		+	+	+		+	
gp25L2 protein	4	X90872							
granalcin	8	M81637			+	+	+		
granulin (GRN)	16	X62320		+	+	+	+		
granulin (GRN) (low match)	1	X62320							
Granulysin (NKG5)	5	M85276		+					
granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) (GZMA)	1	M18737		+	+	+	+		+
GRB2-related adaptor protein (GRAP)	1	U52518	I only						
Grb2-related adaptor protein 2 (GRAP2)	1	AF090456	I					+	
GRO1 oncogene (melanoma growth stimulating activity, alpha) (GRO1)	1	X54489					+		+
growth arrest and DNA-damage-inducible gene (GADD153)	1	S40706							
growth arrest-specific 7 (GAS7)	4	AB007854			+	+			
growth factor receptor-bound protein 2 (GRB2)	1	X62852	B		+			+	+
GS1 (protein of unknown function)	1	M86934			+	+	+		
GS3955	4	D87119			+	+	+		+
GTP binding protein 1 (GTPBP1)	1	U87964			+	+	+		
GTP binding protein similar to S. cerevisiae HBS1 (HBS1)	1	U87791			+	+	+		+
GTPase activating protein-like (GAPL)	1	AB011110			+	+	+		+
GTP-binding protein (low match)	1	Z49068							high fetal brain
GTP-binding protein G(K), alpha subunit (=G(I) ALPHA-3)(=GTP-binding regulatory protein Gi alpha-3 chain)	1	P08754							
Gu protein (GURDB)	2	U41387		+		+	+		+
guanine nucleotide binding protein	1								
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 (GNAI2)	4	J03004		+	+	+	+		+

guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 (GNAI3)	7	M20597	+	+	+	+	+	+	
guanine nucleotide binding protein (G protein), alpha stimulating activity polypeptide 1 (GNAS1)	2	X04409	B, I	+				+	+
guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide 2 (GNAT2)	1	Z18859							
guanine nucleotide binding protein (G protein), beta 5 (GNB5)	2	AF017656		+	+	+		+	
guanine nucleotide binding protein (G protein), beta polypeptide 1 (GNB1)	5	M36430	+	+	+	+	+	+	
guanine nucleotide binding protein (G protein), q polypeptide (GNAQ)	2	AF011496		+	+	+			
guanine nucleotide binding protein-like 1 (GNL1)	1	L25665	+	+	+	+		+	
guanine nucleotide exchange factor	1	L13857	+	+	+	+			
guanine nucleotide regulatory factor (LFP40)	1	X15610	+	+	+	+		+	
guanine nucleotide regulatory factor (LFP40)	1	U72206	+	+	+	+		+	
GUANINE NUCLEOTIDE-BINDING PROTEIN BETA SUBUNIT-LIKE PROTEIN 12.3 (P205) (RECEPTOR OF ACTIVATED PROTEIN KINASE C 1) (RACK1)	1	P25388							
GUANINE-MONOPHOSPHATE SYNTHETASE (GMPS)	1	U10860			+				
guanosine monophosphate reductase (GMPR) (non-exact, 72%)	1	M24470							
guanosine-diphosphatase like protein	1	AF016032							
guanylate binding protein 1, interferon-inducible, 67kD (GBP1)	2	M55542		+	+	+	+	+	
guanylate binding protein 2, interferon-inducible (GBP2)	6	M55543	+	+	+	+		+	
H2A histone family, member C (H2AFC)	1	Z83742							
H2A histone family, member Y (H2AY)	2	AF041483	+	+	+	+		+	
H2B histone family, member L (H2BFL)	2	Z80783	+	+	+	+	+	+	high in adrenal gland tumor
h2-calponin	1	D86059							
H-2K binding factor-2	1	L08904		+	+	+		+	
H3 histone family, member K (H3FK)	1	Z83735							
H3 histone, family 3A (H3F3A)	7	M11353	+	+	+	+		+	high in ovary
H3 histone, family 3B (H3.3B) (H3F3B)	15	Z48950	+	+	+	+		+	high in endothelial cells
hbc647	1	U68494		+	+	+	+		
heat shock 27kD protein 1 (HSPB1)	1	U12404		+	+		+	+	
heat shock 40kD protein 1 (HSPF1)	4	D85429	+	+	+	+	+	+	high in testis
heat shock 60kD protein 1 (chaperonin) (HSPD1)	3	M22382	+	+	+	+	+	+	
heat shock 70kD protein 1 (HSPA1A)	7	M59828	+	+	+	+	+	+	high in activated T cells

heat shock 70kD protein 5 (glucose-regulated protein, 78kD) (HSPA5)	13	X87949		+	+		+		
heat shock 70kD protein 6 (HSP70B) (HSPA6)	4	X51757	+	+	+				
heat shock 70kD protein 9B (mortalin-2) (HSPA9B)	2	L15189		+	+	+	+	+	
HEAT SHOCK COGNATE 71 KD PROTEIN	1	P11142							
heat shock factor binding protein 1 (HSBP1)	2	AF068754							
heat shock protein 90	13	M27024	+	+	+	+	+	+	
heat shock protein, DNAJ-like 2 (HSJ2)	1	D13388		+	+		+	+	high in many libraries
Hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 (HERC1)	1	U50078		+	+	+			
hect domain and RLD 2 (HERC2)	1	AB002391	+	+	+	+		+	
helicase-like protein (HLP)	1	X98378	+	+		+		+	
helix-loop-helix protein HE47 (E2A)	1	M65214						+	
hematopoietic cell-specific Lyn substrate 1 (HCLS1)	18	X16663	+		+	+		+	
heme oxygenase (decycling) 1 (HMOX1)	1	X06985		+		+	+	+	
HEMOGLOBIN ALPHA CHAIN	1	P19015							
hemoglobin beta (beta globin)	5	AF117710							
hemoglobin, alpha 1 (HBA1)	301	V00491			+		+	+	
hemoglobin, alpha 1 (HBA1) (low match)	1	V00491							
hemoglobin, alpha 1 (low match)	1	V00493							
hemoglobin, alpha 1 (non-exact, 76%)	1	J00153							
hemoglobin, alpha 1 (non-exact, 82%)	1	V00493							
hemoglobin, beta (HBB)	129	V00497	+	+	+	+	+	+	high in many libraries
hemoglobin, beta (HBB) (low match)	1	V00497							
hemoglobin, beta (HBB) (low match)	1	L48220							
hemokine (C-X-C motif), receptor 4 (fusin) (CXCR4)	1	D10924	+	+	+	+		+	
hemopoietic cell kinase (HCK)	5	M16591				+		+	
hepatitis C-associated microtubular aggregate protein p44	2	D28908							
hepatoma-derived growth factor	1	D16431	+	+	+	+		+	
Hermansky-Pudlak syndrome (HPS)	2	U65676							
HERV-E integrase (non-exact 76%aa)	1	AF026246							
heterogeneous nuclear protein similar to rat helix destabilizing protein (FBRNP)	2	S63912		+	+	+		+	
heterogeneous nuclear ribonucleoprotein (C1/C2) (HNRPC)	4	M16342							
heterogeneous nuclear ribonucleoprotein A/B (HNRPAB)	1	M65028	+	+	+	+	+	+	

heterogeneous nuclear ribonucleoprotein A1 (HNRPA1)	20	X12671	+	+	+	+	+	+	+	High in alveolar rhabdomyosarcoma
heterogeneous nuclear ribonucleoprotein A2/B1 (HNRPA2B1)	3	M29064	+	+	+	+	+	+	+	High in activated T cell, fetal brain
heterogeneous nuclear ribonucleoprotein D (hnRNP D)	2	D55673	+	+	+	+	+	+	+	
heterogeneous nuclear ribonucleoprotein D-like (HNRPD)	5	D89092	+	+	+	+	+	+	+	
heterogeneous nuclear ribonucleoprotein F (HNRPF)	1	L28010	+	+	+	+			+	
heterogeneous nuclear ribonucleoprotein F (HNRPF) (83%)	1	L28010								
heterogeneous nuclear ribonucleoprotein G (HNRPG)	2	Z23064		+	+	+			+	
heterogeneous nuclear ribonucleoprotein H (HNRPH) (FTP-3)	3	P55795								
heterogeneous nuclear ribonucleoprotein H (HNRPH) (low match)	1	P31943								
heterogeneous nuclear ribonucleoprotein H1 (H) (HNRPH1)	2	L22009	+	+	+	+			+	
heterogeneous nuclear ribonucleoprotein K (HNRPK)	21	S74678	+	+	+	+	+	+	+	
heterogeneous nuclear ribonucleoprotein R (HNRPR)	1	AF000364		+	+	+	+	+	+	
heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) (HNRPU)	3	X65488	+	+	+	+	+	+	+	
hexokinase 1 (HK1)	2	X66957		+	+	+			+	
hexokinase 2 (HK2)	3	Z46376	+	+	+	+			+	
hexokinase 3 (HK3)	2	U51333								
hexosaminidase A (alpha polypeptide) (HEXA)	1	S62047								
HGMP071 gene for olfactory receptor	2	U76377								
High density lipoprotein binding protein (HDLBP)	2	M64098	+	+	+	+	+	+	+	
high-mobility group (nonhistone chromosomal) protein 1 (HMG1)	5	X12597	+	+	+	+	+	+	+	
high-mobility group (nonhistone chromosomal) protein 1 (HMG1) (non-exact 60%)	1	D63874								
High-mobility group (nonhistone chromosomal) protein 17 (HMG17)	2	M12623	+	+	+	+			+	
high-mobility group (nonhistone chromosomal) protein 2 (HMG2)	2	M83665	+	+	+	+	+	+	+	
high-mobility group (nonhistone chromosomal) protein isoforms I and Y	2	L17131	+	+	+			+	+	
high-risk human papilloma viruses E6 oncoproteins targeted protein E6TP1 beta (=AB007900 KIAA0440)	1	AF090990.1								
histidine ammonia-lyase (HAL)	1	D16626					+, only			

histidyl-tRNA synthetase (HARS)	2	Z11518	+	+	+	+	+	+	
histocompatibility antigen (HLA-Cw3), class I	1	U31372							
histone deacetylase 1 (HDAC)	4	U50079	+	+	+	+		+	
histone deacetylase 1 (HDAC1)	2	D50405	+	+	+	+		+	
histone deacetylase 5 (NY-CO-8)	1	AF039691		+	+				
HK2 gene for hexokinase II	1	Z46362							
HL9 monocyte inhibitory receptor precursor	2	U91928				+			
HLA class I heavy chain (HLA-Cw*1701)	1								
HLA class I locus C heavy chain	1	X58536							
HLA class II SB 4-beta chain	1	X03022							
HLA class III region containing NOTCH4 gene	1	U89335	+	+	+	+		+	
HLA-A	1	Z72423							
HLA-A	2	AJ006020							
HLA-A*7402	1	AJ223060							
HLA-A11	1	U02934							
HLA-B	2	X75953							
HLA-B	1	X83401							
HLA-B	1	X78426							
HLA-B associated transcript-1 (D6S81E)	1	Z37166	+	+	+	+	+	+	
HLA-B associated transcript-2 (D6S51E)	2	M33509	+	+	+	+			
HLA-B*1529	4	D44501							
HLA-Bw72 antigen	119	L09736	+	+	+	+	+	+	
HLA-C gene (HLA-Cw*0701 allele)	1	D83957							high in many libraries
HLA-Cw*0701	9	Z46810							
HLA-Cw*0801	1	D64151							
HLA-Cw*1203	1	D64146							
HLA-DC classII histocompatibility antigens alpha-chain (=K01160)	2	X00370							
HLA-DR alpha-chain	17	M60333	+	+	+	+	+	+	high in spleen
HLA-F (leukocyte antigen F)	3	X17093			+	+		+	
HMG box containing protein 1	3	AF019214							
hMLH1 (=U83845)	1	AB017806.1							
Hmob33	3	Y14155							
HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1 (HRMT1L1)	2	U80213	+	+	+	+		+	
hnRNP C1/C2	2	D28382							
homeobox (=X58250 Mouse homeo box protein, put. transcription factor involved in embryogenesis and hematopoiesis)	1	M60721							
homeobox protein (HLX1) (=M60721)	1	U14326							
homeodomain-interacting protein kinase 3 (HIPK3)	1	AF004849	+		+	+		+	
homolog of Drosophila past (PAST)	2	AF001434	+	+	+	+		+	
homolog of yeast (S. cerevisiae) ufd2 (UFD2)	3	D50916		+	+	+		+	

HPV16 E1 protein binding protein	1	U96131		+	+			+	
HRHFB2157	1	AB015344		+	+			+	
HRX-like protein (=AF010403 ALR)	1	Y08836							
hsc70 gene for 71 kd heat shock cognate protein	3	Y00371							
HSPC012	1	AF077036.1							
HSPC021	1	AF077207.1							
HsPex13p	1	U71374							
htra2-beta-2	1	U87836	+	+	+	+		+	
HU-K4	1	U60644							
hunc18b2	1	U63533		+	+	+		+	
HUNK1	1	Y12059	+	+		+	+	+	
huntingtin-interacting protein HYP/AFBP11 (HYPA)	1	AF049528							
hVps41p (HVPS41)	1	U87309							
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit (HADHA)	1	U04627		+	+			+	
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit (HADHB)	1	D16481	+	+	+	+		+	
hydroxysteroid (17-beta) dehydrogenase 1 (HSD17B1)	1	U34879		+				+	
hypothetical protein	1								
hypothetical protein (AL008729) (dJ257A7.2)	1								
hypothetical protein (CIT987SK_2A8_1 chromosome 8)	1	U96629							
hypothetical protein (clone 24640)	1	AF055004							
hypothetical protein (clone ICRFp507G2490)	1	Z70222							
hypothetical protein (dJ1042K10.4) (non-exact 76%)	1	AL022238							
hypothetical protein (dJ465N24.1 similar to predicted yeast and worm proteins)	2	AL031432							
hypothetical protein (dJ487J7.1.1)	2	AL008730							
hypothetical protein (dJ753P9.2)	2	AL023653							
hypothetical protein (DKFZp586I111)	1	AL050131.1							
hypothetical protein (J257A7.2)	1	AL008729							
hypothetical protein (K1AA0440) (=AF026504 R.norvegicus SPA-1 like protein)	1	AB007900							
hypothetical protein (L1H 3' region)	1								
hypothetical protein (S164)	1	P49756							

52

immunoglobulin gamma heavy chain variable region (=X61011)	1	Z66542								
immunoglobulin heavy chain (VI-3B)	1	X62109								
immunoglobulin heavy chain J region	1	X86356								
immunoglobulin heavy chain J region, B1 haplotype	2	X86355								
immunoglobulin heavy chain variable region (IGH) (clone 21u-48)	1	AF062126								
immunoglobulin heavy chain variable region (IGH) (clone 23u-1)	1	AF062212								
immunoglobulin heavy chain variable region V1-18 (IGHV@) (=X60503)	2	M99641								
immunoglobulin heavy chain variable region V3-43 (IGHV@)	2	M99672								
immunoglobulin heavy chain variable region V3-7 (IGHV@)	3	M99649								
immunoglobulin IgH heavy chain Fd fragment	1	U07986								
immunoglobulin kappa light chain	1	X58081								
immunoglobulin kappa light chain V-segment A27	1	X12686								
immunoglobulin light chain	1	D86990								
immunoglobulin light chain (low match)	1	D86996								
immunoglobulin light chain variable region (lambda IIIb subgroup) from IgM rheumatoid factor	1	L29157								
immunoglobulin M heavy chain V region=anti-lipid A antibody	1	S50735								
immunoglobulin mu (IGHM)	9	X57086	+	+		+		+		
immunoglobulin mu binding protein 2 (IGHMBP2)	1	L24544	+	+				+		
immunoglobulin superfamily, member 2 (IGSF2)	1	Z33642								
immunoglobulin VH mRNA (487 bp) (=M99652 immunoglobulin heavy chain variable region V3-11 (IGHV@))	1	X61013								
imogen 38 (IMOGEN38)	1	Z68747		+	+	+			+	
IMP (inosine monophosphate) dehydrogenase 1 (IMPDH1)	1	J05272	+	+	+	+				
IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2)	2	L39210	+	+	+	+			+	
inc finger protein 151 (pHZ-67) (ZNF151)	1	Y09723	+	+	+	+			+	
inc finger protein, C2H2, rapidly turned over (ZNF20)	1	AF011573		+	+					
inducible poly(A)-binding protein (IPABP)	1	U33818	+	+	+	+			+	
inducible poly(A)-binding protein (IPABP) (low match)	1	U33818								

inducible protein (Hs.80313)	2	L47738	+	+	+	+	+	+	+
inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2)	4	M97796	+	+	+	+	+	+	+
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein (IKBKAP)	2	AF044195							
inositol 1,3,4-trisphosphate 5/6-kinase	1	U51336	+	+	+	+	+	+	+
inositol 1,4,5 trisphosphate receptor type 1 (ITPR1)	1	U23850		+	+	+			
inositol 1,4,5-trisphosphate 3-kinase B (ITPKB)	2	X57206	B	+	+		+		
inositol monophosphatase	1	S38980							
inositol polyphosphate-5-phosphatase, 145kD (INPP5D)	2	U84400	+	+	+	+		+	
Ins(1,3,4,5)P4-binding protein	1	X89399		+				+	
insulin-like growth factor 2 receptor (IGF2R)	5	Y00285	+	+	+	+		+	
integral membrane protein 1 (ITM1)	1	L38961			+	+		+	
integral membrane protein 2C (ITM2C)	1	AF038953			+		+	+	
integral membrane protein Tmp21-l (p23)	3	U61734	+	+	+	+	+	+	
integrin beta 4 binding protein (ITGB4BP)	2	AF047433			+			+	
integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41B) (ITGA2B)	3	M34480		+			+		
integrin, alpha 5 (fibronectin receptor, alpha polypeptide) (ITGA5)	4	X06256	+	+	+		+	+	
integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) (ITGAL)	6	Y00796							
integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) (ITGAM)	1	M18044							
integrin, alpha X (antigen CD11C (p150), alpha polypeptide) (ITGAX)	1	M81695	+	+				+	
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2 MSK12) (ITGB1)	2	X07979							
integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit) (ITGB2)	32	M15395	+	+		+		+	
integrin, beta 7 (ITGB7)	1	M68892	+						
Integrin-linked kinase (ILK)	1	U40282	+	+	+	+			
intercellular adhesion molecule 1 (CD54), human rhinovirus receptor (ICAM1)	1	J03132	+			+	+	+	
intercellular adhesion molecule 2 (ICAM2)	1	X15606	+	+	+	+		+	

intercellular adhesion molecule 3 (ICAM3)	6	X69819	+							+
intercellular adhesion molecule 4, Landsteiner-Wiener blood group (ICAM4)	1	L27670								+
Interferon consensus sequence binding protein 1 (ICSBP1)	1	M91196	W, T lymphoma							
Interferon consensus sequence binding protein 1 (ICSBP1) (low match)	1	M91196								
interferon regulatory factor 2 (IRF2)	4	X15949	+	+	+	+				
interferon regulatory factor1 (IRF1)	4	L05072	+	+	+	+			+	
interferon regulatory factor5 (IRF5)	1	U51127	+	+		+				
interferon, gamma-inducible protein 16 (IFI16)	2	M63838	+	+	+	+			+	
interferon, gamma-inducible protein 30 (IFI30)	9	J03909	+	+		+			+	
INTERFERON-INDUCED GUANYLATE-BINDING PROTEIN 1 (GUANINE NUCLEOTIDE-BINDING PROTEIN 1) (non-exact 62%)	1	P32455								
interferon-induced protein 17 (IFI17)	3	X84958		+	+	+			+	
interferon-induced protein 54 (IFI54)	5	M14660								
interferon-inducible (1-8D)	5	X57351	T		+			+	+	
interferon-inducible (1-8U)	1	X57352			+			+	+	
interferon-related developmental regulator 1 (IFRD1)	5	Y10313		+	+				+	
interferon-stimulated transcription factor 3, gamma (48kD) (ISGF3G)	2	M87503		+		+			+	
interleukin 1 receptor, type II (IL1R2)	1	U64094				+				
Interleukin 10 receptor, beta (I.10RB)	1	U08988	T activated		+				+	
interleukin 12 receptor, beta 1 (IL12RB1)	2	U03187	+							only found in T cell
interleukin 13 receptor, alpha 1 (IL13RA1)	2	Y09328		+	+	+	+	+		
interleukin 16 (lymphocyte chemoattractant factor) (IL16)	6	U82972		+						
interleukin 18 receptor 1 (IL18R1)	1	U43672								
interleukin 2 receptor, beta (IL2RB)	9	M26062								
interleukin 2 receptor, gamma (severe combined immunodeficiency) (IL2RG)	6	D11086	+		+				+	
interleukin 4 receptor (IL4R)	3	X52425	+	+		+			+	
interleukin 6 receptor (IL6R)	5	X12830		+					+	
interleukin 6 signal transducer (gp130, oncostatin M receptor) (IL6ST)	1	M57230								
interleukin 7 receptor (IL7R)	14	M29696	+						+	
interleukin 7 receptor (IL7R) (low match)	1	AF043123								
interleukin 8 (IL8)	8	Y00787	+		+		+			High in activated T cells, bone and pancreatic islets

interleukin 8 receptor alpha (IL8RA)	11	L19591									
interleukin 8 receptor, beta (IL8RB)	14	M94582									
interleukin enhancer binding factor 2, 45kD (ILF2)	3	U10323	+	+	+	+	+	+	+	high in uterus	
interleukin enhancer binding factor 3, 90kD (ILF3)	2	U10324									
interleukin-1 receptor-associated kinase 1 (IRAK1)	2	L76191		+	+	+			+		
interleukin-1 receptor-associated kinase 1 (low match)	1	U52112									
interleukin-10 receptor, alpha (IL10RA)	5	U00672	+	+	+	+					
interleukin-11 receptor, alpha (IL11RA)	7	Z38102		+	+						
INTERLEUKIN-14 PRECURSOR (IL-14) (HIGH MOLECULAR WEIGHT B-CELL GROWTH FACTOR) (HMW-BCGF) (non-exact 46%)	1	P40222									
intestinal carboxylesterase; liver carboxylesterase-2 (ICE)	1	U60553		+					+		
inversin protein (non-exact 52%)	1	AF084367									
IQ motif containing GTPase activating protein 1 (IQGAP1)	6	L33075									
IQ motif containing GTPase activating protein 2 (IQGAP2)	1	U51903		+			+				
isocitrate dehydrogenase 1 (NADP+), soluble (IDH1)	1	AF020038	+	+	+	+	+	+	+		
isocitrate dehydrogenase 2 (NADP+), mitochondrial (IDH2)	2	X69433	+	+	+	+	+	+	+		
isocitrate dehydrogenase 3 (NAD+) alpha (IDH3A)	2	U07681			+						
isocitrate dehydrogenase 3 (NAD+) gamma (IDH3G)	1	Z68907	+	+	+	+			+		
isolate Aus3 cytochrome b (CYTB)	1	AF042516									
isolate TzCCR5-179 CCR5 receptor (CCR5)	1	AF011524									
isopentenyl-diphosphate delta isomerase (IDI1)	5	X17025	+	+	+	+			+		
Janus kinase 1 (a protein tyrosine kinase) (JAK1)	4	M64174	+	+	+	+			+		
Janus kinase 2 (a protein tyrosine kinase) (JAK2)	1	AF005216									
JK-recombination signal binding protein (RBPJK)	2	L07876									
JM1 protein	1	AJ005890		+			+				
jumonji (mouse) homolog (JMJ)	1	U57592		+	+	+			+		
jun D proto-oncogene (JUND)	1	X51346	+	+	+	+			+		
jun dimerization protein	1	AF111167									
junction plakoglobin (JUP)	1	M23410		+	+	+			+	only found in germ	

kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4)) (KAI1)	1	U20770	+	+	+	+	+	+	
karyophenn (importin) beta 1 (KPNB1)	2	L39793	+	+	+	+	+	+	
karyophenn (importin) beta 2 (KPNB2)	1	U72395	+	+	+	+			
karyophenn alpha 1 (importin alpha 5) (KPNA1)	1	S75295	+	+	+		+		
karyophenn alpha 2 (RAG cohort 1, importin alpha 1) (DPNA2)	1	U09559							
karyophenn alpha 3 (importin alpha 4) (KPNA3)	1	D89618		+			+		
karyophenn alpha 4 (KPNA4)	1	M17887		+	+				
Kalanin (80 kDa) (KAT)	1	AF052432		+	+	+		+	
KE03 protein	2	AF064604							
Kelch-like ECH-associated protein 1 (KIAA0132) (66%aa)	1	D50922							
Keratin 8 (KRT8)	1	X74929		+	+	+	+	+	
ketoheokinase (fructokinase) (KHK)	1	X78678		+		+	+		
KIAA0001 (KIAA0001) (72% aa)	1	Q15391							
KIAA0001 (KIAA0001) (76% aa)	1	Q15391							
KIAA0001 (KIAA0001) (non-exact 72%)	1	Q15391							
KIAA0002 (KIAA0002)	5	D13627		+	+	+		+	
KIAA0005 (KIAA0005)	4	D13630		+	+	+		+	
KIAA0010 (KIAA0010)	1	D13635		+				+	
KIAA0016 (KIAA0016)	1	D13641	+	+	+	+		+	
KIAA0017 (KIAA0017)	2	D87686							
KIAA0022 (KIAA0022)	2	D14664		+	+	+			
KIAA0023 (KIAA0023)	1	D14689		+					
KIAA0024 (KIAA0024)	1	D14694	+	+	+	+		+	
KIAA0025 (KIAA0025)	1	D14695		+	+	+	+	+	
KIAA0026 (KIAA0026)	2	D14812		+	+	+		+	
KIAA0027	1	D25217		+					
KIAA0032 (KIAA0032)	2	D25215		+	+	+			
KIAA0040 (KIAA0040)	1	D25539	+	+	+	+		+	
KIAA0050 (KIAA0050)	4	D26069							
KIAA0053 (KIAA0053)	17	D29642	+		+	+			
KIAA0057 (KIAA0057)	1	D31762	+	+	+	+	+	+	high in fetal lung
KIAA0058 (KIAA0058)	11	D31767	+		+	+		+	
KIAA0063 (KIAA0063)	3	D31884	+	+	+	+		+	
KIAA0064 (KIAA0064)	1	D31764	+	+	+	+		+	
KIAA0066	1	D31886	+	+	+	+		+	
KIAA0068	1	D38549		+	+	+	+	+	
KIAA0073	3	D38552		+	+	+		+	
KIAA0081	2	D42039		+		+		+	
KIAA0084	2	D42043	+	+	+	+		+	
KIAA0085	26	U30498	+	+	+	+	+	+	
KIAA0088	3	D42041	+	+	+	+	+	+	
KIAA0090	2	D42044	+	+	+	+	+	+	
KIAA0092 (KIAA0092)	1	D42054		+	+	+		+	

KIAA0094	3	D42084				+	+				
KIAA0095 (KIAA0095)	1	D42085									
KIAA0096	1	D43636	+		+	+	+				+
KIAA0097 (KIAA0097)	1	X92474	1		+	+			+		
KIAA0099 (KIAA0099)	3	D43951	+		+	+	+	+	+	+	
KIAA0102 (KIAA0102)	2	D14658			+		+	+	+		
KIAA0105	1	D14661	B		+				+	+	
KIAA0120	2	P37802									
KIAA0120 (non-exact, 65%)	1	M83106									
KIAA0121 (KIAA0121)	1	D50911	+		+	+	+			+	
KIAA0123	1	D21064			+	+	+			+	
KIAA0128	1	D50918	+		+	+	+			+	
KIAA0129 (KIAA0129)	1	D50919	+		+	+	+				
KIAA0130 (KIAA0130)	1	AF055995			+	+	+				
KIAA0136	2	D50926									
KIAA0137 (KIAA0137)	1	AB004885			+	+	+			+	
KIAA0140 (KIAA0140)	1	D50930	+		+		+			+	
KIAA0141 (KIAA0141)	3	D50931									
KIAA0144 (KIAA0144)	3	D63478	+		+	+	+			+	
KIAA0144 (KIAA0144) (low match)	1	D63478									
KIAA0144 (non-exact 61%)	1	Q14157									
KIAA0144 (non-exact 65%)	1	Q14157									
KIAA0146	2	D63480			+	+	+			+	
KIAA0148 (KIAA0148)	1	D63482			+					+	
KIAA0154	2	D63876	+		+	+	+			+	
KIAA0156	1	D63879			+	+	+			+	
KIAA0160	2	D63881									
KIAA0161 (KIAA0161)	1	D79983	+		+		+				
KIAA0164 (KIAA0164)	3	D79986									
KIAA0167 (KIAA0167)	1	D79989			+						
KIAA0168 (KIAA0168)	3	D79990			+	+	+			+	
KIAA0169	3	D79991									
KIAA0171 (KIAA0171)	3	D79993			+	+	+			+	
KIAA0174 (KIAA0174)	7	D79996	+		+	+	+			+	
KIAA0179	2	D80001			+	+	+			+	
KIAA0181	1	D80003			+	+	+			+	
KIAA0183	4	D80005	+		+	+	+	+	+	+	
KIAA0184	1	D80006	+		+	+	+			+	
KIAA0191 (72% aa)	1	D83776									
KIAA0191 (non-exact 77%)	1										
KIAA0193 (KIAA0193)	1	D83777	+		+	+	+			+	
KIAA0200 (KIAA0200)	1	D83785			+	+	+			+	
KIAA0210 (KIAA0210)	3	D86965									
KIAA0217	2	D86971	+		+	+	+			+	
KIAA0219	2	U77700			+	+	+			+	
KIAA0222 (KIAA0222)	1	D86975									
KIAA0223	2	D86976									
KIAA0229	1	D86982	+		+						
KIAA0232 (KIAA0232)	1	D86985			+	+	+			+	
KIAA0233 (KIAA0233)	1	D87071									
KIAA0235	2	D87078	+		+	+	+				
KIAA0239	1	D87076	+		+						

KIAA0239 (non-exact 80%)	1	D87076							
KIAA0240	1	D87077							
KIAA0242	4	D87684	+	+	+	+	+	+	
KIAA0248	2	D87435		+	+	+		+	
KIAA0249 (KIAA0249)	3	D87436	+	+	+	+		+	
KIAA0253	5	D87442	+	+	+	+	+	+	
KIAA0254 (KIAA0254)	1	D87443		+	+	+			
KIAA0255(KIAA0255)	4	D87444		+	+	+		+	
KIAA0262 (KIAA0262)	3	D87451	+	+	+	+		+	
KIAA0263 (KIAA0263)	1	D87452	+	+	+	+		+	
KIAA0264	3	D87453		+	+	+		+	
KIAA0268	1	D87742	+	+		+		+	
KIAA0269	1	Q92558							
KIAA0275 (KIAA0275)	13	D87465	+	+		+		+	
KIAA0304 (KIAA0304)	2	AB002302	+	+	+	+	+	+	
KIAA0308	2	AB002306		+	+			+	
KIAA0310 (KIAA0310)	1	AB002308		+	+	+		+	
KIAA0314 (=U96635 M.musculus ubiquitin protein ligase Nedd-4)	3	AB002312							
KIAA0315 (KIAA0315)	4	AB002313		+	+	+	+	+	
KIAA0325 (=L08505 R.norvegicus cytoplasmic dynein heavy chain (MAP 1C))	2	AB002323							
KIAA0329 (KIAA0329)	1	AB002327		+	+	+		+	
KIAA0330	1	AB002328	+	+	+			+	
KIAA0332	1	AB002330		+	+	+		+	
KIAA0333	2	AB002331		+	+	+	+	+	
KIAA0336 (KIAA0336)	3	AB002334	+	+	+	+		+	
KIAA0336 (KIAA0336) (low match)	1	AB002334							
KIAA0342 (KIAA0342)	1	AB002340		+	+			+	
KIAA0344 (KIAA0344)	2	AB002342				+		+	
KIAA0354 (KIAA0354)	1	AB002352	+	+	+	+		+	
KIAA0365 (KIAA0365)	3	AB002363	+	+	+	+	+	+	
KIAA0370	6	AB002368		+	+	+	+	+	
KIAA0372 (KIAA0372)	1	AB002370							
KIAA0373 (KIAA0373)	1	AB002371		+		+			
KIAA0375 (KIAA0375)	1	AB002373		+		+			
KIAA0377 (KIAA0377)	1	AB002375		+		+	+		
KIAA0379	1	AB002377				+			
KIAA0379 (non-exact, 65%)	1	AB002377							
KIAA0380 (KIAA0380)	1	AB002378	+	+		+		+	
KIAA0380 (KIAA0380) (60%aa)	1	AB002378							
KIAA0382 (KIAA0382)	2	AB002380		+	+	+		+	
KIAA0383	1	AB002381							
KIAA0386 (KIAA0386)	5	AB002384							
KIAA0392	1	AB002390							
KIAA0397 (KIAA0397)	4	AB007857		+	+	+	+	+	
KIAA0403	3	AB007863							
KIAA0404	1	AB007864		+		+			
KIAA0409	1	AB007869		+		+			
KIAA0421	1	AB007881	+	+	+			+	
KIAA0424 (non-exact 82%)	1	AB007884							

KIAA0428 (KIAA0428)	9	Y13829									
KIAA0429 (KIAA0429)	2	AB007889	+	+	+	+				+	
KIAA0430 (KIAA0430)	2	AB007890									
KIAA0432 (KIAA0432)	2	U86753	1	+	+						only in ovary
KIAA0435 (KIAA0435)	1	AB007895									
KIAA0438 (KIAA0438)	1	AB007898									
KIAA0447 (KIAA0447)	3	AB007916	+	+	+	+				+	
KIAA0449	1	AB007918		+	+	+				+	
KIAA0456	1	AB007925								+	
KIAA0458 (KIAA0458)	1	AB007927			+	+	+			+	
KIAA0462	1	AB007931									
KIAA0465	1	AB007934	+	+	+	+				+	
KIAA0476 (KIAA0476)	1	AB007945		+	+	+	+	+	+		
KIAA0489	1	AB007958		+	+	+					
KIAA0494 (KIAA0494)	1	AB007963									
KIAA0515	1	AB011087	+	+	+	+				+	
KIAA0521	3	AB011093	+	+						+	
KIAA0525	1	AB011097		+							
KIAA0530	1	AB011102									
KIAA0532	1	AB011104		+	+	+	+				
KIAA0537 (KIAA0537)	1	AB011109	+	+	+	+				+	
KIAA0540	1	AB011112	+	+	+	+					
KIAA0543	1	AB011115								+	
KIAA0544	1	AB011116								+	
KIAA0549	2	AB011121		+	+	+				+	
KIAA0551	2	AB011123		+	+	+				+	
KIAA0554	8	AB011126		+	+	+				+	
KIAA0561	1	AB011133		+		+				+	
KIAA0562 (KIAA0562)	1	AB011134									
KIAA0563 (KIAA0563)	1	AB011135									
KIAA0569 (KIAA0569)	2	AB011141									
KIAA0571 (KIAA0571)	2	AB011143		+	+	+				+	
KIAA0573	1	AB011145		+	+	+					
KIAA0576	1	AB011148		+		+				+	
KIAA0580	1	AB011152									
KIAA0584	1	AB011156									
KIAA0592	3	AB011164	+	+							
KIAA0596	1	AB011168		+	+					+	
KIAA0598 (KIAA0598)	1	AB011170		+	+	+					
KIAA0608	1	AB011180									
KIAA0614	2	AB014514	+	+	+	+				+	
KIAA0615 (KIAA0615)	1	AB014515									
KIAA0621	1	AB014521									
KIAA0648	1	AB014548		+	+					+	
KIAA0652 (KIAA0652)	1	AB014552	+	+	+	+				+	
KIAA0668	1	AB014568									
KIAA0669	1	AB014569									
KIAA0671 (KIAA0671)	1	AB014571			+	+				+	
KIAA0675 (KIAA0675)	1	AB014575		+		+	+				
KIAA0676	1	AB014576		+	+	+				+	
KIAA0677 (KIAA0677)	2	AB014577		+	+	+	+	+	+		
KIAA0678	1	AB014578	+	+	+	+				+	
KIAA0679	6	AB014579		+	+	+				+	

KIAA0680 (KIAA0680)	1	AB014580							
KIAA0692	1	AB014592	+	+	+	+		+	
KIAA0697	1	AB014597							
KIAA0699	1	AB014599	+	+	+	+		+	
KIAA0700	1	AB014600		+	+	+		+	
KIAA0737 (KIAA0737)	3	AF014837	+	+	+	+		+	
KIAA0748 (KIAA0748)	2	AB018291		+					
KIAA0763 (KIAA0763)	2	AB018306	+	+	+	+		+	
KIAA0769 (KIAA0769)	2	AB018312		+	+	+		+	
KIAA0782	1	AB018325	+	+		+			high in BPH stroma
KIAA0796	1	AB018339		+	+	+		+	
KIAA0798 (KIAA0798)	1	AB018341							
KIAA0823	1	AB020630							
KIAA0854	1	AB020661	+	+	+	+		+	
KIAA0856	1	AB020663		+	+	+		+	
KIAA0860	1	AB020667		+		+			
KIAA0862	1	AF054828		+	+	+			
KIAA0871 (non-exact 88%)	1	AB020678							
KIAA0873	1	AB020680		+	+	+		+	
KIAA0892	1	AB020699	+	+	+	+		+	
KIAA0906	1	AB020713	+	+	+	+		+	
KIAA0991	1	AB023208.1							
killer cell lectin-like receptor subfamily B, member 1 (KLRB1)	1	U11276			+	+		+	
killer cell lectin-like receptor subfamily C, member 4 (KLRC4)	1	U96846							
kinectin 1 (kinesin receptor) (KTN1)	1	D13629							
kinesin family member 5B (KIF5B)	2	X65873		+	+	+			
kinesin-like DNA binding protein	1	AB017430	+	+	+	+		+	
Krueppel-related DNA-binding protein (TF6) (low match)	1	M61869							
Kruppel related gene (clone pHKR1RS)	1	M20675							
Kruppel-like zinc finger protein Zf9	3	U51869	+	+	+	+	+	+	
Kruppel-like zinc finger protein Zf9 (non-exact 76%)	1	U44975		+	+		+	+	
Kruppel-type zinc finger protein, ZK1	1	AB011414.1							
L apoferritin	3	X03742							
lactate dehydrogenase A (LDHA)	3	X02152		+	+	+	+	+	
lactate dehydrogenase A (LDHA) (non-exact, 81%)	1	X02152							
lactate dehydrogenase B (LDHB)	6	X13794	+	+	+	+	+	+	high in fetal lung fibroblast
lactotransferrin (LTF)	1	U07643	+			+		+	high in bone marrow
laminin binding protein (low score)	1	D28372							
laminin receptor 1 (67KD); Ribosomal protein SA (LAMR1)	20	X15005	+	+	+	+	+	+	high in many libraries
laminin receptor homolog (3' region)	1	S35960							
laminin, gamma 1 (formerly LAMB2) (LAMC1)	2	J03202	+	+	+			+	

latent transforming growth factor beta binding protein 1 (LTBP1)	2	M34057		+	+	+		+	
LAZ3/BCL6 (=Z79582:D28522/4)	1	Z79581							
LDLC	2	Z34975	+	+	+	+		+	
lecithin-cholesterol acyltransferase (LCAT) (non-exact, 66%)	1	M17959							
lectin, galactoside-binding, soluble, 2 (galectin 2) (LGALS2)	1	M87842				+			
lectin, galactoside-binding, soluble, 3 binding protein (galectin 6 binding protein) (LGALS3BP)	1	L13210	+	+	+	+		+	
leucine rich repeat (in FLII) interacting protein 1 (LRRFIP1)	5	AJ223075	+	+	+	+	+	+	
leucocyte immunoglobulin-like receptor-5 (LIR-5)	2	AF072099				+			
leucocyte immunoglobulin-like receptor-6a (LIR-6)	7	AF025530							
leucocyte immunoglobulin-like receptor-7 (LIR-7)	2	U82275		+					only found in CNS
leukemia virus receptor 1 (GLVR1)	1	L20859	+	+	+	+		+	
leukocyte adhesion protein p150.95 alpha subunit	1	M29484							
leukocyte antigen, HLA-A2	3	Y13267							
leukocyte immunoglobulin-like receptor (MIR-10)	3	AF025528		+					
leukocyte tyrosine kinase (LTK)	1	X60702	+						found only in blood
leukocyte-associated Ig-like receptor 1 (LIAR1)	3	AF013249				+			
leukotriene A4 hydrolase (LTA4H)	6	J03459	+	+	+	+	+	+	
leupaxin (LDPL)	2	AF062075	+			+		+	
ligase I, DNA, ATP-dependent (LIG1)	1	M36067	B, I	+	+		+	+	
LIM and SH3 protein 1 (LASP1)	2	X82456	+	+	+	+	+	+	
LIM domain kinase 2 (LIMK2)	2	AC002073	+	+	+	+		+	
line-1 protein	1								
Line-1 repeat mRNA with 2 open reading frames	1	U93566	+	+	+	+	+	+	
Line-1 repeat with 2 open reading frames	1	M22332	+	+	+	+	+	+	high in gastric tumor
LINE-1 REVERSE TRANSCRIPTASE HOMOLOG	1	P08547							
lipase A, lysosomal acid, cholesterol esterase (Volman disease) (LIPA)	4	X76488	+	+	+	+		+	
lipase, hormone-sensitive (LIPE)	1	L11706	+	+				+	
LMP7	1	L11045							
Lon protease-like protein (LONP)	2	X74215	+	+	+	+		+	
low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) (LRP1)	2	AF058414					+		only in liver
low density lipoprotein-related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1) (LRPAP1)	1	M63959		+	+		+	+	

low density lipoprotein-related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1) (LRPAP1) (non-exact, 75%)	1	M63959								
low-affinity Fc-gamma receptor IIA	1	L08107								
LPS-induced TNF-alpha factor (PIG7)	9	AF010312	+	+	+	+	+	+		
Lst-1	1	U00921	+	+	+	+			+	
L-type amino acid transporter subunit LAT1	1	AF104032								
lung resistance-related protein (LRP)	1	X79882	+	+	+	+			+	
Lymphocyte antigen 75 (LY75)	1	AF011333	B							
lymphocyte antigen 9 (LY9)	2	L42621								
lymphocyte antigen HLA-B*4402 and HLA-B*5101	2	L42345								
lymphocyte cytosolic protein 1 (L-plastin) (LCP1)	42	J02923								
lymphocyte cytosolic protein 2 (SH2 domain-containing leukocyte protein of 76kD) (LCP2)	4	U20158	T lymphoma, T activated							
lymphocyte glycoprotein T1/Leu-1	2	X04391	+		+					
lymphocyte-specific protein 1 (LSP1)	16	M33552	+	+	+	+			+	
lymphocyte-specific protein tyrosine kinase (LCK)	7	M36881		+					+	
lymphoid phosphatase LyP1	1	AF001847								
lymphoid-restricted membrane protein (LRMP)	4	U10485	+		+	+				
lymphoid-specific SP100 homolog (LYSP100-A)	1	U36500							+	
lymphoma proprotein convertase (LPC)	2	U33849	+	+	+	+			+	
LYSOSOMAL PROTECTIVE PROTEIN PRECURSOR (CATHEPSIN A) (CARBOXYPEPTIDASE C)	1	P10619								
lysosomal-associated membrane protein 1 (LAMP1)	1	J04182	+	+	+	+	+	+		
Lysosomal-associated membrane protein 2 (LAMP2)	1	J04183		+	+	+	+	+		
lysozyme (renal amyloidosis) (LYZ)	39	M19045	+	+	+	+			+	
lysyl-tRNA synthetase (KARS)	2	D32053	+	+	+	+			+	
M phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein) (MPP-10)	1	X98494								
M1-type and M2-type pyruvate kinase	2	X56494								
m6A methyltransferase (MT-A70)	7	AF014837	+	+		+				
mab-21 (C. elegans)-like 1 (MAB21L1)	1	U38810		+	+	+			+	
MacMarcks	1	X70326	+	+	+	+	+	+		
macrophage-associated antigen (MM130)	1	Z22968		+	+	+			+	

MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A) (MEF2A)	1	U49020		+	+	+		+	
MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C) (MEF2C)	1	L08895		+	+	+		+	
major cytoplasmic tRNA-Val(IAC) (=M33940)	1	X17516							
major histocompatibility complex class I beta chain (HLA-B)	1	M95531							
major histocompatibility complex, class I, A (HLA-A)	41	Z93949	+	+	+	+		+	high in villous adenoma
major histocompatibility complex, class I, A (HLA-A) (low match)	1	Z72422							
major histocompatibility complex, class I, C (HLA-C)	82	M24097	+	+	+	+	+	+	
major histocompatibility complex, class I, E (HLA-E)	77	M20022	+	+	+	+		+	
major histocompatibility complex, class II, DM BETA (HLA-DMB)	2	U15085	+	+	+	+		+	
major histocompatibility complex, class II, DP beta 1 (HLA-DPB1)	10	M57466	+	+	+	+		+	
major histocompatibility complex, class II, DR beta 1 (HLA-DRB1)	9	V00522	+	+	+	+		+	
Major histocompatibility complex, class II, Y box-binding protein I; DNA-binding protein B (YB1)	2	M24070		+	+		+	+	
malate dehydrogenase 1, NAD (soluble) (mdh1)	1	D55654	+	+	+	+	+	+	
malate dehydrogenase 1, NAD (soluble) (MDH1)	3	D55654		+	+		+	+	
malonyl-CoA decarboxylase precursor	2	AF097832							
maltase-glucoamylase (mg)	1	AF016833				+			
manic fringe (Drosophila) homolog (MFNG)	1	U94352	+	+	+	+		+	
mannose phosphate isomerase (MPI)	1	X76057		+	+	+		+	
mannose phosphate isomerase (mpi)	2	X76057		+	+	+		+	
mannose-6-phosphate receptor (cation dependent) (M6PR)	3	X56253		+	+		+	+	
mannose-P-dolichol utilization defect 1 (MPDU1)	1	AF038961		+	+	+		+	
mannosidase, alpha B, lysosomal (MANB)	1	U60885		+		+	+	+	
mannosyl (alpha-1,3)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (MGAT1)	1	M55621	+	+	+	+	+	+	
map 4q35 repeat region	1	AF064849							
MAP kinase-interacting serine/threonine kinase 1 (MKNK1)	2	AB000409		+	+	+	+	+	
MAP/ERK kinase kinase 3 (MEKK3)	5	U78876		+					
MAP/ERK kinase kinase 5 (MEKK5)	1	D84476		+	+		+		

MAP/microtubule affinity-regulating kinase 3 (MARK3)	4	M80359		+	+				+
Marenostnin protein	1	Y14441							
MASL1	1	AB016816							
MAX dimerization protein (MAD)	3	L06895							+
MaxiK potassium channel beta subunit	1	AF035046							
MBP-2 for MHC binding protein 2	1	X65644		+	+	+			+
Meis (mouse) homolog 3 (MEIS3)	1	U68385		+	+	+			+
melanoma-associated antigen p97 (melanotransferrin)	1	M12154							
membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen) (MCP)	4	X59405		+	+	+			+
membrane component, chromosome 17, surface marker 2 (ovarian carcinoma antigen CA125) (M17S2)	4	D14696		+	+	+	+	+	
membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10) (MME)	2	J03779	B		+	+	+	+	
membrane protein, palmitoylated 1 (55kD) (MPP1)	2	M64925		+	+	+	+	+	
meningioma expressed antigen (MGEA)	1	U94780				+			
meningioma-expressed antigen 11 (MEA11)	1	U73682	+	+		+	+		
Menkes Disease (ATP7A) putative Cu ⁺⁺ -transporting P-type ATPase	1	L06133		+					
metallothionein 2A (MT2A)	1	V00594		+	+	+	+	+	
metaxin 1 (MTX1)	1	U46920		+		+		+	
methionine adenosyltransferase II, alpha (MAT2A)	2	X68836	+	+	+	+			+
methyl-CpG binding domain protein 1 (MBD1) (non-exact 59%aa)	1	Y10746							
methylene tetrahydrofolate dehydrogenase (NAD ⁺ dependent), methenyltetrahydrofolate cyclohydrolase (MTHFD2)	2	X16396	+	+	+	+			+
methylenetetrahydrofolate dehydrogenase (NADP ⁺ dependent), methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase (MTHFD1)	1	J04031		+	+	+	+	+	
methyltransferase, putative	2	AJ224442							
MHC antigen (HLA-B) (=L42024)	1	U14943							
MHC class I region	2	AF055066							
MHC class I antigen (HLA-A2)	1	U70863							
MHC class I antigen (HLA-A33)	1	U19736							
MHC class I antigen (HLA-C)	1	U38975							

66

MHC class II DQ-alpha associated with DRw6, DQw1 protein	1	M16995	+		+	+		+	
MHC class II DQ-beta associated with DR2, DQw1 protein	2	M17564		+		+		+	
MHC class II HAL-DQ-LTR5 (DQ.w8) DNA fragment, long terminal repeat region	1	M33842							
MHC class II hla-dr alpha-chain (=J00197;M60334;K011171;J00194;M60333;X00274)	1	J00195							
MHC class II HLA-DRB1	1	AF007883							
MHC class II HLA-DRw11-beta-1 chain (DRw11.3)	1	M21966							
MHC class II lymphocyte antigen (DPw4-beta-1)	1	M23907							
MHC CLASS II TRANSACTIVATOR CIITA (non-exact 57%)	1	P33076							
MHC HLA-E2.1 (=X87679)	1	M32507							
MHC HLA-E2.1 (alpha-2 domain) (low match)	1	M32507							
Mi-2 autoantigen 240 kDa protein (non-exact 84%)	1	U08379							
microsomal stress 70 protein ATPase core (stch)	1	U04735							
microtubule-associated protein 4 (MAP4)	1	U19727	+	+	+	+		+	
microtubule-associated protein 7 (MAP7)	1	X73882							
mineralocorticoid receptor (aldosterone receptor) (MLR)	2	M16801		+		+		+	
minichromosome maintenance deficient (S. cerevisiae) 3 (MCM31)	1	X62153		+	+	+		+	
minichromosome maintenance deficient (S. cerevisiae) 3-associated protein (MCM3AP)	1	AB011144		+	+	+		+	
minichromosome maintenance deficient (S. cerevisiae) 5 (cell division cycle 46) (MCM5)	2	X74795	+	+	+	+	+	+	
mitochondrial cytochrome b (CYTB)	1	AF042517							
mitochondrial 16S rRNA	11	Z70759							
mitochondrial ATP synthase (F1-ATPase) alpha subunit	2	X59066							
mitochondrial ATP synthase c subunit (P1 form)	1	X69907							
mitochondrial cytochrome b (CYTB)	6	AF042508							
mitochondrial cytochrome b small subunit of complex II	1	AB006202							
mitochondrial CYTOCHROME C OXIDASE POLYPEPTIDE I	1	P00395							
mitochondrial CYTOCHROME C OXIDASE POLYPEPTIDE II	1	P00403							
mitochondrial cytochrome C oxidase subunit II	2	P00403							

68

murine leukemia viral (bmi-1) oncogene homolog (BMI1)	1	L13689		+		+		+	
mutant (Daudi) beta2 - microglobulin	44	X07621							
mutated in colorectal cancers (MCC)	1	M62397		+	+			+	
myeloid cell leukemia sequence 1 (BCL2-related) (MCL1)	9	L08246	+	+	+	+	+	-	
myeloid cell nuclear differentiation antigen (MNDA)	11	M81750	+					+	
myeloid differentiation primary response gene (88) (MYD88)	4	U70451		+	+	+		+	
myeloid leukemia factor 2 (MLF2)	3	U57342		+		+		+	
myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 7 (MLLT7)	8	U89867		+	+	+		+	
MYH9 (cellular myosin heavy chain)	1	M81105							
myomesin (M-protein) 2 (165kD) (MYOM2)	1	X69089							
myosin IE (MYO1E)	11	X98411		+		+			
myosin light chain kinase (MLCK)	1	U48959	+		+	+		+	
myosin phosphatase, target subunit 1 (MYPT1)	2	D87930		+	+	+		+	
myosin regulatory light chain (=U26162)	2	D50372							
myosin VIIa (low match 71)	1	U55208							
myosin, heavy polypeptide 9, non-muscle (MYH9)	3	M81105	+	+	+	+		+	
myosin, light polypeptide, regulatory, non-sarcomeric (20kD) (MLCB)	6	X54304	+	+	+	+	+	+	
myosin-I beta	1	X98507	+	+	+	+		+	
myristoylated alanine-rich protein kinase C substrate (MARCKS, 80K-L) (MACS)	1	D10522		+	+				
myxovirus (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) (MX1)	1	M30817	+	+	+	+		+	
myxovirus (influenza) resistance 2, homolog of murine (MX2)	3	M30818			+				
N-acetylgalactosaminidase, alpha- (NAGA)	2	M62783		+	+		+	+	
N-acetylglucosamine receptor 1 (thyroid) (NAGR1)	1	L03532		+	+	+		+	
NACP/alpha-synuclein	2	U46896							
N-acylaminoacyl-peptide hydrolase (APEH)	1	D38441		+	+		+	+	
N-acylsphingosine amidohydrolase (acid ceramidase) (ASAH)	11	U47674	+	+	+	+		+	
NAD+-specific isocitrate dehydrogenase beta subunit precursor (encoding mitochondrial protein)	1	U49283	+	+	+	+	+	+	
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5 (13kD, B13) (NDUFA5)	1	U53468.1	+	+	+	+	+	+	

NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 (16kD, SGD1) (NDUFB5)	1	AF047181		+	+	+	+	+	
NADH dehydrogenase (ubiquinone) Fe-S protein 2 (49kD) (NADH-coenzyme Q reductase) (NDUFS2)	1	AF050640		+	+	+	+	+	
NADH dehydrogenase (ubiquinone) flavoprotein 2 (24kD) (NDUFV2)	1	M22538			+	+	+	+	
NADH:ubiquinone dehydrogenase 51 kDa subunit (NDUFV1)	2	AF053070	+	+	+	+	+	+	
NADH-CYTOCHROME B5 REDUCTASE (B5R) (50%aa)	1	P00387							
NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 1	1	P03886							
Nardilysin (N-arginine dibasic convertase) (NRD1)	2	U64898	+	+	+	+		+	
nascent-polypeptide-associated complex alpha polypeptide (NACA)	5	X80909		+	+			+	+
natural killer cell group 7 sequence (NKG7)	8	S69115				+			+
natural killer cell transcript 4 (NK4)	19	M32011	+						
natural killer-associated transcript 3 (NKAT3)	1	U30274	+						blood only
natural killer-associated transcript 5 (NKAT5)	1	AF022045	+						blood only
natural killer-tumor recognition sequence (NKTR)	1	L04288	B		+			+	+
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 (NDST2)	2	AF042084	+	+		+		+	
Ndr protein kinase	3	Z35102		+					
Nedd-4-like ubiquitin-protein ligase WWP1	1	U96113							
nel (chicken)-like 2 (NELL2)	3	D83018		+	+				
N-ethylmaleimide-sensitive factor attachment protein, alpha (NAPA)	1	U39412		+				+	
N-ethylmaleimide-sensitive factor attachment protein, gamma (NAPG)	1	U78107		+	+	+			
neural precursor cell expressed, developmentally down-regulated 5 (NEDD5)	3	X92544	+	+	+	+		+	high in testis
neural precursor cell expressed, developmentally down-regulated 8 (NEDD8)	1	D23662	+	+	+	+	+	+	
neuregulin 1 (NRG1)	1	U02330		+		+	+		
neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)	4	AB020692	+	+	+	+		+	
Neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) (low match)	1	X68286							
Neurofibromin 2 (bilateral acoustic neuroma) (NF2)	1	S73853		+				+	
neuronal apoptosis inhibitory protein (NAIP)	2	U19251	+	+	+			+	
neuronal cell adhesion molecule (NRCAM)	1	AB002341		+	+	+		+	

neuropathy target esterase (NTE)	1	AJ004832		+	+	+		+	
neuropeptide Y3 receptor, 5'UTR (low score)	1	D28433							
neurotrophic tyrosine kinase, receptor, type 1 (NTRK1)	14	X03541	+	+	+	+	+	+	
neutrophil cytosolic factor 4 (40kD)	2	U50720							
NG31	1	AF129756							
NGAL (=X83006)	1	X99133							
nibnn (NBS)	1	AF051334							
NIK	1	AB014587		+	+	+		+	
Ninj1; nerve injury-induced protein-1	1	U72661		+	+	+		+	
nitrilase 1 (NIT1) (=AF069984)	1	AF069987							
NKG2-D (low match) (non-exact, 58%)	1	X54870							
Nmi	1	U32849							
N-myrstoyltransferase 1 (NMT1)	1	AF043324		+	+	+	+	+	
No arches-like (zebrafish) zinc finger protein (NAR)	1	U79569		+	+	+		+	
non-histone chromosome protein 2 (S. cerevisiae)-like 1 (NHP2L1)	1	D50420	+	+	+	+	+	+	
non-muscle (fibroblast) tropomyosin	1								
non-muscle alpha-actinin	1	U48734							
non-muscle myosin alkali light chain (Hs.77385)	3	M22918	+	+	+	+	+	+	High in fetal adrenal gland and BPH stroma
non-neuronal enolase (EC 4.2.1.11)	1	X16289							
non-receptor tyrosine phosphatase 1	1	M33689							
normal keratinocyte subtraction library mRNA, clone H22a	3	X53778	+	+	+	+	+	+	high in many libraries
notch group protein (N)	3	M99437							
novel protein	1	X99961							
novel T-cell activation protein	1	X94232		+	+	+		+	
N-ras protein NRU	1	A60196							
N-sulfoglucosamine sulfohydrolase (sulfamidase) (SGSH)	1	U60111		+				+	
nsulin induced gene 1 (INSIG1)	1	U96876	+	+	+	+	+	+	
ntegnn, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) (ITGA14)	3	L12002	+			+			
nterferon, gamma-inducible protein 16 (IFI16)	1	M63838	+	+	+	+		+	
nterleukin 1, beta (IL1RB)	1	M15330							
nuclear antigen H731-like protein	2	U83908		+	+	+		+	
nuclear antigen Sp100 (SP100)	4	U36501	+			+	+	+	
Nuclear antigen Sp100 (SP100) (85%aa)	1	P23497							
Nuclear antigen Sp100 (SP100) (89%aa)	1	P23497							
nuclear autoantigenic sperm protein (histone-binding) (NASP)	1	M97856	+		+				

nuclear corepressor KAP-1 (KAP-1) (=U95040; X97548 TIF1 beta zinc finger protein)	1	U78773								
Nuclear domain 10 protein (NDP52)	4	U22897	+	+	+	+	+	+		
Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2)	1	S74017		+	+	+	+	+		
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) (NFKB1)	2	M58603		+	+			+	+	
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA)	3	M69043		+	+	+			+	
nuclear factor related to kappa B binding protein (NFRKB)	1	U08191		+	+	+			+	
nuclear mitotic apparatus protein 1 (NUMA1)	3	Z11583	+	+	+	+	+	+		
nuclear receptor coactivator 2 (GRIP1)	1	X97674								
nuclear receptor coactivator 3 (AIB3)	2	AF010227	+	+	+				+	
nuclear receptor coactivator 4 (ELE1)	22	X77548		+	+	+	+	+		
nuclear receptor interacting protein 1 (NRIP1)	1	X84373		+		+			+	
nuclear respiratory factor 1 (NRF1)	1	U02683	B	+	+					
nuclear RNA helicase, DECD variant of DEAD box family (DDXL)	4	U90426	+	+	+	+			+	
nuclear transcription factor Y, alpha (NFYA)	1	X59711	B							
nuclear transcription factor, X-box binding 1 (NFX1)	3	U15306		+	+			+		
nuclear transport factor 2 (placental protein 15) (PP15)	1	X07315	+	+	+	+			+	
nucleobindin (=M96824)	1	U31336								
nucleobindin 1 (NUCB1)	2	M96824	+	+	+	+			+	
nucleolar phosphoprotein p130 (P130)	1	Z34289		+	+					
nucleolar protein (KKE/D repeat) (NOP56)	1	Y12065	+	+	+	+			+	
nucleolar protein (MSP58)	1	AF015308								
nucleolar protein 1 (120kD) (NOL1)	1	M32110	+	+						
nucleolar protein p40	1	U86602	+	+	+	+			+	
nucleolin (NCL)	2	M60858	+	+	+	+			+	
nucleophosmin (nucleolar phosphoprotein B23, numatrin) (NPM1)	14	M28699	+	+	+	+			+	
nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR long form	1	U41742								
nucleoporin (NUP358) (=D42063 RanBP2 (Ran-binding protein 2))	2	L41840								
nucleoporin 153kD (NUP153)	1	Z25535								
nucleoporin 98kD (NUP98)	1	U41815								
nucleosome assembly protein	1	D28430								
nucleosome assembly protein 1-like 1 (NAP1L1)	1	M86667		+	+	+			+	
nucleosome assembly protein 1-like 4 (NAP1L4)	2	U77456	+	+	+	+			+	

nucleosome assembly protein, 5'UTR	1	D28430								
olfactory receptor (OR7-141)	1	U86281								
OLFACTORY RECEPTOR-LIKE PROTEIN HGMP07E (OR17-4) (non-exact 65%)	1	P34982								
oligodendrocyte myelin glycoprotein (OMG)	7	L05367		+						
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase) (OGT)	1	U77413	+	+		+	+	+		
oncofetal trophoblast glycoprotein 5T4 precursor (non-exact 55%)	1	A53531								
Oncogene TIM (TIM) (non-exact 84%)	1	U02082								
ORF (Hs.77868)	1	M68864	+	+	+	+	+	+		
ORF1; MER37; putative transposase similar to pogo element Length = 454	1	U49973								
origin recognition complex, subunit 2 (yeast homolog)-like (ORC2L)	2	U27459				+				
origin recognition complex, subunit 4 (yeast homolog)-like (ORC4L) (low match)	1	AF022108								
ornithine aminotransferase (gyrate atrophy) (OAT)	2	M23204		+	+	+				
ornithine decarboxylase (ODC)	1	M20372								
ornithine decarboxylase antizyme, ORF 1 and ORF 2	11	D78361	+	+	+	+	+	+		High in pancreas, and activated T cells
orphan receptor (Hs.100221)	2	U07132	+	+	+	+		+		
OS-9 precursor	6	AB002806	+	+	+	+	+	+		
osteonectin (=X82259 BM-40)	1	D28381								
ovel centrosomal protein RanBPM (RANBPM)	1	AB008515		+	+	+		+		
over-expressed breast tumor protein	1	L34839								
oviductal glycoprotein 1, 120kD (OVGP1)	1	U09550			+	+	+			
oxidase (cytochrome c) assembly 1-like (OXAIL)	1	X80695		+	+	+	+	+		
oxoglutarate dehydrogenase (lipoamide) (OGDH)	4	D10523	+	+	+		+	+		
oxysterol binding protein (OSBP)	1	M86917	+	+			+			
OZF	1	X70394		+	+	+		+		
OZF (non-exact zinc finger)	1	X70394								
p21/Cdc42/Rac1-activated kinase 1 (yeast Ste20-related) (PAK1)	2	U51120	+	+		+				
P35-related protein (=S80990 ficolin)	1	D63392								
p40	1	U93569								
p40phox (=U50720)	1	X77094								
P47 LBC oncogene	4	U03634								
p53-induced protein (PIG11)	1	AF010315	+	+	+	+				
p54nrb (low match)	1	Y11287								

p62 nucleoporin	1	X58521								
p63 mRNA for transmembrane protein	1	X69910	+	+	+	+			+	
PAC clone DJ0701016 from 7q33-q36 (non-exact 54%)	1	Q07108								
palmitoyl-protein thioesterase (ceroid-lipofuscinosis, neuronal 1, infantile; Haltia-Santavuori disease) (PPT)	10	U44772		+	+	+			+	
papillary renal cell carcinoma (translocation-associated) (PRCC)	1	X99720	+	+	+	+	+	+		
PAR protein	1	AF115850		+		+				
partial EST (clone c-1gh04)	1	Z43627								
PAX3/forkhead transcription factor gene fusion	1	U02358								
paxillin (PXN)	4	D86862		+	+	+			+	
PBK1 protein	2	AJ007398	+	+	+	+			+	
PBS-EST (nz92e01.s1 NCI CGAP GCB1 clone IMAGE:1302936) (low score)	1	AA732534								
PDZ domain protein (Drosophila inaD-like) (INALD)	1	AJ224747	+			+			+	
PEBP2aC Runt domain encoding gene (=Z35728)	1	Z38108								
peptidase D (PEPD)	1	J04605								
peptidylprolyl isomerase A (cyclophilin A) (PPiA)	3	Y00052		+	+	+	+	+		high in many libraries
peptidylprolyl isomerase D (cyclophilin D) (PPiD)	2	L11667	+	+				+	+	
peptidylprolyl isomerase E (cyclophilin E) (PPiE)	1	AF042386		+	+			+	+	
PERB11.1 (=U56942 MHC class I chain-related protein A)	1	U69630								
perforin 1 (preforming protein) (PRF1)	14	M28393								
peroxisomal acyl-CoA thioesterase (PTE1)	2	X86032								
Peroxisomal acyl-coenzyme A oxidase	1	X71440		+	+	+	+	+		
peroxisomal farnesylated protein (PXF)	1	X75535		+	+	+	+	+		
phorbol-12-myristate-13-acetate-induced protein (PMAIP1)	1	D90070	B, W							
phosphate carrier (mitochondrial gene?)	1	X77337								
Phosphate carrier, mitochondrial (PHC)	3	X60036	+	+	+	+			+	
phosphate cytidyltransferase 1, choline, alpha isoform (PCYT1A)	1	L28957	+		+			+		
PROSPHATIDATE CYTIDYLYLTRANSFERASE (CDP-DIGLYCERIDE)	1	Q92903								
phosphatidylinositol 3-kinase delta catalytic subunit	2	U57843								
phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB)	3	AB005910	+	+	+	+			+	
phosphatidylinositol glycan, class H (PIGH)	1	L19783		+	+	+	+	+		

phosphatidylinositol transfer protein (PI-TPbeta)	2	D30037							
phosphatidylinositol transfer protein, membrane-associated (PITPNM)	2	X98654	B, T lymphoma	+					
phosphatidylinositol transfer protein, membrane-associated (PITPNM) (non-exact 64%)	1	X98654							
phosphatidylinositol-4-phosphate 5-kinase, type II, alpha (PIP5K2A)	1	U14957			+		+		
phosphatidylinositol-4-phosphate 5-kinase, type II, beta (PIP5K2B)	1	U85245		+	+	+		+	
phosphodiesterase 7A (PDE7A)	1	L12052	B, W	+	+		+		
phosphodiesterase 1B (PDES1B)	1	U56976		ONLY					
phosphoglucomutase 1 (PGM1)	2	M83088		+	+	+		+	
phosphogluconate dehydrogenase (PGD)	1	U30255			+				
phosphoglycerate kinase 1 (PGK1)	12	V00572							
phosphoglycerate mutase 1 (brain) (PGAM1)	3	J04173	+	+	+	+	+	+	
phosphoglycerate mutase 2 (muscle) (PGAM2)	1	M55673		+	+			+	
phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA)	1	Z29090		+	+	+			
phosphoinositide-3-kinase, catalytic, delta polypeptide (PIK3CD)	4	U86453		+	+	+		+	
phosphoinositide-3-kinase, catalytic, gamma polypeptide (PIK3CG)	1	X83368							
phospholipase C	1	X14034							
phospholipase C, delta 1 (PLCD1)	2	U09117		+	+	+		+	
phospholipase C, gamma 1 (formerly subtype 14B) (PLCG1)	1	M34667	+	+	+	+		+	
phospholipid scramblase	1	AF008445							
phosphoribosyl pyrophosphate synthetase-associated protein 1 (PRPSAP1)	1	D61391		+	+			+	
phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase (GART)	3	X54199		+	+	+	+	+	
phosphorylase kinase, alpha 2 (liver), glycogen storage disease IX (PHKA2)	3	D38616		+	+	+	+	+	
phosphorylase, glycogen; brain (PYGB)	1	U47025	+	+	+			+	
phosphorylase, glycogen; brain (PYGB) (low match, non-exact, 75%)	1	U47025							
phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI) (PYGL)	1	Y15233		+	+	+		+	
phosphorylation regulatory protein HP-10	2								
phosphotidylinositol transfer protein (PITPN)	1	D30036	+	+	+	+		+	

pigment epithelium-derived factor (PEDF)	1	U29953	+	+	+	+	+	+	
pim-1 oncogene (PIM1)	1	M24779	+	+	+				+
pinin, desmosome associated protein (PNN)	1	U77718							+
placenta (Diff33)	5	U49188							
placenta (Diff33) (non-exact, 69%)	1	U49188		+	+	+		+	
placenta (Diff48)	18	U49187	+						
placenta (Diff48) (low match)	1	U49187							
placenta (Diff48) (low match)	1	U49187							
plasminogen activator, urokinase receptor (PLAUR)	1	X74039		+		+		+	
platelet factor 4 (PF4)	1	M25897			+				+
platelet/endothelial cell adhesion molecule (CD31 antigen) (PECAM1)	8	M37780		+	+	+	+	+	
platelet-activating factor acetylhydrolase 2 (40kD) (PAFAH2)	4	U89386		+	+	+			
platelet-activating factor acetylhydrolase, isoform lb, alpha subunit (45kD) (PAFAH1B1)	1	U72342	+	+	+	+	+	+	
platelet-activating factor receptor (PTAFR)	1	D10202		+					+
pleckstrin (PLEK)	10	X07743			+	+			+
pleckstrin (PLEK) (low match)	1	X07743							
pleckstrin homology, Sec7 and coiled/coil domains 1 (cytohesin 1) (PSCD1)	4	M85169	+	+		+			+
pleckstrin homology, Sec7 and coiled/coil domains, binding protein (PSCDBP)	4	L06633	+			+			
pM5 protein	1	X57398	+	+	+	+			+
PMP69	2	Y14322							
poly (ADP-ribose) polymerase (NAD (+) ADP-ribosyltransferase) (=X16674)	1	X56140							
poly(A) polymerase (PAP)	1	X76770	+	+	+	+			+
poly(A)-binding protein-like 1 (PABPL1)	19	Y00345	+	+	+	+	+	+	
poly(rC)-binding protein 1 (PCBP1)	3	X78137	+	+	+	+	+	+	
polyadenylate binding protein	1	U75686							
polycystic kidney disease 1 (autosomal dominant) (PKD1)	5	U24498							
polymerase (DNA directed), beta (POLB)	1	D29013		+			+	+	
polymerase (DNA directed), gamma (POLG)	6	D84103							
polymerase (RNA) II (DNA directed) polypeptide A (220kD) (POLR2A)	1	X63564	+	+	+	+	+	+	
polymyositis/scleroderma autoantigen 2 (100kD) (PMSC2)	1	L01457	+	+	+	+	+	+	
polypyrnidine tract binding protein (heterogeneous nuclear ribonucleoprotein I) (PTB)	1	X65372	+	+	+	+	+	+	

positive regulator of programmed cell death ICH-1L (Ich-1)	3	U13021			+					
postmeiotic segregation increased 2-like 12 (PMS2L12)	1	M16514	+	+	+	+			+	
postmeiotic segregation increased 2-like 8 (PMS2L8)	1	U38964	+	+	+	+			+	
potassium inwardly-rectifying channel, subfamily J, member 15 (KCNJ15)	1	D87291				+			+	
potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1)	1	AF051426		+	+	+			+	
POU domain, class 2, associating factor 1 (POU2AF1)	1	Z49194				+				
POU domain, class 2, transcription factor 1 (POU2F1)	2	X13403		+		+				
PPAR binding protein (PPARBP)	1	Y13467	+	+	+	+			+	
PPAR gamma2	1	D83233								
pre-B-cell colony-enhancing factor (PBEF)	8	U02020								
prefoldin 1 (PFDN1)	1	Y17392	+	+	+	+	+	+	+	
prefoldin 5 (PRFLD5)	3	D89667	B	+	+		+			
prefoldin subunit 3 (=U96759 von Hippel-Lindau binding protein (VBP-1))	1	Y17394								
pregnancy-associated plasma protein A (PAPPA)	1	U28727		+		+				high in placenta
pre-mRNA splicing factor SF3a (60kD), similar to S. cerevisiae PRP9 (spliceosome-associated protein 61) (SF3A60)	1	U08815	+	+	+	+			+	
pre-mRNA splicing factor SF3a (60kD), similar to S. cerevisiae PRP9 (spliceosome-associated protein 61) (SF3A60) (low score)	1	U08815								
pre-mRNA splicing factor SRp20, 5'UTR	2	D28423								
preprotein translocase (TIM17)	3	X97544	+	+	+	+			+	
prion protein	1	X82545								
prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Strausler-Scheinker syndrome, fatal familial insomnia) (PRNP)	1	M13899		+	+	+			+	
pristanoyl-CoA oxidase (low match)	1	Y11411								
pristanoyl-CoA oxidase (low score)	1	Y11411								
procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI) (PLOD)	1	M98252		+	+	+			+	
procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide 1 (P4HA1)	1	M24486	+	+	+	+	+	+	+	

procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide (protein disulfide isomerase; thyroid hormone binding protein p55) (P4HB)	4	X05130	+	+	+	+	+	+	+
prohlin 1 (PFN1)	1	J03191	+	+	+	+	+	+	+
progesterone receptor-associated p48 protein (P48)	2	U28918		+					
prohibitin (PHB)	1	S85655		+	+	+	+	+	+
proliferating cell nuclear antigen (PCNA)	3	J04718	+	+	+	+			+
proliferation-associated gene A (natural killer-enhancing factor A) (PAGA)	4	L19184	+	+	+	+	+	+	+
proline-rich protein BstNI subfamily 2 (PRB2) (non-exact, 43%aa)	1	S62936							
proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1)	1	U94778							
prolyl endopeptidase (PREP)	2	X74496		+		+			+
prolylcarboxypeptidase (angiotensinase C) (PRCP)	5	L13977		+	+	+	+	+	+
promyelocytic leukemia (PML)	1	M80185	+	+	+	+			+
properdin P factor, complement (PFC)	4	X57748	+						
pro-platelet basic protein (includes platelet basic protein, beta-thromboglobulin, connective tissue-activating peptide III, neutrophil-activating peptide-2) (PPBP)	1	M54995			+	+			+
pro-platelet basic protein (includes platelet basic protein, beta-thromboglobulin, connective tissue-activating peptide III, neutrophil-activating peptide-2) (PPBP)	7	M54995	+		+		+		
proprotein convertase subtilisin/kexin type 7 (PCSK7)	4	U40623							
prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) (PSAP)	89	D00422	+	+	+	+	+	+	+
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (PTGS1)	1	U63846	B	+			+	+	
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2)	2	L15326							
prostaglandin-endoperoxide synthase-1 (=L08404; U84208) (all promoters)	1	D64068							
prostate carcinoma tumor antigen (pcta-1)	2	L78132							

protease inhibitor 1 (anti-elastase), alpha-1-antitrypsin (PI)	17	K02212		+	+	+	+	+	high in many libraries
protease inhibitor 2 (anti-elastase), monocyte/neutrophil (ELANH2) (low match)	1	M93056				+		+	
proteasome (prosome, macropain) 26S subunit, ATPase, 1 (PSMC1)	3	L02426	B	+	+			+	
proteasome (prosome, macropain) 26S subunit, ATPase, 3 (PSMC3)	1	M34079	+	+	+	+		+	
proteasome (prosome, macropain) 26S subunit, ATPase, 4 (PSMC4)	2	AF020736							
proteasome (prosome, macropain) 26S subunit, ATPase, 5 (PSMC5)	5	L38810	+	+	+	+	+	+	
proteasome (prosome, macropain) 26S subunit, ATPase, 6 (PMSC6)	2	D78275	+	+	+	+		+	
proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 (PSMD11)	1	AF001212	I	+			+		
proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 (PSMD2)	2	D78151		+	+			+	
proteasome (prosome, macropain) 26S subunit, non-ATPase, 5 (PSMD5)	1	S79862	I	+	+		+		
proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 (Mov34 homolog) (PMSD7)	1	D50063		+	+	+		+	high in many libraries
proteasome (prosome, macropain) 26S subunit, on-ATPase, 12 (PMSD12)	1	AB003103		+	+	+		+	
proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) (PSME1)	3	L07633	+	+	+	+		+	
proteasome (prosome, macropain) subunit, alpha type, 3 (PSMA3)	2	D00762		+	+	+		+	
proteasome (prosome, macropain) subunit, alpha type, 5 (PSMA5)	3	X61970	+	+	+	+		+	
proteasome (prosome, macropain) subunit, alpha type, 7 (PSMA7)	3	AF054185		+	+	+	+	+	
proteasome (prosome, macropain) subunit, alpha type, 7 (PSMA7) (low match)	1	AF022815							
proteasome (prosome, macropain) subunit, beta type, 1 (PSMB1)	1	D00761	+	+	+	+	+	+	
proteasome (prosome, macropain) subunit, beta type, 10 (PSMB10)	1	X71874	+	+		+	+	+	
proteasome (prosome, macropain) subunit, beta type, 6 (PSMB6)	1	D29012		+	+	+		+	
proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7) (PSMB8)	1	U17497	+	+	+	+		+	
proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2) (PSMB9)	3	Z14977	+			+		+	

proteasome (prosome, macropain) subunit, beta type, 7 (PSMB7)	1	D38048	+	+	+	+	+	+	
protective protein for beta-galactosidase (galactosialidosis) (PPGB)	3	M22960	+	+	+	+	+	+	
protein A alternatively spliced form 2 (A-2)	1	U47925		+					
protein activator of the interferon-induced protein kinase (PACT)	1	AF072860		+	+	+		+	high in testis
protein disulfide isomerase-related protein (P5)	2	D49489	+	+	+	+	+	+	
protein geranylgeranyltransferase type I, beta subunit (PGGT1B)	1	L25441	+	+	+				
protein homologous to chicken B complex protein, guanine nucleotide binding (H12.3)	20	M24194	+	+	+	+	+	+	high in many libraries
protein kinase A anchoring protein	1	AF037439		+					
protein kinase C substrate 80K-H (PRKCSH)	2	U50317	+	+	+	+		+	
protein kinase C, beta 1 (PRKCB1)	6	X06318	+	+	+	+		+	
protein kinase C, delta (PRKCD)	1	D10495	+	+	+	+		+	
protein kinase C, eta (PRKCH)	1	M55284			+			+	
protein kinase C, mu (PRKCM) (non-exact 78%)	1	X75756							
Protein kinase C-like 1 (PRKCL1)	2	D26181	+	+	+	+		+	
protein kinase, AMP-activated, gamma 1 non-catalytic subunit (PRKAG1)	1	U42412	B, T lymphoma	+	+				
protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) (PRKAR1A)	4	M18468		+	+	+	+	+	
protein kinase, DNA-activated, catalytic polypeptide (PRKDC)	1	U47077		+	+		+	+	
protein kinase, mitogen-activated 1 (MAP kinase 1; p40, p41) (PRKM1)	1	Z11695	B	+			+		
protein kinase, mitogen-activated 6 (extracellular signal-regulated kinase, p97) (PRKM6)	1	L77964		+		+	+	+	
protein kinase, mitogen-activated, kinase 3 (MAP kinase kinase 3) (PRKMK3)	1	U66839	+	+	+	+	+		
protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA)	5	M63960	+	+	+	+	+	+	
protein phosphatase 1, regulatory subunit 10 (PPPR10)	3	Y13247		+	+	+		+	
protein phosphatase 1, regulatory subunit 7 (PPP1R7)	2	Z50749	+	+	+	+	+	+	
protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (PPP2CB)	1	X12656	+	+	+	+	+	+	
protein phosphatase 2 (formerly 2A), regulatory subunit B" (PR 72), alpha isoform and (PR 130), beta isoform (PPP2R3)	1	L07590			+	+		+	

protein phosphatase 2, regulatory subunit B (B56), alpha isoform (PPP2R5A)	2	L42373	+	+	+	+		+	
protein phosphatase 2, regulatory subunit B (B56), delta isoform (PPP2R5D)	3	D78360		+	+	+		+	
protein phosphatase 2, regulatory subunit B (B56), gamma isoform (PPP2R5C)	1	D26445	+	+	+	+		+	
protein phosphatase 2A regulatory subunit alpha-isotype (alpha-PR65)	5	J02902	+	+	+	+		+	
protein phosphatase 4 (formerly X), catalytic subunit (PPP4C)	2	AF097996	+	+	+	+		+	
protein tyrosine kinase 2 beta (PTK2B)	4	L49207		+		+		+	
protein tyrosine phosphatase epsilon	1	X54134							
protein tyrosine phosphatase type IVA, member 2 (PTP4A2)	2	L48723	+	+	+	+		+	
protein tyrosine phosphatase, non-receptor type 1 (PTPN1)	1	M31724	+	+	+	+			
protein tyrosine phosphatase, non-receptor type 12 (PTPN12)	1	M93425		+	+	+		+	high in testis
protein tyrosine phosphatase, non-receptor type 12 (PTPN12) (non-exact, 70%)	1	M93425							
protein tyrosine phosphatase, non-receptor type 2 (PTPN2)	2	M25393		+	+	+		+	
protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) (PTPN4)	1	M68941			+	+		+	
protein tyrosine phosphatase, non-receptor type 6 (PTPN6)	7	M74903	+	+	+	+		+	
protein tyrosine phosphatase, non-receptor type 7 (PTPN7)	1	D11327	+			+		+	
protein tyrosine phosphatase, receptor type, alpha polypeptide (PTPRA)	1	M34668	+	+	+	+		+	
protein tyrosine phosphatase, receptor type, c polypeptide (PTPRC)	44	Y00638	+	+		+		+	
protein tyrosine phosphatase, receptor type, M (PTPRM)	1	X58288		+	+	+		+	
protein tyrosine phosphatase, receptor type, N polypeptide 2 (PTPRN2)	2	U81561		+		+		+	
protein with polyglutamine repeat (ERPROT213-21)	1	U94836	+	+	+	+		+	
protein-kinase, interferon-inducible double stranded RNA dependent inhibitor (PRKRI)	1	U28424		+	+	+	+	+	
protein-L-isocysteine (D-aspartate) O-methyltransferase (PCMT1)	4	D13892		+	+				
proteoglycan 1, secretory granule (PRG1)	7	J03223		+		+		+	
prothymosin, alpha (gene sequence 28) (PTMA)	12	M14483	+	+	+	+	+	+	

prp28, U5 snRNP 100 kd protein (U5-100K)	7	AF026402	+	+	+	+	+	+	
PRP4/STK/WD splicing factor (HPRP4P)	1	AF001687		+	+	+		+	
PTK7 protein tyrosine kinase 7 (PTK7)	1	U40271		+	+	+		+	
purnergic receptor P2X, ligand-gated ion channel, 4 (P2RX4)	3	AF000234		+	+	+		+	
purnergic receptor P2X, ligand-gated ion channel, 7 (P2RX7)	1	Y12851	+						macrophage only
puromycin-sensitive aminopeptidase (PSA)	1	Y07701		+	+			+	
putative ATP(GTP)-binding protein	2	AJ010842		+				+	
putative brain nuclearly-targeted protein (KIAA0765)	1	AB018308	+	+	+	+		+	
putative chemokine receptor, GTP-binding protein (HM74)	1	D10923	+						
putative dienoyl-CoA isomerase (ECH1)	1	AF030249							
putative G-binding protein	1	AF065393							
Putative human HLA class II associated protein I (PHAP1)	1	U73477	B	+				+	
Putative L-type neutral amino acid transporter (KIAA0436)	1	AB007896							
putative mitochondrial space protein 32.1	1	AF050198							
PUTATIVE MUCIN CORE PROTEIN PRECURSOR 24 (MULTI-GLYCOSYLATED CORE PROTEIN 24) (MGC-24) (MUC-24)	1	Q04900							
putative nucleic acid binding protein	2	X76302	+	+	+	+		+	
putative outer mitochondrial membrane 34 kDa translocase Htom34	1	U58970		+	+	+		+	
putative p150 (non-exact 88%)	1	U93568							
putative translation initiation factor (SUI1)	1	L26247	+	+	+	+	+	+	High in moderately differentiated colon adenocarcinoma
putative tumor suppressor protein (123F2)	1	AF061836		+	+	+		+	
pyrroline 5-carboxylate reductase	1	M77836	+	+	+	+		+	
pyruvate dehydrogenase (lipoamide) alpha 1 (PDHA1)	1	D90084		+	+	+	+	+	
pyruvate dehydrogenase (lipoamide) beta (PDHB)	2	J03576	+	+	+	+		+	
Pyruvate dehydrogenase complex, lipoyl-containing component X; E3-binding protein (PDX1)	3	Y13145		+	+				
pyruvate kinase, muscle (PKM2)	11	M23725						+	
RAB, member of RAS oncogene family-like (RABL)	1	U18420		+	+	+		+	
RAB1, member RAS oncogene family (RAB1)	3	M28209		+	+	+		+	
RAB11A, member RAS oncogene family (RAB11A)	2	X56740	+	+	+	+		+	high in spleen

RAB11B, member RAS oncogene family (Rab11B)	1	D45418		+				+	
RAB27A, member RAS oncogene family (RAB27A)	3	U38654					+		
RAB5B, member RAS oncogene family (RAB5B)	1	X54871		+	+	+		+	
RAB6, member RAS oncogene family (RAB6)	1	M28212		+				+	
RAB7, member RAS oncogene family (RAB7)	1	X93499	+	+	+	+		+	
RAB7, member RAS oncogene family-like 1 (RAB7L1)	2	D84488		+	+	+		+	
RAB9, member RAS oncogene family (RAB9)	1	U44103							
RAD50 (S. cerevisiae) homolog (RAD50)	2	U63139		+	+	+			
RAD51 (S. cerevisiae) homolog C (RAD51C)	1	AF029669		+	+	+		+	
Radin blood group (RD)	2	L03411		+	+	+		+	
RAE1 (RNA export 1, S.pombe) homolog (RAE1)	3	U84720	+	+	+	+		+	
ralA-binding protein (RLIP76)	2	L42542	+	+	+	+			
RAN binding protein 2-like 1 (RANBP2L1)	2	AF012086							
Ran GTPase activating protein 1 (RANGAP1)	3	X82260	+	+	+	+		+	
RAN, member RAS oncogene family (RAN) (low match)	1	M31469							
RanBP2 (Ran-binding protein 2) (=U19248; L41840 sapiens nucleoporin (NUP358))	1	D42063							
ransforming growth factor, beta receptor II (70-80kD) (TGFB2)	4	D50683	+	+	+	+		+	
RAP1A, member of RAS oncogene family (RAP1A)	10	M22995	+	+	+	+	+	+	
RAR-related orphan receptor C (RORC)	1	U16997							+
RAS guanyl releasing protein 2 (calcium and DAG-regulated)	1	Y12336	+	+					
ras homolog gene family, member A (ARHA)	12	X05026	+	+	+	+	+	+	high in ovary
ras homolog gene family, member G (rho G) (ARHG)	1	X61587	+	+	+	+			
ras homolog gene family, member H (ARHH)	2	Z35227	+	+	+			+	
ras inhibitor (RIN1)	2	M37191		+					
Ras-GTPase activating protein SH3 domain-binding protein 2 (KIAA0660)	2	AF053535	+	+	+	+		+	
Ras-GTPase-activating protein SH3-domain-binding protein (G3BP)	3	U32519	+	+	+	+		+	
ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) (RAC2)	11	M29871			+			+	
RAS-RELATED PROTEIN RAP-1B (GTP-BINDING PROTEIN SMG P21B)	1	P09526							
RBQ-1	1	X85133		+	+	+			
rearranged T cell receptor beta variable region (TCRB) (=X58810)	1	L06891							
regulator of Fas-induced apoptosis (TOSO)	1	AF057557	B					+	

regulator of G protein signalling 6 (RGS6)	1	AF073920		+							
regulator of G-protein signalling 14 (RGS14)	2	AF037195	+	+	+	+					
regulator of G-protein signalling 2, 24kD (RGS2)	6	L13391	+	+	+	+				+	
regulator of G-protein signalling 5 (RGS5) (49% aa)	1	O15539									
regulatory factor X, 4 (influences HLA class II expression) (RFX4)	1	M69297			+	+					
regulatory factor X, 5 (influences HLA class II expression) (RFX5)	2	X85786	1	+	+					+	
replication protein A1 (RPA1)	1	M63488	+	+	+	+				+	
replication protein A3 (14kD) (RPA3) (low match)	1	L07493									
reproduction 8 (D8S2298E)	1	D83767		+	+	+					
requiem, apoptosis response zinc finger gene (REQ)	2	U94585	+	+	+	+				+	
requiem, apoptosis response zinc finger gene (REQ) (=AF001433) (low match)	1	U94585									
restin (Reed-Steinberg cell-expressed intermediate filament-associated protein) (RSN)	1	M97501	B, I	+	+						
retinoblastoma 1 (including osteosarcoma) (RB1)	3	L11910	+	+	+	+					
retinoblastoma binding protein 2 homolog 1 (RBBP2H1)	1	AF087481									
retinoblastoma-binding protein 1 (RBBP1)	1	S66427	+	+							
retinoblastoma-binding protein 2 (RBBP2)	5	S66431	+	+	+	+				+	
retinoblastoma-binding protein 4 (RBBP4)	1	X71810		+	+	+				+	
retinoblastoma-binding protein 4 (RBBP4)	1	X74262		+	+	+				+	
retinoblastoma-binding protein 7 (RBBP7)	1	U35143									
retinoblastoma-like 2 (p130) (RBL2)	1	X76061		+	+	+				+	
retinoic acid receptor responder (tazarotene induced) 3 (RARRES3)	1	AF060228		+		+	+	+			
retinoic acid receptor, alpha (RARA)	1	X06538	+	+		+					
retinoic acid responsive (NN8-4AG)	1	U50383		+		+				+	
retinoid X receptor beta (RXR-beta)	2	X66424		+	+	+				+	
REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta (REV3L)	1	AF035537									
Rho GDP dissociation inhibitor (GDI) beta (ARHGDI3)	23	L07916	+	+	+	+	+	+		+	
Rho GTPase activating protein 4 (ARHGAP4)	2	X78817	+	+							
Rho GTPase activating protein 4 (ARHGAP4) (low match)	1	P98171									
Rho-associated, coiled-coil containing protein kinase 2 (ROCK2)	1	AB014519									
ribonuclease 6 precursor (RNASE6PL)	2	U85625	+	+	+	+	+	+	+	+	

ribonuclease 6 precursor (RNASE6PL) (low match)	1	U85625								
ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) (RNASE2)	1	X55988						+		
ribonuclease/angiogenin inhibitor (RNH)	3	M36717	+	+	+	+			+	
ribonucleoside diphosphate reductase M1 subunit	1	X65708								
ribonucleotide reductase M2 polypeptide (non-exact 91%)	1	P31350								
ribophorin I (RPN1)	1	Y00281	+	+	+	+			+	
ribophorin II (RPN2)	1	Y00282	+	+	+	+	+	+		
ribosomal 18S rRNA	3	M10098								
ribosomal 28S RNA	1	M11167								
ribosomal phosphoprotein P0, 5'UTR (low match)	1	D28418								
Ribosomal protein	1									
ribosomal protein L10 (RPL10)	30	L25899	+	+	+	+	+	+		high in many libraries
RIBOSOMAL PROTEIN L10A (CSA-19)	2	P53025								
ribosomal protein L11 (RPL11)	4	X79234	+	+	+	+	+	+		Alveolar rhabdomyosarcoma
ribosomal protein L12 (RPL19)	2	L06505	+	+	+	+	+	+		
ribosomal protein L13 (PRL13)	1	P26373	+	+	+	+	+	+		high in many libraries
ribosomal protein L14 (RPL14)	4	D87735	+	+	+	+	+	+		high in many libraries
ribosomal protein L17 (RPL17)	4	X53777	+							blood only
ribosomal protein L18 (RPL18)	10	L11566	+	+	+	+			+	
ribosomal protein L18a (RPL18A)	5	L05093		+	+	+	+	+		High in fetal adrenal gland and skin
ribosomal protein L18a homologue	2	X80821					+			
ribosomal protein L19 (RPL19)	15	X63527	+	+	+	+	+	+		
ribosomal protein L21 (RPL21)	6	U14967	+	+	+	+	+	+		
ribosomal protein L22 (RPL22)	3	D17652	+	+	+	+			+	
ribosomal protein L23 (RPL23)	2	X55954	+	+	+	+	+	+		high in many libraries
ribosomal protein L23a (RPL23A)	5	U37230	+	+	+	+	+	+		high in many libraries
ribosomal protein L26 (RPL26)	8	X69392	+	+	+	+	+	+		
ribosomal protein L27 (RPL27)	6	L05094	+	+	+	+			+	
ribosomal protein L27a (RPL27A)	10	U14968	+	+	+	+	+	+		
ribosomal protein L28 (RPL28)	6	U14969	+	+	+	+			+	
ribosomal protein L29 (RPL29)	6	U10248	+	+	+	+	+	+		
ribosomal protein L3 (RPL3)	81		+	+	+	+	+	+		high in many libraries
ribosomal protein L3 homologue	81	X06323								
ribosomal protein L30 (RPL30)	6	X79238	+	+	+	+	+	+		high in lymphoma
ribosomal protein L30 (RPL30) (low score)	1	X79238								
ribosomal protein L31 (RPL31)	10	X15940	+	+	+	+	+	+		High in alveolar rhabdomyosarcoma

ribosomal protein L32 (RPL32)	3	X03342	+	+	+	+	+	+	
ribosomal protein L33-like (RPL33L)	1	AF047440		+	+	+		+	
ribosomal protein L34 (RPL34)	5	L38941		+	+	+	+	+	
ribosomal protein L34 (RPL34) (low match)	1	L38941							
ribosomal protein L37 (RPL37)	5	D23661	+	+	+	+	+	+	
ribosomal protein L37a	4	X66699	+	+	+	+	+	+	high in barstead prostate
ribosomal protein L38 (RPL38)	1	Z26876	+	+	+	+	+	+	high in many libraries
ribosomal protein L4 (RPL4)	27	D23660	+	+	+	+	+	+	high in many libraries
ribosomal protein L41 (RPL41)	4	AF026844	+	+	+	+	+	+	high in many libraries
ribosomal protein L5 (RPL5)	14	U14966	+	+	+	+	+	+	High in alveolar rhabdomyosarcoma
ribosomal protein L5 (RPL5) (low match)	1	U14966							
ribosomal protein L6 (RPL6)	7	X69391	+	+	+	+	+	+	high in many libraries
ribosomal protein L7 (RPL7)	14	X52967	+	+	+	+	+	+	high in conom
ribosomal protein L7a (RPL7A)	15	M36072	+	+	+	+	+	+	High in uterus, and seminoma
ribosomal protein L8 (RPL8)	5	Z28407	+	+	+	+	+	+	high in ovary
ribosomal protein L9 (RPL9)	10	U09953		+	+	+	+	+	
ribosomal protein S10 (RPS10)	5	U14972	+	+	+	+	+	+	high in many libraries
ribosomal protein S11 (RPS11)	4	X06617	+	+	+	+	+	+	high in many libraries
ribosomal protein S11 (RPS11) (low match)	1	AB007152							
ribosomal protein S12 (RPS12)	3	X53505	+	+	+	+	+	+	high in many libraries
ribosomal protein S13 (RPS13)	2	L01124		+	+	+	+	+	
ribosomal protein S14 (RPS14)	12	M13934	+	+	+	+	+	+	
ribosomal protein S15 (RPS15)	2	M32405	+	+	+	+	+	+	
ribosomal protein S16 (RPS16)	3	M60854	+	+	+	+	+	+	High in prostate invasive tumor
ribosomal protein S17 (RPS17)	2	M13932	+	+	+	+	+	+	high in many libraries
ribosomal protein S18	8	X69150							
ribosomal protein S19 (RPS19)	7	M81757	+	+	+	+	+	+	high in many libraries
ribosomal protein S2 (RPS2)	4	X17206	+	+	+	+	+	+	high in many libraries
RIBOSOMAL PROTEIN S2 (RPS4)	2	P15880							
ribosomal protein S20 (RPS20)	7	L06498	+	+	+	+	+	+	high in many libraries
ribosomal protein S21 (RPS21)	3	L04483	+	+	+	+	+	+	high in CD34+/CD38-hematopoietic cells and skin tumor
ribosomal protein S23 (RPS23)	3	D14530		+	+	+		+	
ribosomal protein S24 (RPS24)	7	M31520	+	+	+	+	+	+	high in uterus
ribosomal protein S25 (RPS25)	3	M64716	+	+	+	+	+	+	high in barstead prostate
ribosomal protein S26 (RPS26)	2	X69654		+	+	+	+	+	
ribosomal protein S27 ((metalloproteinase 1) (RPS27))	5	U57847	+	+	+	+	+	+	

ribosomal protein S28 (RPS28)	3	U58682	+	+	+	+	+	+	
ribosomal protein S29 (RPS29)	2	U14973	+	+	+	+	+	+	
ribosomal protein S3 (RPS3)	9	X55715	+	+	+	+	+	+	high in many libraries
ribosomal protein S3 (RPS3) (low match)	1	U14990							
ribosomal protein S3A (RPS3A)	21	Z83334		+	+	+	+	+	high in many libraries
ribosomal protein S3A (RPS3A) (low score)	1	M77234							
ribosomal protein S4, X-linked (RPS4X)	9	M58458	+	+	+	+		+	high in ovary and Synovial sarcoma
ribosomal protein S4, Y-linked (RPS4Y)	2	M58459	+	+	+	+	+	+	
ribosomal protein S5 (RPS5)	4	U14970	+	+	+	+	+	+	high in lymphoma
RIBOSOMAL PROTEIN S6 (PHOSPHOPROTEIN NP33)	1	P10660							
ribosomal protein S6 (RPS6)	22	M20020	+	+	+	+	+	+	
ribosomal protein S6 (RPS6) (non-exact 86%)	1	M77232							
ribosomal protein S6 kinase, 90kD, polypeptide 1 (RPS6KA1)	3	L07597	+	+	+	+		+	
ribosomal protein S6 kinase, 90kD, polypeptide 2 (RPS6KA2)	1	X85106							
ribosomal protein S7 (RPS7)	4	Z25749		+	+	+	+	+	
ribosomal protein S8 (RPS8)	6	X67247		+	+	+	+	+	
ribosomal protein S9 (RPS9)	8	U14971							colon tumor
ribosomal protein, large, P0 (RPLP0)	18	M17885	+		+			+	
ribosomal protein, large, P1 (RPLP1)	12	M17886	+	+	+		+		
ribosomal RNA 18S (=M10098; K03432) (=polyadenylating sequence)	11	X03205							
ribosomal RNA 28S	2	M11167							
ribosomal RNA, 16S	1	U25123							
ring finger protein (non-exact 58%)	1	AJ001019							
ring finger protein 3 (RNF3)	1	AJ001019							
ring finger protein 4 (RNF4)	3	AB000468		+	+	+		+	
ring zinc-finger protein (ZNF127-Xp)	3	U41315		+	+	+		+	
RNA (guanine-7-) methyltransferase (RNMT)	1	AB007858		+	+	+		+	
RNA binding motif protein 5 (RBM5)	4	U23946	+	+	+	+		+	
RNA binding motif, single stranded interacting protein 2 (RBMS2)	1	D28483		+		+		+	
RNA helicase (putative), (Myc-regulated DEAD box protein) (MRD8)	1	X98743	+	+	+	+		+	
RNA helicase-related protein	1	AF083255		+	+	+		+	
RNA pol II largest subunit	2	X74872							
RNA polymerase I subunit (RPA40)	1	AF008442		+	+			+	
RTVP-1 protein	2	X91911	+	+	+	+		+	

S100 calcium-binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11)) (S100A10)	2	M81457			+		+	+	
S100 calcium-binding protein A11 (calgizzarin) (S100A11)	1	X80201		+	+	+		+	
S100 calcium-binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog)(S100A4)	3	M80563	B		+		+		
S100 calcium-binding protein A8 (calgranulin A) (S100A8)	7	M21005			+	+		+	high in bone marrow
S100 calcium-binding protein A9 (calgranulin B) (S100A9)	14	X06233			+	+			high in invasive larynx squamous cell carcinoma
S164 gene	1	AF109907							
S-adenosylmethionine decarboxylase 1 (AMD1)	3	M88003	+	+	+	+		+	
SB class II histocompatibility antigen alpha-chain	5	M27487	+	+	+	+		+	
SC35-interacting protein 1 (SRRP129)	5	AF030234	+	+	+	+	+	+	
scaffold attachment factor B (SAFB)	1	U72355	+	+	+	+		+	
scaffold attachment factor B (SAFB) (non-exact 78%)	1	U72355							
scrRNA molecule, transcribed from Alu repeat	1	L13713							
SEC14 (S. cerevisiae)-like (SEC14L)	4	D67029		+	+	+		+	
SEC23-like protein B (SEC23B)	2	X97065	+	+	+	+		+	
SEC63 (SEC63)	1	AF100141		+	+			+	
secreted protein, acidic, cysteine-rich (osteonectin) (SPARC)	7	M25746		+	+	+	+	+	high in bone marrow stroma
secretory carrier membrane protein 1 (SCAMP1)	1	AF038966		+		+			
secretory carrier membrane protein 2 (SCAMP2)	1	AF005038	+	+	+	+	+	+	
secretory carrier membrane protein 3 (SCAMP3)	1	AF005039							
secretory granule proteoglycan core (clones lambda-PG[6,7,8])	1	M33649							
selectin L (lymphocyte adhesion molecule 1) (SELL)	43	X17519	+			+		+	
selectin P ligand (SELPLG)	13	U02297	+	+					
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D (SEMA4D)	2	U60800		+		+		+	
Ser/Arg-related nuclear matrix protein (plenty of prolines 101-like) (SRM160)	4	AF048977		+	+	+	+	+	
serine palmitoyltransferase subunit I (SPTI)	1	Y08685		+	+	+		+	
serine palmitoyltransferase, subunit II (LCB2)	1	AB011098	+	+	+	+		+	

serine protease	1	J02907								
serine protease inhibitor, Kunitz type, 2 (SPINT2)	1	U78095	+	+	+	+			+	
serine/threonine kinase 10 (STK10)	1	AB015718	+	+	+	+			+	
serine/threonine kinase 19 (STK19)	1	L26260	+	+	+	+				
serine/threonine kinase 4 (STK4)	1	U18297		+					+	
serine/threonine protein kinase KKIALRE (KKIALRE)	1	X66358		+	+	+			+	
serine/threonine protein-kinase (NIK)	1	Y10256		+	+	+				
SERINE/THREONINE-PROTEIN KINASE RECEPTOR R3 PRECURSOR (SKR3)	1	P37023								
serologically defined colon cancer antigen 16 (NY-CO-16)	2	AF039694								
serologically defined colon cancer antigen 33 (SDCCAG33)	1	AF039698	B, T	+	+		+			
serologically defined colon cancer antigen 33 (SDCCAG33) (low score)	1	AF039698								
serologically defined colon cancer antigen 33 (SDCCAG33) (low score)	1	AF039698								
serum deprivation response (phosphatidylserine-binding protein) (SDPR) (=S67386)	1	AF085481.1								
serum/glucocorticoid regulated kinase (SGK)	2	Y10032	+	+	+	+			+	
SET domain, bifurcated 1 (SETDB1)	2	D31891	+	+	+				+	
SH2 domain protein 1A, Duncan's disease lymphoproliferative syndrome) (SH2D1A)	1	AF073019	T						+	
SH3 binding protein (SAB)	2	AB005047	+	+	+	+			+	
SH3 domain protein 1B (SH3D1B)	4	U61167	+			+			+	
SH3BGR PROTEIN (=21-GLUTAMIC ACID-RICH PROTEIN;21-GARP) (non-exact 82%aa)	1	P55822								
SH3-binding domain glutamic acid-rich protein like (SH3BGRL)	1	AF042081	+	+	+	+			+	
SH3-domain GRB2-like 1 (SH3GL1)	1	U65999	+	+	+	+			+	
SHC (Src homology 2 domain-containing) transforming protein 1 (SHC1)	2	X68148		+	+	+			+	
siha binding protein 1 (SiahBP1)	2	U51586		+	+	+			+	
siha binding protein 1 (SiahBP1) (non-exact, 69%)	1	U51586								
Sialomucin CD164 (CD164)	9	D14043								
sialophorin (gpL115, leukosialin, CD43) (SNP)	2	J04536								
sialyltransferase (STHM)	1	U14550			+	+			+	
sialyltransferase 1 (beta-galactoside alpha-2,6-sialyltransferase) (SIAT1)	2	X17247	+	+	+	+	+	+	+	

sialyltransferase 4A (beta-galactosidase alpha-2,3-sialyltransferase) (SIAT4A)	1	AF059321	B	+	+		+	+	
sialyltransferase 8 (alpha-2, 8-polysialyltransferase) D (SIAT8D)	1	L41680		+					
signal peptidase 25kDa subunit	1	L38950							
signal recognition particle 14kD (homologous Alu RNA-binding protein) (SRP14)	1	X73459	+	+	+	+	+	+	
signal recognition particle 54kD (SRP54)	1	U51920			+	+		+	
signal recognition particle 9kD (SRP9)	2	U20998		+	+	+	+	+	
signal recognition particle receptor ('docking protein') SRPR	5	X06272							
signal regulatory protein, beta, 1 (SIRP-BETA-1)	5	Y10376		+				+	
signal sequence receptor, alpha (translocon-associated protein alpha) (SSR1)	2	Z12830				+		+	
signal sequence receptor, beta (translocon-associated protein beta) (SSR2)	2	X74104	+	+	+	+		+	
signal transducer and activator of transcription (STAT5A)	4	L41142	+	+	+	+	+	+	
signal transducer and activator of transcription 2, 113kD (STAT2)	1	U18671						+	
signal transducer and activator of transcription 3 (acute-phase response factor) (STAT3)	3	L29277							
signal transducer and activator of transcription 5A (STAT5A)	2	U48730	+	+	+	+	+	+	
signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 (STAM)	1	U43899							
silencing mediator of retinoid and thyroid hormone action (SMRT)	1	U37146							
similar to beta-transducin superfamily proteins (SAZD)	1	U02609	+	+	+			+	
similar to <i>S. cerevisiae</i> SSM4 (TEB4)	1	AB011169		+	+	+		+	
similar to yeast pre-mRNA splicing factors, Prp1/Zer1 and Prp6	1	AF026031	+	+	+	+		+	
SIT protein	1	AJ010059.1							
Sjogren syndrome antigen A1 (52kD, ribonucleoprotein autoantigen SS-A/Ro) (SSA1)	2	M62800					+		
Sjogren syndrome antigen A1 (52kD, ribonucleoprotein autoantigen SS-A/Ro) (SSA1) (non-exact 63%) (match to zinc finger)	1	M62800							
SKAP55 homologue (SKAP-HOM)	1	AJ004886		+	+	+		+	
skb1 (<i>S. pombe</i>) homolog (SKB1)	2	AF015913	+	+	+	+		+	

skeletal muscle abundant protein	1	X87613	+	+	+	+	+	+	
SMA3 (SMA3)	1	X83300	+	+		+		+	
small acidic protein	3	U51678	+	+	+	+		+	
small EDRK-rich factor 2 (SERF2)	2	Y10351	+	+	+	+	+	+	high in fetal lung
small inducible cytokine A5 (RANTES) (SCYA5)	2	M21121	+	+	+	+	+	+	high in many libraries
small inducible cytokine subfamily C, member 2 (SCYC2)	1	D63789							
small nuclear ribonucleoprotein polypeptide B" (SNRPB2)	2	M15841		+	+	+		+	
small nuclear ribonucleoprotein polypeptide N (SNRPN)	4	J04615	+	+	+	+	+	+	
small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB)	2	J04564	+	+	+	+		+	
small nuclear RNA activating complex, polypeptide 5, 19kD (SNAPC5)	1	AF093593	+	+	+	+		+	
smallest subunit of ubiquinol-cytochrome c reductase	1	D55636	+	+	+	+	+	+	high in fetal lung
SMC (mouse) homolog, X chromosome (SMCX)	1	L25270	+	+	+	+		+	
SMT3B protein (2)	2	X99585	+	+	+	+	+	+	
SNARE protein (YK16) (low match)	1	U95735							
SNC19	1	U20428							
SNC73 protein (SNC73)	2	J00220	+	+		+	+	+	high in many libraries
solute carrier family 1 (neutral amino acid transporter), member 5 (SLC1A5)	2	U53347		+		+		+	
Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 (SLC11A1)	7	D50403	+						
solute carrier family 17 (sodium phosphate), member 3 (SLC17A3)	1	U90545				+			
solute carrier family 19 (folate transporter), member 1 (SLC19A1)	1	U17566	B, lymphoma	+			+		
solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1)	1	K03195	+	+	+	+	+	+	
solute carrier family 23 (nucleobase transporters), member 2 (SLC23A2)	3	D87075		+	+	+		+	
solute carrier family 25 (mitochondrial carrier, oxoglutarate carrier), member 11 (SLC25A11)	1	AF070548	B, T	+	+		+	+	
solute carrier family 31 (copper transporters), member 2 (SLC31A2)	3	U83461		+		+			
solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1) (SLC4A2)	1	X62137		+	+			+	
solute carrier family 4, sodium bicarbonate cotransporter, member 8 (SLC4A8)	1	AB018282		+					

solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 (SLC7A5)	2	M80244	T, W	+	+		+		
solute carrier family 7 (cationic amino acid transporter, y+ system), member 6 (SLC7A6)	3	D87432	+	+	+				+
solute carrier family 7 (cationic amino acid transporter, y+ system), member 6 (SLC7A6) (non- exact 77%)	1	D87432							
solute carrier family 9 (sodium/hydrogen exchanger), isoform 6 (SLC9A6)	1	AF030409		+	+	+			+
somatic cytochrome c (HCS)	2	M22877							
SON DNA binding protein (SON)	2	X63753		+	+	+			+
son of sevenless (Drosophila) homolog 1 (SOS1)	1	L13858	+	+		+			
sorcin (SRI)	1	M32886							
sortilin 1 (SORT1)	2	X98248		+					
sortilin-related receptor, L(DLR class) A repeats- containing (SORL1)	6	Y08110				+			+
sorting nexin 1 (SNX1)	3	U53225	+	+	+	+			+
sorting nexin 2 (SNX2)	2	AF043453							
sorting nexin 6 (SNX6) (=U83194.1 TRAF4- associated factor 2)	1	AF121856.1							
Sp3 transcription factor (SP3)	1	X68560	+	+	+	+			+
Sp3 transcription factor (SP3)	4	M97191	+	+	+	+			+
special AT-rich sequence binding protein 1 (binds to nuclear matrix/scaffold- associating DNA's) (SATB1)	1	M97287							
speckle-type POZ protein (SPOP)	4	AJ000644							
speckle-type POZ protein (SPOP) (non-exact)	1	AJ000644							
spectrin SH3 domain binding protein 1 (SSH3BP1)	6	U87166	+	+	+	+			
Spectrin, alpha, non- erythrocytic 1 (alpha-fodrin) (SPTAN1)	2	J05243		+	+				+
spermidine/spermine N1- acetyltransferase (SAT)	11	M55580							
spermidine/spermine N1- acetyltransferase (SAT) (non-exact, 84%)	1	U40369							
spermine synthase (SMS)	1	AD001528	+	+	+	+			+
SPF31 (SPF31)	1	AF083190	+	+	+	+			+
sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase) (SMPD1)	1	X52679		+	+		+		
SPINDLIN HOMOLOG (PROTEIN DXF34)	1	Q99865							
spinocerebellar ataxia 1 (olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1) (SCA1)	3	X79204	B	+			+		

spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, autosomal dominant, ataxin 2) (SCA2)	1	U70323	B					+		
spinocerebellar ataxia 7 (olivopontocerebellar atrophy with retinal degeneration) (SCA7)	2	AJ000517		+						
spliceosome associated protein (SAP 145)	3	U41371		+	+	+	+	+		
splicing factor (CC1.3) (CC1.3)	2	L10910	+	+	+	+	+	+		
splicing factor SRp40-1 (SRp40)	7	U30826	+	+	+	+	+	+		
splicing factor, arginine/serine-rich 11 (SFRS11)	3	M74002	B	+	+			+	+	
splicing factor, arginine/serine-rich 7 (35kD) (SFRS7)	4	L41887		+	+	+			+	
Src-like adapter protein (non-exact, 76%aa)	1	U30473								
Src-like-adapter (SLA)	6	D89077		+	+	+			+	
Src-like-adapter (SLA) (low match)	1	D89077								
Src-like-adapter (SLA) (low score)	1	U44403								
stannin (SNN)	2	AF030196	+	+	+	+			+	
STAT induced STAT inhibitor 3 (SSI-3)	1	AB004904				+				
STE20-like kinase 3 (MSI-3)	2	AF024636	+	+	+	+			+	
step II splicing factor SLU7 (SLU7)	1	AF101074		+		+	+	+		
steroid sulfatase	1	M17591								
steroid sulfatase (microsomal), arylsulfatase C, isozyme S (STS)	1	J04964		+	+	+				
sterol carrier protein 2 (SCP2)	1	M55421		+	+	+	+	+		
sterol O-acyltransferase (acyl-Coenzyme A: cholesterol acyltransferase) 1 (SOAT1)	1	AF059202						+		
stimulated trans-acting factor (50 kDa) (STAF50)	6	X82200	+	+		+				
Striatin, calmodulin-binding protein (STRN) (low match, 71%aa)	1	U17989								
Stromal antigen 2 (STAG2)	2	Z75331			+	+	+	+		
stromal interaction molecule 1 (STIM1)	3	U52426	+	+	+	+			+	
structure specific recognition protein 1 (SSRP1)	1	M86737		+	+	+			+	
succinate dehydrogenase complex, subunit A, flavoprotein (Fp) (SDHA)	5	L21936			+					
succinate dehydrogenase complex, subunit B, iron sulfur (lp) (SDHB)	1	U17248	+	+	+	+			+	
succinate dehydrogenase complex, subunit C, integral membrane protein, 15kD (SDHC)	1	U57877	+	+	+	+			+	
succinate dehydrogenase complex, subunit D, Integral membrane protein (SDHD)	3	AB006202		+	+			+		
succinate-CoA ligase, GDP-forming, beta subunit (SUCLG2)	1	AF058954		+	+	+	+	+		

succinyl CoA synthetase			1	Z68204								
sudD (suppressor of bimD6, Aspergillus nidulans) homolog (SUDD)	2	AF013591			+					+	+	
sulfotransferase family 1A, phenol-preferring, member 1 (SULT1A1)	1	L19999			+					+	+	
sulfotransferase family 1A, phenol-preferring, member 3 (SULT1A3) (non-exact 67%)	1	U37686										
superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) (SOD1)	4	X02317			+	+				+	+	
superoxide dismutase 2, mitochondrial (SOD2)	5	Y00985			+	+	+			+	+	
supervillin (SVIL)	2	AF051851				+	+				+	
suppression of tumorigenicity 5 (ST5)	2	U15131			+		+				+	
suppression of tumorigenicity 5 (ST5) (non-exact 82%)	1	U15779										
suppressor of K+ transport defect 1 (SKD1)	1	AF038960				+	+					
suppressor of Ty (S.cerevisiae) 3 homolog (SUPT3H)	1	AF064804	+		+	+	+				+	
suppressor of Ty (S.cerevisiae) 4 homolog 1 (SUPT4H1)	2	U38817	+		+	+	+				+	
suppressor of Ty (S.cerevisiae) 5 homolog (SUPT5H)	2	U56402			+						+	
suppressor of Ty (S.cerevisiae) 6 homolog (SUPT6H)	2	U46691	+		+	+	+			+	+	
suppressor of vanegation 3-9 (Drosophila) homolog 1 (SUV39H1)	1	AF019968			+	+	+					
survival of motor neuron 1, telomeric (SMN1)	1	U18423										
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 (SMARCA1) (non-exact, 75%)	1	M88163				+	+				+	
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2)	2	D26155			+							
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4)	1	D26156	+		+	+	+	+	+	+	+	
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 2 (SMARCC2)	4	U66616	+		+	+	+	+	+	+	+	
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 (SMARCE1)	2	AF035262	B, W		+	+			+	+		
synaptobrevin-like 1 (SYBL1)	1	X95803			+	+	+				+	
synaptosomal-associated protein, 23kD (SNAP23)	2	AJ011915			+	+	+				+	
syndecan binding protein (syntenin) (SDCBP)	15	AF006636	+		+	+	+				+	

synovial sarcoma, translocated to X chromosome (SSXT)	2	X79201		+						
syntaxin 16	1	AF038897								
syntaxin 3A (STX3A)	2	U32315		+		+		+		
syntaxin 6 (STX6)	1	AJ002078.1								
SYNTAXIN BINDING PROTEIN 3 (UNC-18 HOMOLOG 3) (UNC-18C)	1	O00186								
syntaxin-16C	1	AF008937								
SYT interacting protein (SIP)	1	AF080561		+	+	+		+		
T cell activation, increased late expression (TACTILE)	4	M88282				+				
T cell receptor V alpha gene segment V-alpha-7 (clone IGRa11)	2	X58744								
T cell receptor V alpha gene segment V-alpha-w27	1	X58740								
T3 receptor-associated cofactor-1	5	S83390	+	+	+	+	+	+		
tafazzin (cardiomyopathy, dilated 3A (X-linked); endocardial fibroelastosis 2; Barth syndrome) (TAZ)	1	X92763	+	+		+		+		
TAFII100 protein (non-exact 53%)	1	U80191								
tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase (TNKS)	1	AF082556		+	+	+		+		
TAP1, TAP2, LMP2, LMP7 and DOB	1	X66401								
TAR DNA-binding protein-43	6	U23731	+	+	+	+		+		
Tat interactive protein (60kD) (TIP60)	2	U40989	+	+	+	+		+		
TATA box binding protein (TBP)-associated factor, RNA polymerase II, C1, 130kD (TAF2C1) (non-exact, 55%)	1	O00268								
TATA box binding protein (TBP)-associated factor, RNA polymerase II, F, 55kD (TAF2F)	4	X97999		+	+	+	+	+		
TATA box binding protein (TBP)-associated factor, RNA polymerase II, G, 32kD (TAF2G)	2	U21858		+	+	+	+	+		
TATA box binding protein (TBP)-associated factor, RNA polymerase II, I, 28kD (TAF2I)	1	D63705	+	+	+	+		+		
Tax1 (human T-cell leukemia virus type I) binding protein 1 (TAX1BP1)	1	U33821		+	+	+	+	+		
T-box 2 (TBX2) (non-exact 77%)	1	U28049			+	+		+		
TBP-associated factor 172 (TAF-172)	1	AJ001017		+		+		+		
T-cell death-associated gene 8 (TDAG8)	1	U95218				+				
T-cell leukemia/lymphoma 1A (TCL1A)	1	X82240	+							
T-cell leukemia/lymphoma 1A (TCL1A) (low match)	1	X82240								
T-cell receptor (delta D2-J1-region) (clone K3B)	1	M22197								

96

threonyl-tRNA synthetase (TARS)	1	M63180		+	+	+		+	
thrombin inhibitor	1	Z22658							
thrombospondin 1 (THBS1)	2	X04665		+	+	+	+	+	
thromboxane A synthase 1 (platelet, cytochrome P450, subfamily V) (TBXAZ1)	1	M80647		+		+	+	+	
thymidine kinase 2, mitochondrial (TK2)	2	X76104		+	+		+		
thymidylate kinase (CDC8)	1	L16991		+	+	+		+	
thymine-DNA glycosylase (TDG)	2	U51166	+	+	+	+		+	
Thymosin, beta 10 (TMSB10)	2	M20259	+	+	+	+	+	+	
thymosin, beta 4, X chromosome (TMSB4X)	29	M17733		+	+	+		+	
thyroid autoantigen 70kD (Ku antigen) (G22P1)	7	J04611							
thyroid hormone receptor coactivating protein (SMAP)	1	AF016270		+		+		+	
thyroid hormone receptor interactor 7 (TRIP7)	2	L40357		+	+	+		+	
thyroid hormone receptor interactor 8r (TRIP8)	4	L40411		+					
thyroid hormone receptor-associated protein, 230 kDa subunit (TRAP230)	1	D83783							
thyroid receptor interacting protein 15 (TRIP15)	2	L40388	+	+	+	+			
TI-227H	1	D50525							
TIA1 cytotoxic granule-associated RNA-binding protein (TIA1)	1	M77142		+	+	+		+	
tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) (TIMP1)	1	X02598	+	+	+	+	+	+	
tissue inhibitor of metalloproteinase 2 (TIMP2)	1	M32304	+	+	+	+		+	high in placenta
tissue specific transplantation antigen P35B (TSTA3)	1	U58766	+	+	+	+		+	
titin (TTN)	1	X64697	+	+	+	+		+	high in muscle
TNF receptor-associated factor 2 (TRAF2)	1	U12597		+	+	+		+	
TNF receptor-associated factor 3 (TRAF3)	1	AF110908.1		+					
TNF receptor-associated factor 6 (TRAF6) (low match)	1	U78798							
toll-like receptor 1 (TLR1)	1	U88540				+			
toll-like receptor 2 (TLR2)	1	U88878	+	+		+		+	
toll-like receptor 4 (TLR4)	1	U88880		+			+		
toll-like receptor 5 (TLR5)	1	AF051151		+		+			
topoisomerase (DNA) I (TOP1)	1	J03250		+	+	+			
topoisomerase (DNA) II beta (180kD) (TOP2B)	2	X68060	+	+	+	+		+	
topoisomerase (DNA) III beta (TOP3B)	3	D87012	+						
TR3beta	1	D85245		+					
TRAF family member-associated NF-kB activator (TANK)	3	U63830	+	+	+	+	+	+	
TRANSALDOLASE	1	P37837							
transaldolase 1 (TALDO1)	4	L19437		+	+	+	+	+	

98

transgelin 2 (TAGLN2)	14	D21261	+	+	+	+	+	+	
transgelin 2 (TAGLN2) (non-exact)	1	D21261							
trans-Golgi network protein (46, 48, 51kD isoforms) (TGN51)	2	AF029316		+		+			
transient receptor potential channel 1 (TRPC1)	1	X89066		+	+	+		+	
transketolase (Wernicke-Korsakoff syndrome) (TKT)	7	L12711		+	+	+		+	
translation factor sur1 homolog (GC20)	1	AF064607		+	+	+	+	+	
translin (TSN)	3	X78627	+	+	+	+		+	
translin-associated factor X (TSNAX)	1	X95073		+	+	+		+	
transmembrane glycoprotein (A33)	1	U79725							
transmembrane protein (63kD), endoplasmic reticulum/Golgi intermediate compartment (P63)	1	X69910	+	+	+	+		+	
transmembrane protein 1 (TMEM2)	1	AB001523		+		+		+	
TRANSMEMBRANE PROTEIN SEX PRECURSOR (non-exact 65%)	1	P51805							
transmembrane trafficking protein (TMP21)	2	X97442	+	+	+	+	+	+	
transporter 1, ABC (ATP binding cassette) (TAP1)	3	L21208	+	+	+	+		+	
Treacher Collins-Franceschetti syndrome 1 (TCOF1)	2	U40847	+	+	+	+		+	high in many libraries
triosephosphate isomerase 1 (TPI1)	2	X69723	+	+	+	+	+	+	
tropomyosin	2	X04201		+	+	+		+	
tropomyosin 4 (TPM4)	2	X05276	+	+	+	+		+	
TRPM-2 protein	2	M63376							
tryptase I precursor (non-exact 64%)(=P20231)	1	A35863							
tryptophan rich basic protein (WRB)	1	Y12478							
tryptophanyl-tRNA synthetase (WARS)	1	X59892	+	+	+	+	+	+	
Ts translation elongation factor, mitochondrial (TSFM)	1	L37936	+	+		+		+	
topoisomerase (DNA) II beta (180kD)	1	Z15115		+	+			+	
Tu translation elongation factor, mitochondrial (TUFM)	4	L38995							
tuberous sclerosis 1 (TSC1)	1	AF013168		+	+	+		+	
tuberous sclerosis 2 (TSC2)	1	X75621		+	+	+		+	
tubulin, alpha 1 (testis specific) (TUBA1)	1	X06956		+			+		
tubulin, alpha, ubiquitous (K-ALPHA-1)	11	K00558	+	+	+	+	+	+	high in many libraries
tubulin, alpha, ubiquitous (K-ALPHA-1) (low match)	1	K00558							
tubulin-specific chaperone c (TBCC)	1	U61234		+	+	+		+	
tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10)	7	U37518		+	+	+		+	

tumor necrosis factor (ligand) superfamily, member 13 (TNFSF13)	1	AF046888	+	+		+		+		
tumor necrosis factor (ligand) superfamily, member 14 (TNFSF14)	1	AF036581								
tumor necrosis factor (ligand) superfamily, member 6 (TNFSF6)	1	D38122	+							Found only in library 386: T-cell lymphoma
tumor necrosis factor (ligand) superfamily, member 8 (TNFSF8)	1	L09753	B only							
tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains (FIP2)	1	AF061034		+	+	+			+	
tumor necrosis factor receptor superfamily, member 7 (TNFRSF7)	2	M63928		+				+		
tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B)	1	AF016266		+	+	+	+	+		
tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain (TNFRSF10C)	3	AF012629						+		
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain (TNFRSF10D) (non-exact 84%)	1	AF023849								found only in prostate
tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein) (TNFRSF12)	1	U94508	+	+	+	+			+	
tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) (TNFRSF14)	1	U70321	+	+	+	+			+	
tumor necrosis factor receptor superfamily, member 1B (TNFRSF1B)	5	U52165	+	+	+	+			+	
tumor necrosis factor receptor superfamily, member 6 (TNFRSF6)	1	X63717	B, W						+	
tumor necrosis factor receptor superfamily, member 7 (TNFRSF7)	1	M63928	+	+						
tumor necrosis factor, alpha-induced protein 2 (TNFAIP2)	8	M92357		+	+			+		
tumor necrosis factor, alpha-induced protein 3 (TNFAIP3)	2	M59465								
tumor protein 53-binding protein, 1 (TP53BP1)	1	AF078776		+	+	+			+	
tumor protein p53 (Li-Fraumeni syndrome) (TP53)	1	M14695	+	+					+	
tumor protein p53-binding protein (TP53BPL)	1	U82939	+			+			+	
tumor protein, translationally-controlled 1 (TPT1)	35	X16064								
tumor protein, translationally-controlled 1 (TPT1) (low score)	1	X16064								
tumor rejection antigen (gp96) 1 (TRA1)	9	X15187	+	+	+	+	+	+	+	

tumorous imaginal discs (Drosophila) homolog (TID1)	2	AF061749		+							
TXK tyrosine kinase (TXK)	2	L27071									
type II integral membrane protein (NKG2-E)	1	AJ001685						+			found only in fetal liver/spleen
TYRO protein tyrosine kinase binding protein (TYROBP)	3	AF019562			+						
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide (YWHAB)	1	X57346	+	+	+	+			+		high in ecnorm
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (YWHAZ)	1	M86400									
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (YWHAZ)	1	M86400									
tyrosine kinase 2 (TYK2)	3	X54637		+	+	+			+		
TYROSINE-PROTEIN KINASE ZAP-70 (70 KD. ZETA-ASSOCIATED PROTEIN) (SYK-RELATED TYROSINE KINASE)	2	P43403									
tyrosyl-tRNA synthetase (YARS)	1	U89436	+	+	+	+			+		
U1 small nuclear RNA	1	M14387									
U19H snoRNA (=M63485 R.norvegicus matrin 3)	1	AJ224166									
U2(RNU2) small nuclear RNA auxiliary factor 1 (non-standard symbol) (U2AF1)	1	M96982		+	+	+			+		
U22 snoRNA host gene (UHG)	2	U40580									
U4/U6-associated RNA splicing factor (HPRP3P)	4	AF016370		+	+	+			+		
U49 small nuclear RNA	1	X96649									
U5 snRNP-specific protein (220 kD), ortholog of S. cerevisiae Prp8p (PRP8)	1	AB007510	+	+	+	+			+		
U5 snRNP-specific protein, 116 kD (U5-116KD)	4	D21163	+	+	+	+			+		
U5 snRNP-specific protein, 200 kDa (DEXH RNA helicase family) (U5-200-KD)	3	Z70200									
Uba80 mRNA for ubiquitin	4	S79522	+	+	+	+	+	+	+		high in ovary
ubiquinol-cytochrome c reductase (6.4kD) subunit (UQCR)	1	D55636	+	+	+	+	+	+	+		high in fetal lung
UBIQUINOL-CYTOCHROME C REDUCTASE IRON-SULFUR SUBUNIT PRECURSOR (RIESKE IRON-SULFUR PROTEIN) (RISP) (low match)	1	P47985									
ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52)	2	X56999									
ubiquitin activating enzyme E1-like protein (GSA7)	1	AF094516		+	+				+		
ubiquitin C (UBC)	5	AB009010		+	+	+	+	+	+		high in ovary

ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) (UCHL3)	1	M30496	+	+	+	+		+	
ubiquitin fusion degradation 1-like (UFD1L)	1	U64444	+	+	+	+		+	
ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome) (UBE3A)	1	U84404	B	+	+			+	
ubiquitin specific protease 10 (USP10)	4	D80012	+	+	+	+		+	
ubiquitin specific protease 11 (USP11)	1	U44839	+	+	+	+	+	+	
ubiquitin specific protease 15 (USP15)	3	AB011101	+	+	+	+		+	
ubiquitin specific protease 19 (USP19)	1	AB020698		+					
ubiquitin specific protease 4 (proto-oncogene) (USP4)	1	AF017305	B	+	+			+	+
ubiquitin specific protease 4 (proto-oncogene) (USP4) (non-exact, 66%)	1	AF017306							
ubiquitin specific protease 7 (herpes virus-associated) (USP7)	1	Z72499		+	+	+		+	
ubiquitin specific protease 8 (USP8)	5	D29956		+	+	+		+	
UBIQUITIN-ACTIVATING ENZYME E1 (A1S9 PROTEIN) (56%)	1	P22314							
ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing) (UBE1)	1	M58028	+	+	+	+		+	
ubiquitin-activating enzyme E1, like (UBE1L)	1	L34170	+	+		+		+	
UBIQUITIN-BINDING PROTEIN P62; phosphotyrosine independent ligand for the Lck SH2 domain p62 (P62)	1	U41806			+		+		
ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1)	2	U49278	+	+	+	+	+	+	
ubiquitin-conjugating enzyme E2 variant 2 (UBE2V2)	1	X98091							
UBIQUITIN-CONJUGATING ENZYME E2-17 KD (UBIQUITIN-PROTEIN LIGASE)	1	Q16781							
ubiquitin-conjugating enzyme E2B (RAD6 homolog) (UBE2B)	1	M74525	+	+	+	+		+	
ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7) (UBE2G2)	1	AF032456	+	+	+	+		+	
ubiquitin-conjugating enzyme E2H (homologous to yeast UBC8) (UBE2H)	1	Z29328	+	+	+	+		+	
ubiquitin-conjugating enzyme E2L 1 (UBE2L1)	1	X92962		+	+			+	
ubiquitin-conjugating enzyme E2L 3 (UBE2L3)	3	AJ000519		+	+	+		+	
ubiquitin-conjugating enzyme E2L 6 (UBE2L6)	4	AF031141		+	+	+	+	+	
ubiquitin-like 1 (sentrin) (UBL1)	2	U61397	+	+	+	+		+	

UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylglucosaminyltransferase 2 (GalNAc-T2) (GALNT2)	2	X85019								
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylglucosaminyltransferase 3 (GalNAc-T3) (GALNT3) (non-exact 65%)	1	X92689								
inactive progesterone receptor, 23 Kd (P23)	2	L24804		+	+	+			+	
unconventional myosin-ID (MYO1F)	3	U57053								
uncoupling protein homolog (UCPH)	1	U94592								
uncoupling protein homolog (UCPH) (low match 67%)	1	U94592								
Unknown gene product	1	AC002310								
unknown mRNA (clone 24514)	1	AF070542								
unknown protein (clone ICRFp507L0677)	2	Z70223								
unknown protein (Hs.93832)	1	AF070626	+	+	+	+	+	+	+	
unknown protein IT14	1	AF040966								
uppressor of Ty (S.cerevisiae) 6 homolog	1	D79984	+	+	+	+	+	+	+	
upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1)	74	S73591	+	+	+	+			+	high in heart
upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1) (low match)	1	S73591								
upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1) (low match)	1	S73591								
upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1) (low score)	1	S73591								
upstream binding factor (hUBF)	1	X53461	+	+		+			+	
UV radiation resistance associated gene (UVRAG)	2	X99050		+	+	+			+	
vacuolar proton-ATPase, subunit D; V-ATPase, subunit D (ATP6DV)	4	X71490		+	+	+	+	+	+	
v-akt murine thymoma viral oncogene homolog 1 (AKT1)	1	M63167	+	+	+	+			+	
Vanin 2 (VNN2)	3	AJ132100								
vasodilator-stimulated phosphoprotein (VASP)	3	Z46389	+		+	+			+	
vav 1 oncogene (VAV1)	1	M59834							+	
vav 2 oncogene (VAV2)	1	S76992	+	+						
v-crak avian sarcoma virus CT10 oncogene homolog (CRK)	1	D10656	W	+	+			+		
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ERBB3)	1	M29366							+	
VERSICAN CORE PROTEIN PRECURSOR	1	P13611								
Vesicle-associated membrane protein 1 (synaptobrevin 1) (VAMP1)	1	M36196		+	+	+			+	

104

X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining; Ku autoantigen, 80kD) (XRCC5)	1	M30938	+	+	+	+		+	high in spleen
XRPA protein	1	AJ007590							
yellow differentiation primary response gene (88) (MYD88)	1	U84408		+	+	+		+	
zeta-chain (TCR) associated protein kinase (70kD) (ZAP70)	1	L05148	+			+			
zeta-chain (TCR) associated protein kinase (70kD) (ZAP70) (low match)	1	L05148							
zinc finger protein (Hs.47371)	2	U69274	+	+	+	+		+	
zinc finger protein (Hs.78765)	1	U69645	+	+	+	+		+	
zinc finger protein 10 (KOX 1) (ZNF10)	1	X78933							+ only
ZINC FINGER PROTEIN 124 (HZF-16) (non-exact 51%)	1	Q15973							
zinc finger protein 124 (HZF-16) (ZNF124) (non-exact, 78%)	1	S54641							
ZINC FINGER PROTEIN 133	1	P52736							
zinc finger protein 136 (clone pHZ-20) (ZNF136)	1	U09367			+	+			
zinc finger protein 140 (clone pHZ-39) (ZNF140)	1	U09368		+		+		+	
zinc finger protein 140 (clone pHZ-39) (ZNF140) (non-exact 59%)	1	AF060865							
zinc finger protein 140 (clone pHZ-39) (ZNF140) (non-exact 73%)	1	U09368							
zinc finger protein 140 (clone pHZ-39) (ZNF140) (non-exact 73%aa)	1	S66508							
zinc finger protein 140 (clone pHZ-39) (ZNF140) (non-exact, 80%)	1	U09368							
zinc finger protein 143 (clone pHZ-1) (ZNF143)	2	U09850	+	+	+	+	+	+	
zinc finger protein 143 (clone pHZ-1) (ZNF143) (low match)	1	U09850							
zinc finger protein 148 (pHZ-52) (ZNF148)	1	AF039019	+						
ZINC FINGER PROTEIN 151 (MIZ-1 PROTEIN) (low match)	1	Q13105							
zinc finger protein 173 (ZNF173)	1	U09825	B, T	+	+		+		
zinc finger protein 192 (ZNF192) (non-exact, 66%)	1	U57796							
zinc finger protein 198 (ZNF198)	1	AJ224901		+	+	+			
zinc finger protein 2 (ZNF2) (low match)	1	X60152							
zinc finger protein 200 (ZNF200)	1	AF060866		+		+			
zinc finger protein 207 (ZNF207)	6	AF046001	+	+	+	+	+	+	high in prostate
zinc finger protein 216 (ZNF216)	2	AF062072	+	+	+	+		+	

zinc finger protein 217 (ZNF217)	1	AF041259	1 activated							+	
ZINC FINGER PROTEIN 22 (ZINC FINGER PROTEIN KOX15) (non-exact 58%)	1	P17026									
zinc finger protein 230 (ZNF230)	1	U95044		+							
zinc finger protein 239 (ANF239)	1	L26914		+			+				
zinc finger protein 261 (ZNF261)	1	AB002383		+	+	+				+	
zinc finger protein 262 (ANF262)	1	AB007885		+	+	+				+	
zinc finger protein 263 (ZNF263)	1	D88827									
zinc finger protein 264 (ZNF264)	1	AB007872		+	+	+					
ZINC FINGER PROTEIN 33A (ZINC FINGER PROTEIN KOX31) (KIAA0065) (HA0946)	1	Q06730									
zinc finger protein 42 (myeloid-specific retinoic acid-responsive) (ZNF42)	1	M58297	+	+	+	+				+	
zinc finger protein 43 (HTF6) (ZNF43) (low match)	1	X59244									
zinc finger protein 43 (HTF6) (ZNF43) (non-exact, 54%)	1	X59244									
zinc finger protein 43 (HTF6) (ZNF43) (non-exact, 71%)	1	X59244									
ZINC FINGER PROTEIN 43 (ZINC PROTEIN HTF6) (non-exact 67%)	1	P28160									
zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide) (ZNF45)	1	L75847									only found in testis
ZINC FINGER PROTEIN 46 (ZINC FINGER PROTEIN KUP) (non-exact 62%)	1	P24278									
zinc finger protein 6 (CMPX1) (ZNF6)	1	X56465		+	+	+				+	
zinc finger protein 74 (Cos52) (ZNF74) (non-exact, 67%)	1	X71623									
zinc finger protein 76 (expressed in testis) (ZNF76)	1	M91592		+	+	+				+	
ZINC FINGER PROTEIN 83 (ZINC FINGER PROTEIN HPF1) (non-exact 65%)	1	P51522									
zinc finger protein 84 (HPF2) (ZNF84)	1	M27878	1 activated	+	+					+	
zinc finger protein 85 (ZNF85)	2	U35376		+	+	+					
zinc finger protein 9 (ZNF9)	5	M28372		+	+	+	+	+			
ZINC FINGER PROTEIN 93 (=ZINC FINGER PROTEIN HTF34) (non-exact 70%)	1	P35789									
zinc finger protein C2H2-25 (ZNF25)	3	U38904		+	+	+					
zinc finger protein clone L3-4	1	AF024706									
zinc finger protein homologous to Zfp-36 in mouse (ZFP36)	4	M92843	+								blood only

ZINC FINGER PROTEIN HRX (ALL-1) (71%a.a.)	1	Q03164							
zinc finger protein HZF4	1	X78927							
zinc finger protein RIZ	1	D45132	+	+	+	+		+	
zinc finger protein, subfamily 1A. 1 (Ikaros) (LYF1)	1	U40462	+						
zinc finger protein, subfamily 1A. 1 (Ikaros) (LYF1) (low match)	1	U40462							
zinc finger transcriptional regulator (GOS24)	1	M92844							
zinc-finger helicase (hZFH)	2	U91543	+	+	+	+		+	
Zn-15 related zinc finger protein (rff)	1	U22377		+	+	+			
Zn-15 related zinc finger protein (rff) (non-exact 56%)	1	U22377							
ZNF80-linked ERV9 long terminal repeat	1	X83497							
ZW10 (Drosophila) homolog, centromere/kinetochore protein (ZW10)	2	U54996		+					
zyxin (ZYX)	4	X95735							

Column 1: List of unique genes derived from 6,283 known ESTs from blood cells.

Column 2: Number of genes found in randomly sequenced ESTs from blood cells.

5 Column 3: Accession number. Column 4: "+" indicates the presence of the unique gene in publicly available cDNA libraries of blood (Bl), brain (Br), heart (H), kidney (K), liver (Li) and lung (Lu). **Comparison to previously identified tissue-specific genes was determined using the GenBank of the National Centre of Biotechnology Information (NCBI) Database.

10

Discussion

Every cell and tissue comprising the human body share the necessary genetic information required to maintain cellular homeostasis. These "housekeeping" genes function in basic cellular maintenance, including energy metabolism and cellular structure in all cell types. However, in certain situations, even the housekeeping genes show altered expression. Thus, it is necessary to define the use of these genes as internal controls from one investigation to another. Current results from the human blood cell EST database indicate that over 50% of the transcripts are

widely expressed throughout the human body. Most of the cell or tissue specific genes are also detectable in blood cells by RT-PCR analysis.

For example, isoformic myosin heavy chain genes are known to be generally expressed in cardiac muscle tissue. In the rodent, the β MyHC gene is only
5 highly expressed in the fetus and in diseased states such as overt cardiac hypertrophy, heart failure and diabetes; the α MyHC gene is highly expressed shortly after birth and continues to be expressed in the adult heart. In the human, however, β MyHC is highly expressed in the ventricles from the fetal stage through adulthood. This highly expressed β MyHC, which harbours several mutations, has been demonstrated to be
10 involved in familial hypertrophic cardiomyopathy (Geisterfer-Lowrance *et al.* 1990). It was reported that mutations of β MyHC can be detected by PCR using blood lymphocyte DNA (Ferrie *et al.*, 1992). Most recently, it was also demonstrated that mutations of the myosin-binding protein C in familial hypertrophic cardiomyopathy can be detected in the DNA extracted from lymphocytes (Niimura *et al.*, 1998).

15 Similarly, APP and APC, which are known to be tissue specific and predominantly expressed in the brain and intestinal tract, are also detectable in the transcripts of blood. These cell- or tissue-specific transcripts are not detectable by Northern blot analysis. However, the low number of transcript copies can be detected by RT-PCR analysis. These findings strongly demonstrate that genes preferentially
20 expressed in specific tissues can be detected by a highly sensitive RT-PCR assay. In recent years, evidence has been obtained to indicate that expression of cell or tissue-restricted genes can be detected in the peripheral blood of patients with metastatic transitional cell carcinoma (Yuasa *et al.* 1998) and patients with prostate cancer (Gala *et al.* 1998).

25 Atrial natriuretic factor (ANF) and zinc finger protein (ZFP), which are known to be highly expressed in heart tissue biopsies and in the plasma of heart failure patients, are also detectable in the transcripts of blood. Differential expression of zinc finger protein among the normal, diabetic and asymptomatic preclinical

subjects may have additional value as a prophylactic "early warning system". On a related note, there is now more attention/discussion in the cardiovascular disease field being focused on Syndrome X, loosely defined as a continuum of hypertension, increasing sugar levels, diabetes, kidney failure, culminating in heart failure, with the possibility of stroke and heart attack at any time in the continuum. The early identification of patients at risk of organ failure has been a challenge to the medical community for some time and the present method has the potential of resolving or, at least, ameliorating this challenge.

The present invention demonstrates that a simple drop of blood may be used to determine the quantitative expression of various mRNAs that reflect the health/disease state of the subject through the use of RT-PCR analysis. This entire process takes about three hours or less. The single drop of blood may also be used for multiple RT-PCR analyses. There is no need for large samples and/or costly and time-consuming separation of cell types within the blood for this method as compared to the methods described by Kimoto (1998) and Chelly et al. (1989; 1988). It is believed that the present finding can potentially revolutionize the way that diseases are detected, diagnosed and monitored because it provides a non-invasive, simple, highly sensitive and quick screening for tissue-specific transcripts. The transcripts detected in whole blood have potential as prognostic or diagnostic markers of disease, as they reflect disturbances in homeostasis in the human body. Delineation of the sequences and/or quantitation of the expression levels of these marker genes by RT-PCR will allow for an immediate and accurate diagnostic/prognostic test for disease or to assess the efficacy and monitor a particular therapeutic.

In addition to RT-PCR, other methods of amplifying may also be used for the purpose of measuring/quantitating tissue-specific transcripts in human blood. For example, mass spectrometry may be used to quantify the transcripts (Koster et al., 1996; Fu et al., 1998). The application of presently disclosed method for detecting tissue-specific transcripts in blood does not restrict to subjects undergoing course of

therapy or treatment, it may also be used for monitoring a patient for the onset of overt symptoms of a disease. Furthermore, the present method may be used for detecting any gene transcripts in blood. A kit for diagnosing, prognosing or even predicting a disease may be designed using gene-specific primers or probes derived from a whole blood sample for a specific disease and applied directly to a drop of blood. A cDNA library specific for a disease may be generated from whole blood samples and used for diagnosis, prognosis or even predicting a disease.

The following references were cited herein:

- Claudio JO *et al.* (1998). *Genomics* 50:44-52.
- 10 Chelly J *et al.* (1989). *Proc. Nat. Acad. Sci. USA*. 86:2617-2621.
- Chelly J *et al.* (1988). *Nature* 333:858-860.
- Drews J & Ryser S (1997). *Nature Biotech.* 15:1318-9.
- Ferrie RM *et al.* (1992). *Am. J. Hum. Genet.* 51:251-62.
- Fu D-J *et al.* (1998). *Nat. Biotech* 16: 381-4.
- 15 Gala JL *et al.* (1998). *Clin. Chem.* 44(3):472-81.
- Geisterfer-Lowrance AAT *et al.* (1990). *Cell* 62:999-1006.
- Groden J *et al.* (1991). *Cell* 66:589-600.
- Hwang DM *et al.* (1997). *Circulation* 96:4146-4203.
- Jandreski MA & Liew CC (1987). *Hum. Genet.* 76:47-53.
- 20 Jin O *et al.* (1990). *Circulation* 82:8-16
- Kimoto Y (1998). *Mol. Gen. Genet* 258:233-239.
- Koster M *et al.* (1996). *Nat. Biotech* 14: 1123-8.
- Liew & Jandreski (1986). *Proc. Nat. Acad. Sci. USA*. 83:3175-3179
- Liew CC *et al.* (1990). *Nucleic Acids Res.* 18:3647-3651.
- 25 Liew CC (1993). *J Mol. Cell. Cardiol.* 25:891-894
- Liew CC *et al.* (1994). *Proc. Natl. Acad. Sci. USA*. 91:10645-10649.
- Liew *et al.* (1997). *Mol. and Cell. Biochem.* 172:81-87.
- Niimura H *et al.* (1998). *New Eng. J. Med.* 338:1248-1257.

Ogawa M (1993). *Blood* 81:2844-2853.

Santoro IM & Groden J (1997). *Cancer Res.* 57:488-494.

Yuasa T *et al.* (1998). *Japanese J. Cancer Res.* 89:879-882.

Any patents or publications mentioned in this specification are
5 indicative of the levels of those skilled in the art to which the invention pertains.
Further, these patents and publications are incorporated by reference herein in their
entirety to the same extent as if each individual publication was specifically and
individually indicated to be incorporated by reference.

One skilled in the art will appreciate readily that the present invention
10 is well adapted to carry out the objects and obtain the ends and advantages mentioned,
as well as those objects, ends and advantages inherent herein. The present examples,
along with the methods, procedures, treatments, molecules, and specific compounds
described herein are presently representative of preferred embodiments, are
exemplary, and are not intended as limitations on the scope of the invention. Changes
15 therein and other uses will occur to those skilled in the art which are encompassed
within the spirit of the invention as defined by the scope of the claims.

1. A method for detecting expression of a gene in blood from a subject, comprising the steps of:

- 5 a) quantifying RNA from a subject blood sample; and
 b) detecting expression of said gene in the quantified RNA,
wherein the expression of said gene in said quantified RNA indicates expression of said gene in the subject blood.

10 2. The method of claim 1, wherein the quantification is performed by mass spectrometry.

3. A method for detecting expression of one or more genes in blood from a subject, comprising the steps of:

- 15 a) obtaining a subject blood sample;
 b) extracting RNA from said blood sample;
 c) amplifying said RNA;
 d) generating expressed sequence tags from the amplified RNA product; and
20 e) detecting expression of said genes in the expressed sequence tags, wherein the expression of said genes in said expressed sequence tags indicates expression of said genes in the subject blood.

25 4. The method of claim 3, wherein said genes are non-cancer-associated genes.

5. The method of claim 3, wherein said genes are tissue-specific genes.

6. The method of claim 3, wherein said subject is a fetus, an embryo, a child, an adult or a non-human animal.

5 7. The method of claim 3, wherein the amplification is performed by RT-PCR.

8. The method of claim 7, wherein said RT-PCR utilizes primers selected from the group consisting of random sequence primers and gene-specific
10 primers.

9. A method for detecting expression of one or more genes in blood from a subject, comprising the steps of:

- 15
- a) obtaining a subject blood sample;
 - b) extracting DNA fragment(s) from said blood sample;
 - c) amplifying said DNA fragment(s); and
 - d) detecting expression of said genes in the amplified DNA product, wherein the expression of said genes in said amplified DNA product indicates expression of said genes in the subject blood.

20

10. A method for monitoring a course of therapeutic treatment in an individual, comprising the steps of:

- 25
- a) obtaining a blood sample from said individual;
 - b) extracting RNA from said blood sample;
 - c) amplifying said RNA;
 - d) generating expressed sequence tags from the amplified RNA product; and

e) detecting expression of genes in said expressed sequence tags, wherein the expression of said genes is associated with the effect of said therapeutic treatment; and

f) repeating steps a)-e), wherein the course of said therapeutic treatment is monitored by detecting the change of expression of said genes in the expressed sequence tags.

11. The method of claim 10, wherein the amplification is performed by RT-PCR.

12. The method of claim 11, wherein the change of expression of said genes in the expressed sequence tags is monitored by sequencing the expressed sequence tags and comparing the resulting sequences at various time points.

13. The method of claim 11, wherein the change of expression of said genes in the expressed sequence tags is monitored by performing single nucleotide polymorphism analysis and detecting the variation of a single nucleotide in the expressed sequence tags at various time points.

14. The method of claim 10, wherein said individual is monitored for the onset of overt symptoms of a disease, and wherein the expression of said genes is associated with the onset of said symptoms.

15. A method for diagnosing a disease in a test subject, comprising the steps of:

a) generating a cDNA library for said disease from a whole blood sample from a normal subject;

b) generating expressed sequence tag (EST) profile from the normal subject cDNA library;

c) generating a cDNA library for said disease from a whole blood sample from a test subject;

5 d) generating EST profile from the test subject cDNA library; and

e) comparing the test subject EST profile to the normal subject EST profile, wherein if said test subject EST profile differs from said normal subject EST profile, said test subject might be diagnosed with said disease.

10 16. A kit for diagnosing, prognosing or predicting a disease, comprising:

a) gene-specific primers; wherein said primers are designed in such a way that the sequences of said primers contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and

15 b) a carrier, wherein said carrier immobilizes said primer(s).

17. The kit of claim 16, wherein said gene-specific primer(s) are selected from the group consisting of insulin-specific primers, atrial natriuretic factor-specific primers, zinc finger protein gene-specific primers, beta-myosin heavy chain
20 gene-specific primers, amyloid precursor protein gene-specific primers, and adenomatous polyposis-coli protein gene-specific primers.

18. The kit of claim 17, wherein the sequences of said gene-specific primers are selected from the group consisting of SEQ ID Nos. 1 and 2, and
25 SEQ ID Nos. 5 and 6.

19. A method for diagnosing, prognosing or predicting a disease in a test subject, comprising the step of:

applying the kit of claim 16 to a test subject whole blood sample, wherein quantitative expression levels of specific genes associated with said disease are detected and compared to the levels of said specific genes expressed in a normal subject, therefore, said disease may be diagnosed, prognosed or predicted.

5

20. The method of claim 19, wherein said method is used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of said disease.

10

21. A kit for diagnosing, prognosing or predicting a disease, comprising:

a) probes derived from a whole blood sample for a specific disease; and

b) a carrier, wherein said carrier immobilizes said probes.

15

22. A method for diagnosing, prognosing or predicting a disease in a test subject, comprising the step of:

applying the kit of claim 21 to a test subject whole blood sample, wherein quantitative expression levels of specific genes associated with said disease are detected and compared to the levels of said specific genes expressed in a normal subject, therefore, said disease may be diagnosed, prognosed or predicted.

20

23. The method of claim 22, wherein said method is used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of said disease.

25

24. A cDNA library specific for a disease, wherein said cDNA library is generated from whole blood samples.

1 2 3 4




FIGURE 3




FIGURE 4

177




FIGURE 1


1 2 3 4 5 6 7 8




FIGURE 2

A.

5/7



B.



C.





FIGURE 5

CC view Sept 1999

6/7

A



B







FIGURE 6

Total :13, 283 ESTs
 Known: 6,283
 Mitochondrial: 405
 Ribosome: 498
 Repeat: 868
 Mis. : 156
 Novel: 2,718

Human Blood



- Cell Division
- Cell Signalling/Communication
- Cell structure/Motility
- Cell/organism defense
- Gene/Protein expression
- Metabolism
- Unclassified

Human Fetal Heart




FIGURE 7

SEQUENCE LISTING

<110> Liew, Choong-Chin
<120> Method for the Detection of Gene Transcripts
in Blood and Uses Thereof

<130> 2173/0003

<150> US Number not yet assigned
<151> 2000-01-04

<150> US 60/115,125
<151> 1999-01-06
<160> 10

<210> 1
<211> 18
<212> DNA
<213> artificial sequence
<220>
<221> primer_bind
<223> forward primer of exon 1 of insulin gene used
for quantitative RT-PCR analysis
<400> 1
gccctctggg gacctgac 18

<210> 2
<211> 18
<212> DNA
<213> artificial sequence
<220>
<221> primer_bind
<223> reverse primer of exons 1 and 2 of insulin
gene used for quantitative RT-PCR analysis
<400> 2
cccacctgca ggtcctct 18

<210> 3
 <211> 24
 <212> DNA
 <213> artificial sequence
 <220>
 <221> primer_bind
 <223> forward primer of β MyHC gene used for
 quantitative RT-PCR analysis
 <400> 3
 gctggaacgt agagactccc tgct 24

<210> 4
 <211> 24
 <212> DNA
 <213> artificial sequence
 <220>
 <221> primer_bind
 <223> reverse primer of β MyHC gene used for
 quantitative RT-PCR analysis
 <400> 4
 ggatccttcc agatcatcca ctg 24

<210> 5
 <211> 20
 <212> DNA
 <213> artificial sequence
 <220>
 <221> primer_bind
 <223> forward primer of ANF used for quantitative
 RT-PCR analysis
 <400> 5
 ggatttcaag aatttgctgg 20

<210> 6
 <211> 20
 <212> DNA
 <213> artificial sequence
 <220>
 <221> primer_bind
 <223> reverse primer of ANF used for quantitative
 RT-PCR analysis
 <400> 6
 gcagatcgat cagaggagtc 20

<210> 7
 <211> 20
 <212> DNA
 <213> artificial sequence
 <220>
 <221> primer_bind
 <223> forward primer of APP used for quantitative
 RT-PCR analysis
 <400> 7
 ggatgcttca tgtgaacgtg 20

<210> 8
 <211> 19
 <212> DNA
 <213> artificial sequence
 <220>
 <221> primer_bind
 <223> reverse primer of APP used for quantitative
 RT-PCR analysis
 <400> 8
 tcattcacac cagcacatg 19

<210> 9
<211> 21
<212> DNA
<213> artificial sequence
<220>
<221> primer_bind
<223> forward primer of ZFP used for quantitative
RT-PCR analysis
<400> 9
cacargagrc arggtcaacg a 21

<210> 10
<211> 22
<212> DNA
<213> artificial sequence
<220>
<221> primer_bind
<223> reverse primer of ZFP used for quantitative
RT-PCR analysis
<400> 10
ggattaaaat gaagcaccca ga 22

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 July 2000 (13.07.2000)


PCT

(10) International Publication Number
WO 00/40749 A3

- (51) International Patent Classification⁷: **C12Q 1/68**
- (21) International Application Number: **PCT/CA00/00005**
- (22) International Filing Date: **5 January 2000 (05.01.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/115,125 6 January 1999 (06.01.1999) US
09/477,148 4 January 2000 (04.01.2000) US
- (71) Applicant (for all designated States except US): **GENE-NEWS INC. [CA/CA]; 45 Bevdale Road, Toronto, Ontario, M2R 1L8 (CA).**
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **LIEW, Choong-Chin [CA/CA]; 81 Millersgrove Drive, Willowdale, Ontario M2R 3S1 (CA).**
- (54) Agent: **DEETH WILLIAMS WALL; National Bank Building, Suite 400, 150 York Street, Toronto, Ontario M5H 3S5 (CA).**
- (81) Designated States (national): **AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**
- Published:
— with international search report
- (88) Date of publication of the international search report:
19 July 2001

[Continued on next page]

(54) Title: **METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF**



(57) Abstract: The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/00005

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, CHEM ABS Data, BIOSIS, EMBASE, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 49342 A (COCKBAIN JULIAN R M ; FORSKNINGSPARKEN I AAS AS (NO); LOENNEBORG AN) 5 November 1998 (1998-11-05)	1-15, 21-24
Y	the whole document	19,20
X	WO 98 24935 A (AN GANG ; HARA MARK O (US); RALPH DAVID (US); VELTRI ROBERT (US); U) 11 June 1998 (1998-06-11)	1-15, 21-24
Y	the whole document	19,20
X	EP 0 534 640 A (PFIZER) 31 March 1993 (1993-03-31)	16
Y	the whole document	17-20
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 June 2000

Date of mailing of the international search report

12/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hagenmaier, S

INTERNATIONAL SEARCH REPORT

Inter: xnal Application No
PCT/CA 00/00005

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PATENT ABSTRACTS OF JAPAN vol. 1997, no. 11, 28 November 1997 (1997-11-28) & JP 09 187299 A (NIPPON BIO SERAPII KK), 22 July 1997 (1997-07-22) abstract & DATABASE GCG_GENESEQ 'Online! AC:V00198, March 1998 (1998-03) NIPPON BIOTHERAPY: "HUMAN INSULIN SENSE PRIMER INS-7" abstract</p> <p style="text-align: center;">---</p>	17,18
Y	<p>DATABASE GENBANK 'Online! AC:V00565, March 1995 (1995-03) BELL ET AL.: "HUMAN GENE FOR PREPROINSULIN" XP002141055 abstract</p> <p style="text-align: center;">---</p>	17,18
Y	<p>DATABASE GENBANK 'Online! AC:M54947, April 1993 (1993-04) SEIDMAN ET AL.: "HUMAN ATRIAL NATRIURETIC FACTOR GENE" XP002141054 abstract</p> <p style="text-align: center;">---</p>	17,18
Y	<p>DATABASE GENBANK 'Online! AC:X52889, September 1993 (1993-09) LIEW: "HUMAN GENE FOR CARDIAC BETA MYOSIN HEAVY CHAIN" XP002141056 abstract</p> <p style="text-align: center;">---</p>	17
Y	<p>DATABASE GENBANK 'Online! AC:2808656, December 1998 (1998-12) BERNOT ET AL.: "A TRANSCRIPTIONAL MAP OF THE FMF REGION/ZINC FINGER PROTEIN" XP002141057 abstract</p> <p style="text-align: center;">---</p>	17
Y	<p>YOSHIKAI ET AL.: "GENOMIC ORGANIZATION OF THE HUMAN AMYLOID BETA-PROTEIN PRECURSOR GENE" GENE, vol. 87, 1990, pages 257-263, XP002141053 the whole document</p> <p style="text-align: center;">---</p>	17
Y	<p>DATABASE GENBANK 'Online! AC:M73548, January 1995 (1995-01) JOSLYN ET AL.: "HUMAN POLYPOSIS LOCUS mRNA" XP002141058 abstract</p> <p style="text-align: center;">---</p>	17
	-/--	

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.
PCT/CA 00/00005

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 18906 A (CLAYCOMB WILLIAM CREIGHTON ;PROCTER & GAMBLE (US)) 7 May 1998 (1998-05-07) the whole document ----	
A	US 5 352 775 A (MARKHAM ALEXANDER F ET AL) 4 October 1994 (1994-10-04) the whole document ----	
A	DE 44 35 919 C (DEUTSCHES KREBSFORSCH) 7 December 1995 (1995-12-07) the whole document ----	
A	US 5 837 449 A (ECKER DAVID J ET AL) 17 November 1998 (1998-11-17) the whole document ----	
A	WO 98 33942 A (NAKAO KOICHI ;BRISTOW MICHAEL R (US); LEINWAND LESLIE A (US); MINO) 6 August 1998 (1998-08-06) the whole document -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/00005

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9849342	A	05-11-1998	AU 7222698 A EP 0979308 A NO 995296 A	24-11-1998 16-02-2000 14-12-1999
WO 9824935	A	11-06-1998	AU 5515198 A EP 0960214 A	29-06-1998 01-12-1999
EP 0534640	A	31-03-1993	AT 143700 T CA 2078703 A DE 69214243 D DE 69214243 T DK 534640 T ES 2092056 T FI 924242 A GR 3021721 T JP 2703156 B JP 5192199 A US 5643730 A	15-10-1996 24-03-1993 07-11-1996 06-02-1997 17-03-1997 16-11-1996 24-03-1993 28-02-1997 26-01-1998 03-08-1993 01-07-1997
JP 09187299	A	22-07-1997	NONE	
WO 9818906	A	07-05-1998	AU 5149998 A EP 0956341 A NO 991894 A	22-05-1998 17-11-1999 24-06-1999
US 5352775	A	04-10-1994	US 5648212 A US 5691454 A US 5783666 A US RE36713 E AU 1366992 A EP 0569527 A WO 9213103 A	15-07-1997 25-11-1997 21-07-1998 23-05-2000 27-08-1992 18-11-1993 06-08-1992
DE 4435919	C	07-12-1995	WO 9611267 A EP 0784680 A JP 10506789 T	18-04-1996 23-07-1997 07-07-1998
US 5837449	A	17-11-1998	AU 3249793 A CA 2126451 A EP 0644889 A JP 6511387 T WO 9313114 A	28-07-1993 08-07-1993 29-03-1995 22-12-1994 08-07-1993
WO 9833942	A	06-08-1998	AU 6141098 A	25-08-1998

CORRECTED VERSION

**(19) World Intellectual Property Organization
International Bureau**



(43) International Publication Date
13 July 2000 (13.07.2000)

PCT

(10) International Publication Number
WO 00/40749 A3

(S1) International Patent Classification⁷: C12Q 1/68

(21) International Application Number: PCT/CA00/00005

(22) International Filing Date: 5 January 2000 (05.01.2000)

(25) Filing Language: English

(26) **Publication Language:** English

(30) Priority Data:
60/115.125 6 January 1999 (06.01.1999) US
09/477.148 4 January 2000 (04.01.2000) US

(71) **Applicant** (for all designated States except US): **GENE-NEWS INC.** [CA/CA]; 45 Bevdale Road, Toronto, Ontario, M2R 1L8 (CA).

(72) Inventor; and


(75) **Inventor/Applicant (for US only): LIEW, Choong-Chin**
[CA/CA]: 81 Millersgrove Drive, Willowdale, Ontario
M2R 3S1 (CA).

(74) Agent: **DEETH WILLIAMS WALL**: National Bank Building, Suite 400, 150 York Street, Toronto, Ontario M5H 3S5 (CA).


(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

[Continued on next page]

(54) Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF



(57) Abstract: The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.



WO 00/40749 A3



(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(48) **Date of publication of this corrected version:**

23 August 2001

(15) **Information about Correction:**

see PCT Gazette No. 34/2001 of 23 August 2001, Section II

Published:

— with international search report

(88) **Date of publication of the international search report:**
19 July 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**METHOD FOR THE DETECTION OF GENE TRANSCRIPTS
IN BLOOD AND USES THEREOF**

5

BACKGROUND OF THE INVENTION

Cross-Reference to Related Application

This application claims the benefit of priority of provisional patent application U.S. Serial Number 60/115,125, filed January 6, 1999 and of a U.S. application
10 entitled "Method for the Detection of Gene Transcripts in Blood and uses Thereof"
filed on January 4, 2000 (application number not yet assigned).

Field of the Invention

The present invention relates generally to the molecular biology of
15 human diseases. More specifically, the present invention relates to a process using the
genetic information contained in human peripheral whole blood for the diagnosis,
prognosis and monitoring of genetic and infectious disease in the human body.

Description of the Related Art

20 The blood is a vital part of the human circulatory system for the human
body. Numerous cell types make up the blood tissue including monocytes,
leukocytes, lymphocytes and erythrocytes. Although many blood cell types have been
described, there are likely many as yet undiscovered cell types in the human blood.
Some of these undiscovered cells may exist transiently, such as those derived from
25 tissues and organs that are constantly interacting with the circulating blood in health
and disease. Thus, the blood can provide an immediate picture of what is happening
in the human body at any given time.

The turnover of cells in the hematopoietic system is enormous. It was reported that over one trillion cells, including 200 billion erythrocytes and 70 billion neutrophilic leukocytes, turn over each day in the human body (Ogawa 1993). As a consequence of continuous interactions between the blood and the body, genetic changes that occur within the cells or tissues of the body will trigger specific changes in gene expression within blood. It is the goal of the present invention that these genetic alterations be harnessed for diagnostic and prognostic purposes, which may lead to the development of therapeutics for ameliorating disease.

The complete profile of gene expression in the circulating blood remains totally unexplored. It is hypothesized that gene expression in the blood is reflective of body state and, as such, the resultant disruption of homeostasis under conditions of disease can be detected through analysis of transcripts differentially expressed in the blood alone. Thus, the identification of several key transcripts or genetic markers in blood will provide information about the genetic state of the cells, tissues, organs and systems of the human body in health and disease.

The prior art is deficient in non-invasive methods of screening for tissue-specific diseases. The present invention fulfills this long-standing need and desire in the art.

20

SUMMARY OF THE INVENTION

This present invention discloses a process of using the genetic information contained in human peripheral whole blood in the diagnosis, prognosis and monitoring of genetic and infectious disease in the human body. The process described herein requires a simple blood sample and is, therefore, non-invasive compared to conventional practices used to detect tissue specific disease, such as biopsies.

One object of the present invention is to provide a non-invasive method for the diagnosis, prognosis and monitoring of genetic and infectious disease in humans and animals.

In one embodiment of the present invention, there is provided a
5 method for detecting expression of a gene in blood from a subject, comprising the steps of: a) quantifying RNA from a subject blood sample; and b) detecting expression of the gene in the quantified RNA, wherein the expression of the gene in quantified RNA indicates the expression of the gene in the subject blood.

In another embodiment of the present invention, there is provided a
10 method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; and e) detecting expression of the genes in the ESTs, wherein the expression of the genes in the ESTs indicates the expression of
15 the genes in the subject blood. Preferably, the genes are tissue-specific genes.

In still another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting DNA fragments from the blood sample; c) amplifying the DNA fragments; and d) detecting
20 expression of the genes in the amplified DNA product, wherein the expression of the genes in the amplified DNA product indicates the expression of the genes in the subject blood.

In yet another embodiment of the present invention, there is provided a method for monitoring a course of a therapeutic treatment in an individual,
25 comprising the steps of: a) obtaining a blood sample from the individual; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; e) detecting expression of genes in the ESTs, wherein the expression of the genes is associated with the effect of

the therapeutic treatment: and f) repeating steps a)-e), wherein the course of the therapeutic treatment is monitored by detecting the change of expression of the genes in the ESTs. Such a method may also be used for monitoring the onset of overt symptoms of a disease, wherein the expression of the genes is associated with the onset of the symptoms.

In still yet another embodiment of the present invention, there is provided a method for diagnosing a disease in a test subject, comprising the steps of: a) generating a cDNA library for the disease from a whole blood sample from a normal subject; b) generating expressed sequence tag (EST) profile from the normal subject cDNA library; c) generating a cDNA library for the disease from a whole blood sample from a test subject; d) generating EST profile from the test subject cDNA library; and e) comparing the test subject EST profile to the normal subject EST profile, wherein if the test subject EST profile differs from the normal subject EST profile, the test subject might be diagnosed with the disease.

In still yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) gene-specific primers; wherein the primers are designed in such a way that their sequences contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and b) a carrier, wherein the carrier immobilizes the primer(s). Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease.

In yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) probes derived from a whole blood sample for a specific disease; and b) a carrier, wherein the carrier immobilizes the probes. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease.

Furthermore, the present invention provides a cDNA library specific for a disease, wherein the cDNA library is generated from whole blood samples.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.

5

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope. not be considered to limit the scope of the invention.

Figure 1 shows the following RNA samples prepared from human blood; **Figure 1A**: Lane 1, Molecular weight marker; Lane 2, RT-PCR on APP gene; Lane 3, PCR on APP gene; Lane 4, RT-PCR on APC gene; Lane 5, PCR on APC gene; **Figure 1B**: Lanes 1 and 2, RT-PCR and PCR of β MyHC, respectively; Lanes 3 and 4, RT-PCR of β MyHC from RNA prepared from human fetal and human adult heart, respectively; Lane 5, Molecular weight marker.

Figure 2 shows quantitative RT-PCR analysis performed on RNA samples extracted from a drop of blood. Forward primer (5'-GCCCTCTGGGGACCTGAC-3', SEQ ID No. 1) of exon 1 and reverse primer (5'-CCCACCTGCAGGTCCTCT-3'', SEQ ID No. 2) of exons 1 and 2 of insulin gene. Blood samples of 4 normal subjects were assayed. Lanes 1, 3, 5 and 7 represent overnight "fasting" blood sample and lanes 2, 4, 6 and 8 represent "non-fasting" samples.

Figure 3 shows quantitative RT-PCR analysis performed on RNA samples extracted from a drop of blood. Lanes 1 and 2 represent normal healthy person and lane 3 represents late-onset diabetes (Type II) and lane 4 represents asymptomatic diabetes.

5 **Figure 4** shows multiple RT-PCR assay in a drop of blood. Primers were derived from insulin gene (INS), zinc-finger protein gene (ZFP) and house-keeping gene (GADH). Lane 1 represents normal person. Lane 2 represents late-onset diabetes and lane 3 represents asymptomatic diabetes.

Figure 5 shows standardized levels of insulin gene (**Figure 5A**) and
10 ZFP gene (**Figure 5B**) expressed in a drop of blood. The first three subjects were normal, second two subjects showed normal glucose tolerance, and the last subject had late onset diabetes type II. **Figure 5C** shows standardized levels of insulin gene expressed in each fractionated cell from whole blood.

Figure 6 shows the differential screening of human blood cell cDNA
15 library with different cDNA probes of heart and brain tissue. **Figure 6A** shows blood cell cDNA probes vs. adult heart cDNA probes. **Figure 6B** shows blood cell cDNA probes vs. human brain cDNA probes.

Figure 7 graphically shows the 1,800 unique genes in human blood and in the human fetal heart grouped into seven cellular functions.

20

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques
25 within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid

Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription and Translation" [B.D. Hames & S.J. Higgins eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984). Therefore, if appearing
5 herein, the following terms shall have the definitions set out below.

A "cDNA" is defined as copy-DNA or complementary-DNA, and is a product of a reverse transcription reaction from an mRNA transcript. "RT-PCR" refers to reverse transcription polymerase chain reaction and results in production of cDNAs that are complementary to the mRNA template(s).

10 The term "oligonucleotide" is defined as a molecule comprised of two or more deoxyribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide. The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced
15 synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be
20 sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and the method used. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides,
25 although it may contain fewer nucleotides. The factors involved in determining the appropriate length of primer are readily known to one of ordinary skill in the art.

As used herein, random sequence primers refer to a composition of primers of random sequence, i.e. not directed towards a specific sequence. These

sequences possess sufficient complementary to hybridize with a polynucleotide and the primer sequence need not reflect the exact sequence of the template.

“Restriction fragment length polymorphism” refers to variations in DNA sequence detected by variations in the length of DNA fragments generated by restriction endonuclease digestion.

A standard Northern blot assay can be used to ascertain the relative amounts of mRNA in a cell or tissue obtained from plant or other tissue, in accordance with conventional Northern hybridization techniques known to those persons of ordinary skill in the art. The Northern blot uses a hybridization probe, e.g. radiolabelled cDNA, either containing the full-length, single stranded DNA or a fragment of that DNA sequence at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100 consecutive nucleotides in length). The DNA hybridization probe can be labelled by any of the many different methods known to those skilled in this art. The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. Proteins can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from ^3H , ^{14}C , ^{32}P , ^{35}S , ^{36}Cl , ^{51}Cr , ^{57}Co , ^{58}Co , ^{59}Fe , ^{90}Y , ^{125}I , ^{131}I , and ^{186}Re . Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized.

The preferred are peroxidase, β -glucuronidase, β -D-glucosidase, β -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.

5 As used herein, "individual" refers to human subjects as well as non-human subjects. The examples herein are not meant to limit the methodology of the present invention to human subjects only, as the instant methodology is useful in the fields of veterinary medicine, animal sciences and such.

10 In one embodiment of the present invention, there is provided a method for detecting expression of a gene in blood from a subject, comprising the steps of: a) quantifying RNA from a subject blood sample; and b) detecting expression of the gene in the quantified RNA, wherein the expression of the gene in quantified RNA indicates the expression of the gene in the subject blood. An example of the quantifying method is by mass spectrometry.

15 In another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; and e) detecting expression of the genes in
20 the ESTs, wherein the expression of the genes in the ESTs indicates the expression of the genes in the subject blood. Preferably, the subject is a fetus, an embryo, a child, an adult or a non-human animal. The genes are non-cancer-associated and tissue-specific genes. Still preferably, the amplification is performed by RT-PCR using random sequence primers or gene-specific primers.

25 In still another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting DNA fragments from the blood sample; c) amplifying the DNA fragments; and d) detecting

expression of the genes in the amplified DNA product, wherein the expression of the genes in the amplified DNA product indicates the expression of the genes in the subject blood.

In yet another embodiment of the present invention, there is provided a method for monitoring a course of a therapeutic treatment in an individual, comprising the steps of: a) obtaining a blood sample from the individual; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; e) detecting expression of genes in the ESTs, wherein the expression of the genes is associated with the effect of the therapeutic treatment; and f) repeating steps a)-e), wherein the course of the therapeutic treatment is monitored by detecting the change of expression of the genes in the ESTs. Such a method may also be used for monitoring the onset of overt symptoms of a disease, wherein the expression of the genes is associated with the onset of the symptoms. Preferably, the amplification is performed by RT-PCR, and the change of the expression of the genes in the ESTs is monitored by sequencing the ESTs and comparing the resulting sequences at various time points; or by performing single nucleotide polymorphism analysis and detecting the variation of a single nucleotide in the ESTs at various time points.

In still yet another embodiment of the present invention, there is provided a method for diagnosing a disease in a test subject, comprising the steps of: a) generating a cDNA library for the disease from a whole blood sample from a normal subject; b) generating expressed sequence tag (EST) profile from the normal subject cDNA library; c) generating a cDNA library for the disease from a whole blood sample from a test subject; d) generating EST profile from the test subject cDNA library; and e) comparing the test subject EST profile to the normal subject EST profile, wherein if the test subject EST profile differs from the normal subject EST profile, the test subject might be diagnosed with the disease.

In still yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) gene-specific primers; wherein the primers are designed in such a way that their sequences contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and b) a carrier, wherein the carrier immobilizes the primer(s). Preferably, the gene-specific primers are selected from the group consisting of insulin-specific primers, atrial natriuretic factor-specific primers, zinc finger protein gene-specific primers, beta-myosin heavy chain gene-specific primers, amyloid precursor protein gene-specific primers, and adenomatous polyposis-coli protein gene-specific primers. Further preferably, the gene-specific primers are selected from the group consisting of SEQ ID Nos. 1 and 2; and SEQ ID Nos. 5 and 6. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease by detecting the quantitative expression levels of specific genes associated with the disease in the test subject and then comparing to the levels of same genes expressed in a normal subject. Such a kit may also be used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of a disease.

In yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) probes derived from a whole blood sample for a specific disease; and b) a carrier, wherein the carrier immobilizes the probes. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease by detecting the quantitative expression levels of specific genes associated with the disease in the test subject and then comparing to the levels of same genes expressed in a normal subject. Such a kit may also be used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of a disease.

Furthermore, the present invention provides a cDNA library specific for a disease, wherein the cDNA library is generated from whole blood samples.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

5

EXAMPLE 1

Construction of a cDNA library

RNA extracted from human tissues (including fetal heart, adult heart, liver, brain, prostate gland and whole blood) were used to construct unidirectional cDNA libraries. The first mammalian heart cDNA library was constructed as early as 1982. Since then, the methodology has been revised and optimal conditions have been developed for construction of human heart and hematopoietic progenitor cDNA libraries (Liew *et al.*, 1984; Liew 1993, Claudio *et al.*, 1998). Most of the novel genes which were identified by sequence annotation can now be obtained as full length transcripts.

15

EXAMPLE 2

Catalogue of blood cell ESTs

20

Random partial sequencing of expressed sequence tags (ESTs) of cDNA clones from the blood cell library was carried out to establish an EST database of blood. The known genes as derived from the ESTs were categorized into seven major cellular functions (Hwang, Dempsey *et al.*, 1997).

EXAMPLE 3

Differential screening of cDNA library

5 cDNA probes generated from transcripts of each tissue were used to hybridize the blood cell cDNA clones (Liew *et al.*, 1997). The "positive" signals which were hybridized with ³²P-labelled cDNA probes were defined as genes which shared identity with blood and respective tissues. The "negative" spots which were not exposed to ³²P-labelled cDNA probes were considered to be blood-cell-enriched or
10 low frequency transcripts.

EXAMPLE 4

Reverse transcriptase-polymerase chain reaction (RT-PCR) assay

15 RNA extracted from samples of human tissue was used for RT-PCR analysis (Jin *et al.* 1990). Three pairs of forward and reverse primers were designed for human cardiac beta-myosin heavy chain gene (β MyHC), amyloid precursor protein (APP) gene and adenomatous polyposis-coli protein (APC) gene. The PCR products were also subjected to automated DNA sequencing to verify the sequences as
20 derived from the specific transcripts of blood.

EXAMPLE 5

Detection of tissue specific gene expression in human blood using RT-PCR

25 The beta-myosin heavy chain gene (β MyHC) transcript (mRNA) is known to be highly expressed in ventricles of the human heart. This sarcomeric protein is important for heart muscle contraction and its presence would not be expected in other non-muscle tissues and blood. In 1990, the gene for human cardiac

β MyHC was completely sequenced (Liew *et al.* 1990) and was comprised of 7 exons and 42 introns.

The method of reverse transcription polymerase chain reaction (RT-PCR) was used to determine whether this cardiac specific mRNA is also present in human blood. A pair of primers was designed; the forward primer (SEQ ID No. 3) was on the boundary of exons 21 and 22, and the reverse primer (SEQ ID No. 4) was on the boundary of exons 24 and 25. This region of mRNA is only present in β MyHC and is not found in the alpha-myosin heavy chain gene (α MyHC).

A blood sample was first treated with lysing buffer and then undergone centrifuge. The resulting pellets were further processed with RT-PCR. RT-PCR was performed using the total blood cell RNA as a template. A nested PCR product was generated and used for sequencing. The sequencing results were subjected to BLAST and the identity of exons 21 to 25 was confirmed to be from β MyHC (Figure 1A).

Using the same method just described, two other tissue specific genes - amyloid precursor protein (APP, forward primer, SEQ ID No. 7; reverse primer, SEQ ID No. 8) found in the brain and associated with Alzheimer's disease, and adenomatous polyposis coli protein (APC) found in the colon and rectum and associated with colorectal cancer (Grodén *et al.* 1991; Santoro and Grodén 1997) - were also detected in the RNA extracted from human blood (Figure 1B).

EXAMPLE 6

Multiple RT-PCR analysis on a drop of blood from a normal/diseased individual

A drop of blood was extracted to obtain RNA to carry out quantitative RT-PCR analysis. Specific primers for the insulin gene were designed: forward primer (5'-GCCCTCTGGGGACCTGAC-3', SEQ ID No. 1) of exon 1 and reverse primer (5'-CCCACCTGCAGGTCCTCT-3', SEQ ID No. 2) of exons 1 and 2 of insulin gene. Such reverse primer was obtained by deleting the intron between the

exons 1 and 2. Blood samples of 4 normal subjects were assayed. It was found that the insulin gene is expressed in the blood and the quantitative expression of the insulin gene in a drop of blood is influenced by fasting and non-fasting states of normal healthy subjects (Figure 2). This very low level of expression of the insulin gene reflects the phenotypic status of a person and strongly suggests that there is a physiological and pathological role for its expression, contrary to the basal or illegitimate theory of transcription suggested by Chelly *et al.* (1989) and Kimoto (1998).

Same quantitative RT-PCR analysis was performed using insulin specific primers on RNA samples extracted from a drop of blood from a normal healthy person, a person having late-onset diabetes (Type II) and a person having asymptomatic diabetes. It was found that the insulin gene is expressed differentially amongst subjects that are healthy, diagnosed as type II diabetic, and also in an asymptomatic preclinical patient (Figure 3).

Similarly, specific primers for the atrial natriuretic factor (ANF) gene were designed (forward primer, SEQ ID No. 5; reverse primer, SEQ ID No. 6) and RT-PCR analysis was performed on a drop of blood. ANF is known to be highly expressed in heart tissue biopsies and in the plasma of heart failure patients. However, atrial natriuretic factor was observed to be expressed in the blood and the expression of the atrial natriuretic factor gene is significantly higher in the blood of patients with heart failure as compared to the blood of a normal control patient.

Specific primers for the zinc finger protein gene (ZFP, forward primer, SEQ ID No. 9; reverse primer, SEQ ID No. 10) were also designed and RT-PCR analysis was performed on a drop of blood. ZFP is known to be high in heart tissue biopsies of cardiac hypertrophy and heart failure patients. In the present study, the expression of ZFP was observed in the blood as well as differential expression levels of ZFP amongst the normal, diabetic and asymptomatic preclinical subjects (Figure 4); although neither of the non-normal subjects has been specifically diagnosed as

suffering from cardiac hypertrophy and/or heart failure, the higher expression levels of the ZFP gene in their blood may indicate that these subjects are headed in that general direction.

5 It was hypothesized that a housekeeping gene such as glyceraldehyde dehydrogenase (GADH) which is required and highly expressed in all cells would not be differentially expressed in the blood of normal vs. disease subjects. This hypothesis was confirmed by RT-PCR using GADH specific primers (Figure 4). Thus, GADH is useful as an internal control.

10 Standardized levels of insulin gene or ZFP gene expressed in a drop of blood were estimated using a housekeeping gene as an internal control relative to insulin or ZFP expressed (Figures 5A & 5B). The levels of insulin gene expressed in each fractionated cell from whole blood were also standardized and shown in Figure 5C.

15

EXAMPLE 7

Human blood cell cDNA library

20 In order to further substantiate the present invention, differential screening of the human blood cell cDNA library was conducted. cDNA probes derived from human blood, adult heart or brain were respectively hybridized to the human blood cDNA library clones. As shown in Figure 7, more than 95% of the "positively" identified clones are identical between the blood and other tissue samples.

25 DNA sequencing of randomly selected clones from the human whole blood cell cDNA library was also performed. This allowed information regarding the cellular function of blood to be obtained concurrently with gene identification. More than 20,000 expressed sequence tags (ESTs) have been generated and characterized to date, 17.6% of which did not result in a statistically significant match to entries in the

GenBank databases and thus were designated as "Novel" ESTs. These results are summarized in Figure 7 together with the seven cellular functions related to percent distribution of known genes in blood and in the fetal heart.

From 20,000 ESTs, 1,800 have been identified as known genes which may not all appear in the hemapoietic system. For example, the insulin gene and the atrial natriuretic factor gene have not been detected in these 20,000 ESTs but their transcripts were detected in a drop of blood, strongly suggesting that all transcripts of the human genome can be detected by performing RT-PCR analysis on a drop of blood.

In addition, approximately 400 novel genes have been identified from the 20,000 ESTs characterized to date, and these will be subjected to full length sequencing and open reading frame alignment to reduce the actual number of novel ESTs prior to screening for disease markers.

Analysis of the approximately 6,283 ESTs which have known matches in the GenBank databases revealed that this dataset represents over 1,800 unique genes. These genes have been catalogued into seven cellular functions. Comparisons of this set of unique genes with ESTs derived from human brain, heart, lung and kidney demonstrated a greater than 50% overlap in expression (Table 1).

TABLE 1

Overlap of Genes Expressed in Blood *

<u>Tissues</u>	<u>ESTs**</u>	<u>Overlap in Blood</u>
brain	134,000	60%
heart	65,000	59%
lung	60,200	58%
kidney	32,300	54%

* Estimated from limited known genes of about 1,800 as derived from the database of 6,297 ESTs from human blood cell library.

** Obtained from the National Centre of Biotechnology Information (NCBI), U.S.A.

5

EXAMPLE 8

Blood cell ESTs

The results from the differential screening clearly indicate that the
10 transcripts expressed in the whole blood are reflective of genes expressed in all cells
and tissues of the body. More than 95% of detectable spots were identical from two
different tissues. The remaining 5% of spots may represent cell- or tissue-specific
transcripts; however, results obtained from partial sequencing to generate ESTs of
these clones revealed most of them not to be cell- or tissue-specific transcripts.
15 Therefore, the negative spots are postulated to be reflective of low abundance
transcripts in the tissue from which the cDNA probes were derived.

An alternative approach that was employed to identify transcripts
expressed at low levels is the large-scale generation of expressed sequence tags
(ESTs). There is substantial evidence regarding the efficiency of this technology to
20 detect previously characterized (known) and uncharacterized (unknown or novel)
genes expressed in the cardiovascular system (Hwang & Dempsey *et al.*, 1997). In
the present invention, 20,000 ESTs have been produced from a human blood cell
cDNA library and resulted in the identification of approximately 1,800 unique known
genes (Table 2)

25 In the most recent GenBank release, analysis of more than 300,000
ESTs in the database (dbESTs) generated more than 48,000 gene clusters which are
thought to represent approximately 50% of the genes in the human genome. Only
4,800 of the dbESTs are blood-derived. In the present invention, 20,000 ESTs have

been obtained to date from a human blood cDNA library, which provides the world's most informative database with respect to blood cell transcripts. From the limited amount of information generated so far (i.e. 1,800 unique genes), it has already been determined that more than 50% of the transcripts are found in other cells or tissues of the human body (Table 2). Thus, it is expected that by increasing the number of ESTs generated, more genes will be identified that have an overlap in expression between the blood and other tissues. Furthermore, the transcripts for several genes which are known to have tissue-restricted patterns of expression (i.e. β MyHC, APP, APC, ANF, ZFP) have also been demonstrated to be present in blood.

Most recently, a cDNA library of human hematopoietic progenitor stem cells has also been constructed. From the limited set of 1,000 ESTs, there are at least 200 known genes that are shared with other tissue related genes (Claudio *et al.* 1998).

Table 2 demonstrates the expression of known genes of specific tissues in blood cells. Previously, only the presence of "housekeeping" genes would have been expected. Additionally, the presence of at least 25 of the currently known 500 genes corresponding to molecular drug targets was detected. These molecular drug targets are used in the treatment of a variety of diseases which involve inflammation, renal and cardiovascular function, neoplastic disease, immunomodulation and viral infection (Drews & Ryser, 1997). It is expected that additional novel ESTs will represent future molecular drug targets.

TABLE 2

Comparison of 1.800 Unique Genes Identified in the Blood Cell cDNA Library to Genes Previously Identified in Specific Tissues

5

Gene Identification	No. of ESTs	Accession No.	Tissue Distribution					
			Bl	Br	H	K	Li	Lu
100 kDa coactivator	2	U22055		+				+
10kD protein (BC10)	2	AF053470		+	+		+	+
14-3-3 epsilon	2	U54778		+	+			+
14-3-3 protein	11	U28964		+	+		+	
15 kDa selenoprotein (SEP15)	1	AF051894		+	+			+
1-phosphatidylinositol-4-phosphate 5-kinase isoform C	1	S78798						
23 kD highly basic protein	21	X56932	+	+	+	+	+	+
2-5A-dependent RNase	1	L10381						
2'-5'oligoadenylate synthetase 2 (OAS2)	4	M87284	B					
26S proteasome subunit 11	1	AF086708						
36 kDa phosphotyrosine protein	2	AJ223280	T		+			
3-7 gene product (non-exact 86%aa)	1	D64159						
3-phosphoglycerate dehydrogenase (PGAD)	1	AF006043	T	+	+			+
3-prime-phosphoadenosine 5-prime-phosphosulfate synthase 1 (PAPSS1)	2	U53447	+	+	+	+		+
46kd mannose 6-phosphate receptor (MPR46) (low match)	1	X56257						
5-aminoimidazole-4-carboxamide ribonucleotide transformylase	1	D89976						
5'-nucleotidase	3	D38524	T	+			+	
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4)	1	D49818		+				
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PF2K)	1	AF041829						
71 kd heat shock cognate protein hsc70	23	Y00371						
76 kDa membrane protein (P76)	2	U81006		+	+	+	+	+
8-oxoguanine DNA glycosylase (OGG1)	1	U96710	B				+	+
a disintegrin and metalloprotease domain 10 (ADAM10)	1	AF009615	T				+	
a disintegrin and metalloprotease domain 8 (ADAM8)	1	D26579	B	+				
A kinase anchor protein 95 (AKAP95)	2	Y11997	B, T activated		+			+
A kinase anchor protein, 149kD (AKAP149)	2	X97335		+	+	+		+

A4 differentiation-dependent protein (A4), triple LIM domain protein (LMO6), and synaptophysin (SYP); calcium channel alpha-1 subunit (CACNA1F)	1	U93305								
ABL and putative M8604 Met protein	1	U07561								
Absent in melanoma 1 (AIM1)	1	U83115	+	+					+	
accessory proteins BAP31/BAP29 (DXS1357E)	2	Z31696		+	+					
acetyl-Coenzyme A acyltransferase (peroxisomal 3-oxoacyl-Coenzyme A thiolase) (ACAA)	2	X12966	+	+	+	+	+	+		
acetyl-Coenzyme A transporter (ACATN)	1	D88152	T lymphoma	+	+					
acidic 82 kDa protein	4	U15552								
acidic protein rich in leucines (SSP29)	1	Y07969	B	+	+			+	+	
Aconitase 2, mitochondrial (ACO2)	1	U80040	+	+	+	+			+	
actin binding protein MAYVEN	1	AF059569								
actin, beta (ACTB)	158	X04098	T, B	+	+			+		
actin, beta (ACTB) (non-exact, low match 73%)	1	M10277								
actin, gamma (low score)	1	K00791								
actin, gamma 1 (ACTG1)	4	X04098	+	+	+	+	+	+	+	high in many libraries
actin-binding LIM protein (ABLM)	4	D31883		+	+	+			+	
Actinin, alpha 1 (ACTN1)	8	M95178		+	+	+			+	
actinin, alpha 4 (ACTN4)	1	D89980		+	+			+		
activated p21cdc42Hs kinase (ACK)	1	L13738	B	+					+	
activated RNA polymerase II transcription cofactor 4 (PC4)	1	X79805	+	+	+	+			+	
activating transcription factor 1 (ATF1)	1	X55544			+					
activating transcription factor 2 (ATF2)	1	X15875		+	+			+		
activating transcription factor 4 (tax-responsive enhancer element B67) (ATF4)	2	M86842						+	+	
active BCR-related gene (ABR)	1	U01147	+	+	+	+			+	
acyl-CoA oxidase (AOX)	1	U03254								
acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain (ACADM)	2	M16827								
acyl-Coenzyme A dehydrogenase, very long chain (ACADVL)	3	D43682	+	+	+	+	+	+	+	
acyloxyacyl hydrolase (neutrophil) (AOAH)	3	M62840	T		+			+	+	
adaplin, delta (ADTD)	2	U91930		+	+			+		
adaplin, delta (ADTD) (non-exact 59%)	1	AC005328								
adaplin, gamma (ADTG)	1	Y12226		+	+	+			+	
adaptor complex sigma3B (AP3S3)	2	X99459		+		+			+	
adaptor protein p150	1	Y08991								
adducin 1 (alpha) (ADD1)	2	L07261		+	+			+		

adducin 1 (alpha) (add1)	3	L29296	+	+	+	+	+	+
adducin 3 (gamma) (ADD3)	3	U37122	B, W	+	+	+	+	+
adenine nucleotide translocator 2 (fibroblast) (ANT2)	2	M57424		+	+	+	+	+
adenine nucleotide translocator 2 (fibroblast) (ANT2) (non-exact 81%)	1	J02683						
adenine nucleotide translocator 2 (fibroblast) (ANT2) (non-exact, 79%)	1	J02683						
adenine nucleotide translocator 2 (fibroblast) (ANT2) (non-exact, 86%)	1	J02683						
adenine nucleotide translocator 3 (liver) (ANT3)	3	J03592		+	+	+	+	+
adenosine deaminase, RNA-specific (ADAR)	6	U18121		+	+	+	+	+
adenylate cyclase 3 (ADCY3)	2	AF033861		+	+	+	+	+
adenylate cyclase 7 (ADCY7)	1	D25538						
adenylate kinase 2 (AK2)	2	U39945		+	+	+	+	+
adenylate kinase 3 (AK3) (non-exact, 67%)	1	X60673						
adenylyl cyclase-associated protein (CAP)	28	M98474			+	+	+	+
adipose differentiation-related protein; adipophilin (ADFP)	1	X97324			+	+	+	+
ADP-ribosylation factor 1 (ARF1)	13	M84326		+	+	+	+	+
ADP-ribosylation factor 3 (ARF3)	2	M33384		+	+	+	+	+
ADP-ribosylation factor 4 (ARF4)	1	M36341	T lymphoma	+	+	+	+	+
ADP-ribosylation factor 5 (ARF5)	1	M57567			+	+	+	+
ADP-ribosylation factor domain protein 1, 64kD (ARFD1)	1	L04510		+				
ADP-ribosyltransferase (NAD ⁺ ; poly (ADP-ribose) polymerase) (ADPRT)	4	M32721	+	+	+	+	+	+
adrenergic, beta, receptor kinase 1 (ADRBK1)	2	X61157	B	+			+	
adrenoleukodystrophy-like 1 (ALDL1)	1	AJ000327						
AE-binding protein 1 (AEBP1) (non-exact, 62%)	1	D86479						
AF-17	1	U07932						
A-gamma-globin	1	V00514						
A-gamma-globin (chromosome 11 allele)	1	J00176						
agammaglobulinaemia tyrosine kinase (ATK)	1	U78027						
AHNAK nucleoprotein (desmoyokin) (AHNAK)	4	M80899	+	+	+	+	+	+
alanine (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150) (ANPEP)	1	X13276			+		+	
alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5)	1	M29872						
aldehyde dehydrogenase 1, soluble (ALDH1)	1	AF003341		+			+	+

aldehyde dehydrogenase 10 (fatty aldehyde dehydrogenase) (ALDH10)	2	U75286								
aldehyde reductase 1 (low Km aldose reductase) (ALDR1)	3	J04795	B	+	+	+	+			
aldo-keto reductase family 1, member A1 (aldehyde reductase) (AKR1A1)	2	J04794	B	+	+		+			
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) (AKR1C3)	1	D17793		+	+	+		+		
aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) (AKR7A2)	1	Y16675		+	+			+	+	
aldolase A, fructose-bisphosphate (ALDOA)	7	X12447		+	+			+		
aldolase C, fructose-bisphosphate (ALDOC)	2	X05196		+	+			+		
alkaline phosphatase, liver/bone/kidney (ALPL)	1	4502062								
ALL-1 (=L04731;L04284 HRX)	4	Z69780								
alpha mannosidase II isozyme	1	D55649		+				+		
alpha thalassemia/mental retardation syndrome X-linked (ATRX)	3	U75653	+	+	+	+			+	
alpha-2 macroglobulin	1	Z11711								
alpha-2-globin	2	V00516								
alpha-2-macroglobulin receptor/lipoprotein receptor protein (A2MR/LRP)	1	U06985								
alpha-polypeptide of N-acetyl-alpha-glucosaminidase (HEXA)	1	M13520								
alpha-spectrin	1	X86901								
alpha-subunit of G12 a (GTP-binding signal transduction protein)	1	X07854								
aminin receptor 1 (67kD); Ribosomal protein SA (LAMR1)	2	J03799	T	+	+			+	+	
aminolevulinate, delta-, dehydratase (ALAD)	1	X64467		+						
amino-terminal enhancer of split (AES)	2	X73358	+	+	+	+			+	
amino-terminal enhancer of split (AES)	3	U04241	B	+	+			+	+	
AMP deaminase isoform L (AMPD2)	8	M91029		+					+	
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) (AMPH)	1	U07616	B	+					+	
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) (AMPH)(non-exact, 68%)	1	U07616								
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) (AMPH)(non-exact, 68%)	1	U07616								
amphiphysin II	4	U87558		+	+			+		
amphiphysin II (67%aa amphiphysin?)	1	AF068915								
amphiphysin II (non-exact 69% aa)	1	AF001383								

amphiphysin-like (AMPHL)	1	U68485		+	+					
amphiphysin-like (AMPHL) (low match)	1	AF068918								
AMY-1	1	D50692	B, T					+		
amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) (APBB1)	1	L77864		+	+	+			+	
amyloid beta (A4) precursor-like protein 2 (APLP2)	6	L27631	T lymphoma	+	+			+	+	
ankyrin 3, node of Ranvier (ankyrin G) (ANK) (non-exact, 50%)	1	U43965								
annexin I (lipocortin I) (ANX1)	1	X05908		+	+	+			+	
annexin II	1	D28364								
annexin II (lipocortin II; calpactin I, heavy polypeptide) (ANX2)	7	D00017	+	+	+	+	+	+	+	high in many libraries
annexin IV (placental anticoagulant protein II) (ANX4)	1	M19383		+	+	+	+	+	+	
annexin V (endonexin II) (ANX5)	2	M21731		+	+	+			+	
annexin V (endonexin II) (ANXV)	1	M19384		+	+	+			+	
annexin VI (p68) (ANX6)	6	Y00097		+	+	+			+	
annexin VII (synexin) (ANX7)	1	J04543		+	+	+			+	
antigen identified by monoclonal antibodies 12E7, F21 and O13 (MIC2)	2	M16279		+	+	+			+	
antigen identified by monoclonal antibodies 4F2, TRA1.10, TROP4, and T43 (MDU1)	3	J02939		+	+	+	+	+	+	
antigen TQ1	1									
anti-oxidant protein 2 (non-selenium glutathione peroxidase, acidic calcium-independent phospholipase A2) (KIAA0106)	1	D14662		+	+	+	+	+	+	
APEX nuclease (multifunctional DNA repair enzyme) (APEX)	5	X66133		+	+			+	+	
Apolipoprotein L (APOL) (59%aa)	1	Z82215								
apoptosis inhibitor 1 (API1)	1	L49431		+	+	+	+	+	+	
apoptosis inhibitor 4 (survivin) (API4)	1	U75285	B, W	+	+			+		
apoptosis inhibitor 5 (API5)	1	U83857	T lymphoma	+				+		
apoptosis specific protein (ASP)	1	Y11588	B	+				+	+	
apoptotic protease activating factor (APAF1)	1	AF013263	B	+	+			+		
aquaporin 3 (AQP3)	1	AB001325	T					+		
aquaporin 9 (AQP9)	7	AB008775	T activated					+		
arachidonate 12-lipoxygenase (ALOX12)	1	M58704	T					+	+	
arachidonate 5-lipoxygenase-activating protein (ALOX5AP)	3	X52195	+	+		+			+	
anadine homolog (ARI)	1	AJ009771	+	+	+	+			+	
anadine-2 (D. melanogaster) homolog (all-trans retinoic acid inducible RING finger) (ARI2)	1	AF099149	+	+	+	+			+	

ARP1 (actin-related protein 1, yeast) homolog A (centractin alpha) (ACTR1A)	1	X82206		+				+		
ARP2 (actin-related protein 2, yeast) homolog (ACTR2)	9	AF006082		+	+			+	+	
ARP2/3 protein complex subunit 34 (ARC34)	5	AF006085	I activated, W	+	+			+		
Arp2/3 protein complex subunit p41 (ARC41)	6	AF006084	monocyte stimulated	+	+			+		
Arp2/3 protein complex subunit p41 (ARC41)) (low match)	1	AF006084								
Arp2/3 protein complex subunit p16 (ARC16)	20	AF017807		+	+			+	+	
Arp2/3 protein complex subunit p20 (ARC20)	2	AF006087		+	+			+	+	
Arp2/3 protein complex subunit p21(ARC21)	3	AF006086	W					+	+	
ARP3 (actin-related protein 3, yeast) homolog (ACTR3)	11	AF006083	W		+			+	+	
arrestin, beta 2 (ARRB2)	1	AF106941	B, T, W	+	+			+		
arsA (bacterial) arsenite transporter, ATP-binding, homolog 1 (ASNA1)	1	AF047469	B, T	+				+		
aryl hydrocarbon receptor nuclear translocator-like (ARNTL)	2	AF044288	B	+	+			+		
aryl hydrocarbon receptor-interacting protein (AIP)	1	U31913	+	+	+	+			+	
arylsulfatase A (ARSA)	1	X52151	I activated	+				+		
asialoglycoprotein receptor 2 (ASGR2)	1	M11025						+	+	
asparaginyl-tRNA synthetase (NARS)	3	D84273		+	+			+		
aspartyl-tRNA synthetase (DARS)	1	J05032	B	+	+			+		
ataxia telangiectasia mutated (includes complementation groups A, C and D) (ATM)	1	U82828	B, T		+			+		
ataxin-2-like protein A2LP (A2LG)	1	AF034373	B, T activated	+	+				+	
ATF6	1	AF005887		+				+		
ATP binding cassette transporter (ABCR) (non-exact 80%)	1	U88667								
ATP synthase (F1-ATPase) alpha subunit, mitochondrial	1	X59066								
ATP synthase beta subunit gene	1	M19482								
ATP synthase, H ⁺ transporting, mitochondrial F0 complex, subunit b, isoform 1 (ATP5F1)	1	X60221	+	+	+	+			+	
ATP synthase, H ⁺ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 (ATP5G1)	1	X69907	I activated	+	+			+	+	
ATP synthase, H ⁺ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1)	3	D14710								
ATP synthase, H ⁺ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1) (low match)	1	D14710								

ATP synthase, H ⁺ transporting, mitochondrial F1 complex, beta polypeptide (ATP5B)	2	M27132								
ATP synthase, H ⁺ transporting, mitochondrial F1 complex, gamma polypeptide 1 (ATP5C1)	1	D16563	W	+	+	+	+			
ATP synthase, H ⁺ transporting, mitochondrial F1F0, subunit g (ATP5JG)	1	AF092124	+	+	+	+	+	+		
ATP/GTP-binding protein (HEAB)	2	U73524	+	+	+	+			+	
ATPase, Ca ⁺⁺ transporting, ubiquitous (ATP2A3)	5	Z69881		+						
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump) 21kD (ATP6F)	2	D89052	+	+	+	+			+	
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump) 31kD (ATP6E)	1	X76228		+	+	+			+	
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump) 42kD; Vacuolar proton-ATPase, subunit C; V-ATPase, subunit C (ATP6D)	5	X69151		+	+	+			+	
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump), alpha polypeptide, 70kD, isoform 1 (ATP6A1)	3	L09235		+		+				
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump), beta polypeptide, 56/58kD, isoform 2 (ATP6B2)	6	X62949	+	+	+	+			+	
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump), member J (ATP6J)	2	AF038954	+	+	+	+			+	high in testis
ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump), subunit 1 (ATP6S1)	1	D16469		+	+	+			+	
ATP-binding cassette 50 (TNF-alpha stimulated) (ABC50)	1	AF027302	+	+	+	+			+	
ATP-binding cassette protein M-ABC1 (mitochondrial)	1	AF047690								
ATP-dependent RNA helicase	1	AJ010840	T lymphoma		+			+		
autoantigen (Hs.75528)	2	L05425	T activated		+					
autoantigen (Hs.75528) (non-exact 84%)	1	L05425								
autoantigen (Hs.75682)	1	U17474	B	+					+	
autoantigen La/SS-B	1	Z35127								
axin (AXIN1)	1	AF009674	T	+						
axonemal dynein heavy chain (DNAH17)	1	AJ000522							+	
BAIT-associated protein 3 (BAIAP3) (non-exact 54%)	1	AB017111								
basement membrane-induced gene (ICB1)	1	AF044896								
basic leucine zipper nuclear factor 1 (JEM-1) (BLZF1)	2	U79751								
basic transcription factor 3 (BTF3)	5	X74070	+	+	+	+	+	+		
basigin (BSG)	1	L10240		+				+		
BC-2	1	AF042384	B		+	+	+			

B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6)	1	U00115		+	+				
B-cell translocation gene 1, anti-proliferative (BTG)	1	X61123			+				+
BCL2/adenovirus E1B 19kD-interacting protein 2 (BNIP2)	1	U15173	B	+			+	+	
BCL2/adenovirus E1B 19kD-interacting protein 3-like (BNIP3L)	2	AF067396		+	+	+		+	
bedin 1 (coiled-coil, myosin-like BCL2-interacting protein) (BECN1)	1	AF077301	B	+	+		+		
beta-1,2-N-acetylglucosaminyltransferase II (MGAT2)	2	U15128							
beta-2-microglobulin (B2M)	63	S82297	+	+	+	+	+	+	high in invasive prostate tumor
beta-hexosaminidase alpha chain (HEXA)	1	M16411							
beta-tubulin	7	V00599	+	+	+	+	+	+	high in many libraries
beta-tubulin (non-exact, 76%)	1	AF070561							
beta-tubulin, pseudogene	1	J00315							
BING4	1	Z97184							
biotinidase (BTD) (non-exact 62%)	1	U03274							
biotinidase (BTD) (non-exact 70%)	1	U03274							
biotinidase (BTD) (non-exact, 56%)	1	U03274							
BIOTINIDASE PRECURSOR	1	P43251							
biphenyl hydrolase-like (serine hydrolase) (BPHL)	1	X81372		+			+		
bone marrow stromal cell antigen 1 (BST1)	1	D21878					+		
box-dependent myc-interacting protein isoform BIN1-10 (BIN1)	1	AF043900							
box-dependent myc-interacting protein isoform BIN1-10 (BIN1) (non-exact, 64%)	1	AF043900							
brain my047 protein	1	AF063605	T	+	+		+		
branched chain keto acid dehydrogenase E1, alpha polypeptide (maple syrup urine disease) (BCKDHA)	3	Z14093	T	+	+		+		
BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) (BAP1)	1	D87462	+	+	+	+			
BRCA1, Rho7 and vatl genes, and ipf35	1	L78833							
breakpoint cluster region protein, uterine leiomyoma, 1; barrier to autointegration factor (BCRP1)	2	AF044773		+	+				
breakpoint cluster region protein, uterine leiomyoma, 2 (BCRP2)	2	AF044774		+	+		+	+	
breast cancer anti-estrogen resistance 3 (BCAR3) (non-exact 73%)	1	U92715							
bromodomain-containing protein, 140kD (peregrin) (BR140)	2	M91585		+					
Bruton's agammaglobulinemia tyrosine kinase (Btk)	1	U13424							

Bruton's tyrosine kinase (BTK)	1	U78027								
Bruton's tyrosine kinase (BTK), alpha-D-galactosidase A (GLA), L44-like ribosomal protein (L44L) and FTP3 (FTP3)	1	U78027								
BS4	1	AF108083								
BTG2 (BTG2)	6	Y09943	+	+	+	+			+	
BTK region clone ftp	1	U78027	+	+	+	+			+	
BTK region clone ftp-3	1	U01923		+	+			+		
BUB3 (budding uninhibited by benzimidazoles 3, yeast) homolog (BUB3)	4	AF053304	+	+	+	+			+	
butyrate response factor 1 (EGF-response factor 1) (BRF1)	4	X79067	+	+	+	+			+	
butyrophilin (BTF1)	7	U90543		+	+			+		
butyrophilin like receptor	1	AB020625.1								
CAG repeat containing (CTG4A)	2	U80744		+	+					
CAGH32	2	U80743		+	+			+		
calcium channel, voltage-dependent, L type, alpha 1D subunit (CACNA1D) (low match)	1	M83566								
calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma (CAMK2G)	1	AF069765		+	+	+			+	
calcium/calmodulin-dependent protein kinase kinase (KIAA0787)	1	AF101264	B	+	+			+		
calmodulin (=M19311)	7	D45887								
calmodulin 1 (phosphorylase kinase, delta) (CALM1)	6	M27319	B	+	+			+	+	
calnexin (CANX)	3	M94859	I	+				+	+	
calpain, large polypeptide L1 (CAPN1)	5	X04366		+	+			+	+	
calpain, large polypeptide L2 (CAPN2)	5	M23254		+	+					
calpain, small polypeptide (CAPN4)	1	X04106		+	+			+	+	
calpastatin (CAST)	3	D16217						+		
Calponin 2	2	D83735		+			+		+	
calponin 2 (CNN2)	1	D83735	B, I	+				+		
calponin 2 (CNN2) (low score)	1	D83735								
calumenin (CALU)	3	AF013759	B		+			+	+	
cAMP response element-binding protein CRE-Bpa (H GS165L15.1)	4	L05912								
cAMP-dependent protein kinase type II (Ht31)	1	M90360								
canicular multispecific organic anion transporter (CMOAT2)	1	AF009670				+	+	+		
capping protein (actin filament) muscle Z-line, alpha 1 (CAPZA1)	6	U56637	B, I		+				+	
capping protein (actin filament) muscle Z-line, alpha 2 (CAPZA2)	2	U03269	B	+	+					
capping protein (actin filament) muscle Z-line, beta (CAPZB)	1	U03271	+	+	+	+			+	

capping protein (actin filament), gelsolin-like (CAPG)	8	M94345	+	+		+		+	
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD)	1	D78586	+	+	+	+		+	
carbonic anhydrase V, mitochondrial (CA5)	1	L19297		+				+	
carboxypeptidase D (CPD)	3	U65090	B	+	+				
camitine/acylcarnitine translocase (CACT)	1	Y10319		+	+			+	
Cas-Br-M (munne) ecotropic retroviral transforming sequence (cbl)	2	X57110						+	
casein kinase 1, alpha 1 (CSNK1A1)	1	L37042	+	+	+	+		+	
casein kinase 2, alpha 1 polypeptide (CSNK2A1)	2	M55265	B	+				+	+
casein kinase I gamma 3L (CSNK1G3L)	1	AF049090.1							
casein kinase II alpha subunit(=S72393)	1	X69951							
CASP8 and FADD-like apoptosis regulator (CFLAR)	4	AF015450		+	+	+	+	+	
caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) (CASP1)	7	U13697	+			+			
caspase 10, apoptosis-related cysteine protease (CASP10)	1	U60519	B, T activated, T lymphoma					+	
caspase 3, apoptosis-related cysteine protease (CASP3)	3	U13737	B, T	+	+	+	+		
caspase 4, apoptosis-related cysteine protease (CASP4)	6	U25804	+	+	+	+		+	
caspase 5, apoptosis-related cysteine protease (CASP5)	1	U28015			+				
caspase 8, apoptosis-related cysteine protease (CASP8)	2	X98173		+		+		+	
caspase 9, apoptosis-related cysteine protease (CASP9)	1	U56390	B			+	+		
catalase (CAT)	5	X04076	B	+	+			+	
catechol-O-methyltransferase (COMT)	1	M65213		+	+			+	
catenin (cadherin-associated protein), alpha 1 (102kD) (CTNNA1)	6	D14705		+	+				
cathelicidin antimicrobial peptide (CAMP)	1	X89658	B						
cathepsin B (CTSB)	4	L16510			+			+	+
cathepsin C (CTSC)	3	U79415		+	+	+		+	
cathepsin D (lysosomal aspartyl protease) (CTSD)	4	M11233		+	+			+	
cathepsin E (CTSE)	1	J05036						+	
cathepsin G (CTSG)	1	M16117	T, W		+				
cathepsin S (CTSS)	34	M86553	B, Monocyte stimulated, T lymphoma					+	+
cathepsin W (lymphopain) (CTSW)	4	AF013611						+	
CBF1 interacting corepressor CIR (=U03644 recepin)	1	AF098297							

CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA)	3	X87248		+	+	+	+	+	
CCAAT/enhancer binding protein (C/EBP), delta (CEBPB)	1	S63168			+			+	+
CCAAT-box-binding transcription factor (CBF2)	2	M37197	T lymphoma				+	+	
CCR5 receptor (CCR5) (non-exact?)	1	AF011504							
CD14 antigen (CD14)	11	M86511	+	+	+	+			+
CD18 (=M95293)	4	X64071							
CD1C antigen, c polypeptide (CD1C)	2	M28827							+
CD2 antigen (cytoplasmic tail)-binding protein 2 (CD2BP2)	1	AF104222							
CD2 antigen (p50), sheep red blood cell receptor (CD2)	4	M14362	+		+	+			+
CD2 cytoplasmic tail-binding protein 1 (CD2BP1)	2	AF038602						+	
CD20 antigen (CD20)	1	X12530							
CD20 receptor (S7)	1	X07203							
CD22 antigen (CD22)	1	U62631	B						
CD24 signal transducer	1	M58664							
CD33 antigen (gp67) (CD33)	1	M23197						+	
CD33 antigen-like 2; OB binding protein-2 (CD33L2) (non-exact, 68%)	1	U71383							
CD33L2 (61% aa)	1	D86359							
CD36 antigen (collagen type I receptor, thrombospondin receptor) (CD36)	7	M98398	T lymphoma		+			+	+
CD37 antigen (CD37)	5	X14046	+	+		+			+
CD38 alt	1	D84277							
CD39 antigen (CD39)	1	U87967	B	+				+	+
CD3D antigen, delta polypeptide (TIT3 complex) (CD3D)	1	X03934			+	+			+
CD3E antigen, epsilon polypeptide (TIT3 complex) (CD3E)	1	X03884	+			+			
CD3G antigen, gamma polypeptide (TIT3 complex) (CD3G)	2	X06026	W					+	
CD3Z antigen, zeta polypeptide (TIT3 complex) (CD3Z)	2	J04132	+			+			
CD3-zeta (clone pBS NK1)	1	X55510							
CD4 (low match)	1	S68043							
CD4 antigen (p55) (CD4)	4	M12807		+	+			+	
CD44 antigen (homing function and Indian blood group system) (CD44)	6	X56794	W					+	+
CD48 antigen (B-cell membrane protein) (CD48)	3	X06341	+	+	+	+			+
CD53 antigen (CD53)	10	L11670	+	+		+			+
CD53 antigen (CD53) (low match)	1	M60871							
CD63 antigen (melanoma 1 antigen) (CD63)	3	M59907							
CD68 antigen (CD68)	2	S57235		+	+			+	+

CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) (CD74)	72	K01144	+	+	+	+	+	+	high in many libraries
CD79A antigen (immunoglobulin-associated alpha) (CD79A)	2	M80462			+				
CD79B antigen (immunoglobulin-associated beta) (CD79B)	2	M89957	+						
CD8 antigen, alpha polypeptide (p32) (CD8A)	2	M27161	+			+		+	
CD8 antigen, beta polypeptide 1 (p37) (CD8B1)	1	X13445	W						
CD81 antigen (target of antiproliferative antibody 1) (CD81)	1	M33680		+	+			+	
CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) (CD83)	1	Q01151	B	+	+			+	
CD84 antigen (leukocyte antigen) (CD84)	1	U82988		+	+			+	
CD86 antigen	1	L25259		+					
CD9 antigen (p24) (CD9)	2	M38690			+		+	+	
CD97 antigen (CD97)	12	X84700	+	+		+			
CD97 antigen (CD97) (non-exact 59%)	1	P48960							
CD97 antigen (CD97) (non-exact 62%)	1	X94630	+	+		+			
CDC23 (cell division cycle 23, yeast, homolog) (CDC23)	1	AF053977		+			+	+	
CDC37 homolog	1	U63131	B	+	+		+	+	
Cdc42 effector protein 3 (CEP3)	2	AF104857	B	+	+		+		
CDC-like kinase (CLK)	1	L29219		+	+	+		+	
CDC-like kinase 2 (CLK2)	1	AF023268	B	+	+				
CDW52 antigen (CAMPATH-1 antigen) (CDW52)	13	X15183	1 activated	+	+		+		
cell cycle progression restoration 8 protein(CPR8)	1	AF011794							
cell division cycle 10 (homologous to CDC10 of S. cerevisiae) (CDC10)	4	S72008	+	+	+	+		+	
cell division cycle 20, S.cerevisiae homolog (CDC20)	1	U05340		+	+	+			
cell division cycle 25B (CDC25B)	6	Z68092	+	+	+	+		+	
cell division cycle 2-like 1 (PITSLRE proteins) (CDC2L1) (non-exact 42%)	1	AF067514							
cell division cycle 42 (GTP-binding protein, 25kD) (CDC42)	5	M35543	+	+	+	+		+	
cell division protein (non-exact 68%)	1	AF063015							
CELL-CYCLE NUCLEAR AUTOANTIGEN SG2NA (S/G2 NUCLEAR ANTIGEN)	1	Q13033							
centromere protein B (80kD) (CENPB)	1	X55039		+			+		
cep250 centrosome associated protein	3	AF022655	B	+			+		

ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease) (CLN2)	7	AF017456	+	+	+	+	+	+	high in bone
c-fgr (=M63877 nonreceptor protein-tyrosine kinase (fgr))	6	X52206							
CGF-19 protein	3	AF132953.1							
chaperonin containing TCP1, subunit 3 (gamma) (CCT3)	1	X74801		+	+			+	
chaperonin containing TCP1, subunit 4 (delta) (CCT4)	1	AF026291		+	+		+	+	
chaperonin containing TCP1, subunit 6A (zeta 1) (CCT6A)	4	L27706	B	+	+				
chaperonin containing TCP1, subunit 7 (eta) (CCT7)	4	AF026292	B	+				+	
Chediak-Higashi syndrome 1 (CHS1)	1	U67615	B, T lymphoma	+	+		+		
Chediak-Higashi syndrome 1 (CHS1) (low score)	1	U67615							
chemokine (C-C motif) receptor 2 (CCR2)	4	U03905							
chemokine (C-C motif) receptor 4 (CCR4) (low match) (may contain repeat)	1	X85740							
chemokine (C-C motif) receptor 7 (CCR7)	6	L31581							
chemokine (C-X3-C) receptor 1 (CX3CR1)	5	U20350		+					
chemokine (C-X-C motif), receptor 4 (fusin) (CXCR4)	5	M99293	+	+	+	+		+	
chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1)	2	M80927		+		+		+	
chitinase 3-like 2 (CHI3L2)	2	U49835		+		+		+	
chloride channel 1, skeletal muscle (CLCN1)	1	G18280							
chloride channel 6 (CLCN6)	1	D28475		+	+				
chloride intracellular channel 1 (CLIC1)	1	U93205	+	+	+	+		+	
chondroitin sulfate proteoglycan 2 (versican) (CSPG2)	5	X15998			+				
chondroitin sulfate proteoglycan core protein	2	J02814			+			+	
chromatin assembly factor 1 p48 subunit (CAF-1 P48 subunit) (retinoblastoma binding protein p48) (retinoblastoma-binding protein 4) (MSI1 protein homolog)	1	Q09028							
chromodomain helicase DNA binding protein 1 (CHD1)	2	AF006513							
chromodomain helicase DNA binding protein 1-like (CHD1L)	1	AF054177							
chromodomain helicase DNA binding protein 2 (CHD2)	1	AF006514	B	+	+		+		
chromodomain helicase DNA binding protein 3 (CHD3)	1	AF006515							
chromodomain helicase DNA binding protein 4 (CHD4)	5	X86691	+	+	+	+		+	

chromosome 1 open reading frame 7 (C1ORF7)	1	AF054176							
chromosome 1 specific transcript KIAA0493	1	AB007962							
chromosome 17 open reading frame 18 (C17ORF1B)	1	AJ008112	T	+					
chromosome 4 open reading frame 1 (C4ORF1)	1	AF006621		+	+	+		+	
chromosome condensation 1-like (CHC1L)	2	AF060219		+	+	+		+	
chromosome X open reading frame 5 (CXORF5)	1	Y15164	B	+	+		+		
chromosome-associated polypeptide C(CAP-C)	2	AF092564	B	+	+		+	+	
cig42	1	AF026944							
cig5	3	AF026941							
citrate synthase (CS)	2	AF047042	B	+	+		+	+	
class I major histocompatibility antigen (HLA-Cw3)	2	U31372							
class I major histocompatibility antigen (HLA-Cw3) (low match)	1	U31372							
clathrin assembly protein lymphoid myeloid leukemia (CALM)	3	U45976	B	+	+			+	
clathrin heavy chain	1	X55878							
clathrin, heavy polypeptide-like 2 (CLTCL2)	1	D21260							
clathrin, light polypeptide (Lca) (CLTA) (low match)	1	M20472							
clathrin-associated/assembly/adapt or protein, medium 1 (CLAPM1)	3	D63475		+	+	+	+	+	
cleavage stimulation factor, 3' pre-RNA, subunit 2 64kD (CSTF2) (non-exact 82%)	1	M85085							
cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kD (CSTF3)	1	U15782	B	+	+		+		
clk3	1	L29220	B	+	+				
clone 23815 (Hs.82845)	1	U90916		+	+			+	
clone 24592 mRNA sequence	1	D88378	+	+	+	+		+	
Clq/MBL/SPA receptor C1qR(p) ()	1	U94333							
clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J) (CLU)	1	M64722	+	+	+	+	+	+	
CMP-sialic acid transporter (CMPST)	1	D87969	B	+	+				
CMRF35	3	X66171							
c-myc oncogene containing coxIII	1	X54629							
coagulation factor II (thrombin) receptor (F2R)	1	M62424		+	+			+	
coagulation factor V (proaccelerin, labile factor) (F5)	1	M14335		+		+	+		
coagulation factor XIII a subunit	3	M21998							
coagulation factor XIII, A1 polypeptide (F13A1)	6	M14354		+	+	+		+	
coated vesicle membrane protein (RNP24)	1	X92098	+	+	+	+	+	+	

coatomer protein complex, subunit alpha (COPA)	5	U24105	I	+				+		
Cofilin 1 (non-muscle) (CFL1)	13	X95404	+	+	+	+	+	+	+	high in fetal brain
cold inducible RNA-binding protein (CIRBP)	7	D78134		+	+				+	
cold shock domain protein A (CSDA)	3	X95325		+	+					
collagen, type IX, alpha 2 (COL9A2)	3	AF019406	B							
colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog (CSF1R)	3	X03663		+				+	+	
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB)	5	M59941								
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB) (low match)	1	M59941								
colony stimulating factor 3 receptor (granulocyte) (CSF3R)	16	X55720		+						
complement component 5 receptor 1 (C5a ligand) (C5R1)	1	M62505	L							
conserved gene amplified in osteosarcoma (OS4)	2	AF000152		+	+	+			+	
COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 3 (COPS3)	2	AF031647		+	+				+	
COP9 homolog (HCOP9)	2	U51205	B	+	+	+	+	+	+	
COP11 protein, homolog of s. cerevisiae SEC23p (SEC23A)	4	X97064		+	+					
copine I (CPNE1)	2	U83246	B	+	+			+		
copine I (CPNE1) (low score)	1	U83246								
coproporphyrinogen oxidase (coproporphyrin, harderoporphyrin) (CPO)	1	D16611			+			+	+	
core-binding factor, beta subunit (CBFB)	1	L20298		+						
coronin	22	X89109	T, W	+	+			+		
coronin (low match)	1	U34690								
coronin (non-exact, 71%)	1	X89109								
cot (cancer Osaka thyroid) oncogene (COT)	1	D14497	+	+	+	+			+	
cryptochrome 1 (photolyase-like) (CRY1)	1	D84657		+	+				+	
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 (CTDP1)	1	AF081287		+	+	+			+	
C-terminal binding protein 1 (CTBP1)	1	U37408	B	+	+			+		
C-terminal binding protein 2 (CTBP2)	2	AF016507		+	+			+		
CUG triplet repeat, RNA-binding protein 1 (CUGBP1)	3	U63289		+	+	+			+	
cullin 1 (CUL1)	3	U58087		+	+	+			+	
cullin 3 (CUL3)	2	U58089		+	+	+			+	
cut (Drosophila)-like 1 (CCAAT displacement protein) (CUTL1)	1	M74099	B	+						

cyclin D2 (CCND2)	2	D13639		+	+	+		+	
cyclin D3 (CCND3)	5	M92287	B, T lymphoma		+			+	
cyclin G1 (CNNG1)	1	D78341	B	+	+			+	
cyclin I	3	D50310	B	+				+	
cyclin I2 (CNNT2)	1	AF048732	B, T lymphoma	B					
cyclin-dependent kinase 2 (CDK2)	1	X62071							
cyclin-dependent kinase inhibitor (p27Kip1)	1	S76986							
cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A)	2	S67388	+	+	+	+	+	+	
CYP2D7-CYP2D6 intergenic region (partial)	1	X90926							
cystatin B (stefin B) (CSTB)	1	L03558			+			+	+
cysteine and glycine-rich protein 3 (cardiac LIM protein) (CSRP3)	5	L54057			+				
cytidine deaminase (CDA)	2	L27943						+	
cytochrome b	1	AF042500							
cytochrome b (CYTB) (isolate Aus5)	1	AF042518							
cytochrome b(-245) beta chain N-terminal region (X-linked granulomatous disease gene)	2	X05895							
cytochrome b-245, beta polypeptide (chronic granulomatous disease) (CYBB)	2	X04011	+				+		+
cytochrome C	1	P00001							
cytochrome c oxidase subunit IV (COX4)	1	U90915	I	+	+			+	+
cytochrome c oxidase subunit Vb (COX5B)	2	M59250						+	
cytochrome c oxidase subunit VII-related protein (COX7RP)	6	AB007618	+	+	+	+			+
cytokine suppressive anti-inflammatory drug binding protein 1 (p38 MAP kinase) (CSBP1)	1	L35263	lymphocyte	+	+			+	
Cytoplasmic antiproteinase=38 kda intracellular serine proteinase inhibitor	1	S69272			+				
cytotoxic granule-associated RNA-binding protein p40-TIA-1	1	S70114							
DT23 (DT23)	1	D14878	+	+			+		+
D2-2	1	AF019226							
D38	1	X74802							
damage-specific DNA binding protein 1 (127kD) (DDB1)	2	AJ002955	+	+	+	+	+	+	
DCHT (low match)	1	AF017635							
DEAD/H (Asp-Glu-Ala-Asp/His) box binding protein 1 (DDXBP1)	1	U78524		+	+	+	+	+	
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide (72KD) (P72)	2	U59321	I	+	+			+	+
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1 (DDX1)	1	X70649	.	+	+				+

DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 15 (DDX15)	2	AB001636								
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 16 (DDX16)	2	AB011149	+	+	+	+			+	
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3 (DDX3)	3	U50553	+	+	+	+			+	
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA helicase, 68kD) (DDX5)	37	X15729	+	+	+	+			+	
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA helicase, 68kD) (DDX5) (low match)	1	AF015812								
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 6 (RNA helicase, 54kD) (DDX6)	2	D17532	+	+						
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 8 (RNA helicase, 54kD) (DDX8)	1	D50487		+	+	+			+	
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 9 (RNA helicase A, nuclear DNA helicase II; leukophysin) (DDX9)	3	L13848	+	+	+	+			+	
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide, Y chromosome (DBY)	1	AF000985		+	+			+		
Death associated protein 3 (DAP3)	2	X83544	+	+	+	+	+	+	+	
death effector domain-containing protein (DEDD)	1	AF083236		+	+	+			+	
death-associated protein 6 (DAXX)	2	AF039136		+	+	+			+	
dedicator of cyto-kinesis 2 (DOCK2)	4	D86964	+	+		+			+	
defender against cell death 1 (DAD1)	1	D15057			+			+	+	
Defensin, alpha 1, myeloid-related sequence (DEFA1)	4	L12690				+		+	+	
DEK gene (D6S231E)	1	X64229	B		+			+		
delta sleep inducing peptide, immunoreactor (DSIP)	4	Z50781	+	+	+	+			+	
dendritic cell protein (GA17)	3	AF064603	+	+	+	+			+	
deoxycytidine kinase (DCK)	1	M60527								
deoxynucleonuclease II, lysosomal (DNASE2)	3	AB004574								
DGS-I	2	L77566		+						
diacylglycerol kinase	3	D16440								
diacylglycerol kinase alpha (DAGK1) (clone 24)	3	AF064771		+						
diacylglycerol kinase alpha (DAGK1) (clone 24) (low match)	1	AF064771								
diaphanous (Drosophila, homolog) 1 (DIAPH1)	1	AF051782	B. monocyte stimulated	+	+			+	+	
diaphorase (NADH) (cytochrome b-5 reductase) (DIA1)	1	Y09501	+	+	+	+		+	+	
differentiated Embryo Chondrocyte expressed gene 1 (DEC1)	1	AB004066		+				+	+	

differentiated Embryo Chondrocyte expressed gene 1 (DEC1) (low match)	1	AB004066								
differentiation antigen CD20	1	L23415								
DiGeorge syndrome critical region gene 2 (DGCR2)	1	X84076		+	+				+	
dihydrolipoamide dehydrogenase (E3 component of pyruvate dehydrogenase complex, 2-oxo-glutarate complex, branched chain keto acid dehydrogenase complex) (DLD)	2	J03620		+				+	+	
dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex) (DLAT)	1	Y00978	B	+				+		
dihydropyrimidinase-like 2 (DPYSL2)	1	D78013		+	+			+	+	
dinG gene	1	Y10571								
diphtheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2 (DPH2L2)	3	AF053003	B	+	+			+	+	
disintegrin-protease (non-exact 72%)	1	Y13323								
DJ-1 protein	2	AF021819	+	+	+	+			+	
Dmx-like 1 (DMXL1)	1	AJ005821	+		+	+				
DNA (cytosine-5)-methyltransferase 1 (DNMT1)	3	X63692	T activated, lymphoma	+				+	+	
DNA fragmentation factor, 40 kD, beta subunit (DFFB)	1	AF064019								
DNA fragmentation factor, 45 kD, alpha subunit (DFFA)	2	U91985	T	+	+				+	
DNA mismatch repair protein (hMLH1)	1	U17840								
DNA segment on chromosome X (unique) 648 expressed sequence	3	M64241	+	+	+	+	+	+	+	high in many libraries
DNA segment, single copy probe LNS-CAI/LNS-CAII (deleted in polyposis (D5S346)	3	M73547		+	+	+			+	
DNA-damage-inducible transcript 1 (DDIT1) (low match)	1	L24498								
DnaJ protein	1	AJ001309								
DnaJ protein	1	AJ001309								
docking protein 2, 56kD (DOK2)	1	AF034970								
dolichyl-diphosphooligosaccharide-protein glycosyltransferase (DDOST)	1	D89060	+	+	+	+	+	+	+	activated T cell
dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit (DPM1)	1	D86198	T activated	+	+			+		
down-regulated by activation (immunoglobulin superfamily) (DORA)	1	AJ223183						+		
down-regulated in adenoma DRA (low match)	1	P40879								
D-type cyclin-interacting protein 1 (DIP1)	1	AF082569	B					+	+	

dual specificity phosphatase 1 (DUSP1)	4	X68277	+	+	+	+	+	+	
dual specificity phosphatase 11 (RNA/RNP complex 1-interacting) (dusp11)	1	AF023917	+	+	+	+		+	
dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related) (DUSP3)	1	L05147		+	+			+	+
dual specificity phosphatase 6 (DUSP6)	6	X93920	+	+	+	+	+	+	
dynactin 1 (p150, Glued (Drosophila) homolog) (DYTN1)	3	X98801							
dynactin 1 (p150, Glued (Drosophila) homolog) (DYTN1) (low match)	1	X98801	B	+	+				
dynamitin 2 (DNM2)	1	L36983							
dynamitin (dynactin complex 50 kD subunit) (DCTN-50) (non-exact 88%)	1	U50733							
dynein, axonemal, heavy polypeptide 17-like (non-exact, 57%aa)	1	X99947							
dynein, cytoplasmic, light intermediate polypeptide 2 (DNCL12)	1	AF035812	B	+	+				+
dynein, cytoplasmic, light intermediate polypeptide 2 (DNCL12) (non-exact, 69%)	1	AF035812							
dyskeratosis congenita 1, dyskerin (DKC1)	1	U59151	B	+				+	+
dystonia 1, torsion (autosomal dominant) (DYT1)	1	AF007871		+	+	+			+
dystrobrevin, beta (DTNB)	1	AF022728		+					
dystrophia myotonica-containing WD repeat motif (DMWD)	1	L19267		+	+			+	+
dystrophia myotonica-protein kinase (DMPK)	1	L08835	+	+	+				+
dystrophin (muscular dystrophy, Duchenne and Becker types) (DMD) (low match, 59%aa)	1	X14298							
ETB-55kDa-associated protein	1	AJ007509	W	+	+			+	+
E2F transcription factor 3 (E2F3)	2	D38550		+	+	+		+	+
E2F transcription factor 4, p107/p130-binding (E2F4)	1	X86096	B	+				+	
E2F transcription factor 5, p130-binding (E2F5)	2	U15642	+	+		+			+
E74-like factor 1 (ets domain transcription factor) (ELF1)	1	M82882	B		+			+	+
E74-like factor 4 (ets domain transcription factor) (ELF4)	3	U32645		+	+				+
E74-like factor 4 (ets domain transcription factor) (ELF4) (non-exact, 71%)	1	U32645							
early development regulator 2 (homolog of polyhomeotic 2) (EDR2)	4	U89278	+	+	+	+			+
EBV induced G-protein coupled receptor (EBI2)	1	L08177	W						
ecotropic viral integration site 2B (EVI2B)	3	M50830		+		+			

ectin, galactoside-binding, soluble, 1 (galectin 1) (LGALS1)	1	J04456								+	
EGF-like-domain, multiple 4 (EGFL4)	1	AB011541									
elF-2-associated p67 homolog	3	U13261	B	+						+	
elastin (supravalvular aortic stenosis, Williams-Beuren syndrome) (ELN) (low match)	1	M24782		+	+						
elav-type RNA-binding protein (ETR-3)	3	U69546									
electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II) (ETFA)	2	J04058		+							
ELK3, ETS-domain protein (SRF accessory protein 2) (ELK3)	2	Z36715			+					+	
elongation factor 1-beta	1	L26404									
elongation factor 1s (mitochondrial protein)	1	AF110399									
elongation factor 1u-nuclear encoded mitochondrial	1	X84694									
eMDC II protein	1	AJ242015.1									
ems1 sequence (mammary tumor and squamous cell carcinoma-associated (p80/85 src substrate) (EMS1)	1	M98343		+	+			+	+		
endogenous retroviral element HC2	1	Z70664									
endosulfine alpha (ENSA)	1	X99906	I	+							
endothelial differentiation, sphingolipid G-protein-coupled receptor, 1 (EDG1)	2	M31210		+	+	+				+	
endothelial differentiation, sphingolipid G-protein-coupled receptor, 1 (EDG1) (low match 66%)	1	M31210									
endothelial monocyte-activating polypeptide (EMAPII)	1	U10117	+	+	+	+				+	
enolase 1, (alpha) (ENO1)	12	M14328	+	+	+	+	+	+	+		
enolase 2, (gamma, neuronal) (ENO2)	1	X51956		+							
enolase-alpha	1	D28437									
enoyl Coenzyme A hydratase 1, peroxisomal (ECH1)	2	U16660									
enoyl Coenzyme A hydratase, short chain, 1, mitochondrial (ECHS1)	1	D13900	+	+	+	+	+	+	+		
ENOYL-COA HYDRATASE, MITOCHONDRIAL PRECURSOR (SHORT CHAIN ENOYL-COA HYDRATASE) (SCEH) (ENOYL-COA HYDRATASE 1) (low match, non-exact 56%)	1	P30084									
epidermal growth factor receptor pathway substrate 15 (EPS15)	2	U07707		+		+				+	

EPIDIDYMAL SECRETORY PROTEIN E1 PRECURSOR (EPI-1) (HE1) (EPIDIDYMAL SECRETORY PROTEIN 14.6) (ESP14.6)	2	Q15668										
epithelial membrane protein 3 (EMP3)	1	U87947	+	+	+	+			+			
Epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1)	1	L29766										+ only
ERCC2 (=L47234)	1	X52221										
ERF-2	3	U07802	+	+	+	+			+			high in gall bladder
ERp28 protein	1	X94910	+	+	+	+			+			
erythrocyte membrane protein	2	M81635										
erythroleukemic cells K562	2	L25343										
EST (Hs.189509)	2	U24166										
estrogen receptor-related protein (hERRa1)	1	L38487										
ESTs, Highly similar to ADENYLOSUCCINATE SYNTHETASE	1	X66503	B, T	+	+							
ESTs, Moderately similar to cysteine-rich fibroblast growth factor receptor	1	U28811	+	+	+	+			+			
ET binding factor 1 (SBF1)	1	U93181	+	+								
ets domain protein ERF	1	U15655	+	+	+	+			+			
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)	326	X03558	+	+	+	+			+			
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) (low match)	1	X03558										
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) (low match)	1	X03558										
eukaryotic translation elongation factor 1 beta 2 (EEF1B2)	5	X60489	+	+	+	+			+			
eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) (EEF1D)	1	Z21507	+	+	+	+	+	+	+			
eukaryotic translation elongation factor 1 gamma (EEF1G)	31	Z11531										
eukaryotic translation elongation factor 2 (EEF2)	2	X51466		+					+			
eukaryotic translation initiation factor 2, subunit 1 (alpha, 35kD) (EIF2S1)	1	J02645										
eukaryotic translation initiation factor 2, subunit 2 (beta, 38kD) (EIF2S2)	1	M29536										
eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD) (EIF2S3)	3	L19161		+	+							
eukaryotic translation initiation factor 3, subunit 10 (theta, 150/170kD) (EIF3S10)	2	U78311										
eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD) (EIF3S2)	3	U36764	+	+	+	+	+	+	+			high in white blood cells
eukaryotic translation initiation factor 3, subunit 3 (gamma, 40kD) (EIF3S3)	6	U54559	+	+	+	+			+			high in spleen
eukaryotic translation initiation factor 3, subunit 4 (delta, 44kD) (EIF3S4)	9	AF020833		+	+	+			+			

eukaryotic translation initiation factor 3, subunit 6 (48kD) (EIF3S6)	4	U94175	+	+	+	+	+	+	high in bladder
eukaryotic translation initiation factor 3, subunit 6 (EIF3S6)	1	U62962		+	+	+		+	Highly represented (1.4833 pct) in library 36 human gall bladder
eukaryotic translation initiation factor 3, subunit 7 (zeta, 66/67kD) (EIF3S7)	3	U54558	+	+	+	+		+	
eukaryotic translation initiation factor 3, subunit 8, 110KD (EIF3S8)	5	U46025	+	+	+	+	+	+	high in testis
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G)	1	AF012088							
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G) (low match)	1	AF012088							
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G1)	2	D12686							
eukaryotic translation initiation factor 4 gamma, 2 (EIF4G2)	6	U73824	+	+	+	+	+	+	
eukaryotic translation initiation factor 4 gamma, 2 (EIFG2)	2	U76111	+	+	+	+	+	+	
eukaryotic translation initiation factor 4A, isoform 1 (EIF4A1)	29	D13748							
eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2)	11	D30655	+	+	+	+	+	+	
eukaryotic translation initiation factor 4B (EIF4B)	18	X55733	+	+	+	+		+	
eukaryotic translation initiation factor 4E (EIF4E)	1	P06730							
Eukaryotic translation initiation factor 4E binding protein 2 (EIF4EBP2)	3	L36056	T, B	+				+	+
eukaryotic translation initiation factor 4H (EIF4H)	2	Q15056							
eukaryotic translation initiation factor 5 (EIF5)	2	U49436	+	+	+	+	+	+	
eukaryotic translation termination factor 1 (ETF1)	2	U90176	+	+	+	+		+	
EV12 protein	1	M55266		+					
Ewing sarcoma breakpoint region 1 (EWSR1)	1	X66899	+	+	+	+		+	
EWS/FLI1 activated transcript 2 homolog (EAT-2)	2	AF020264							
EWS-E1A-F chimenc protein	1	U35622							
excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) (ERCC1)	1	M28650	+	+	+	+		+	
excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome)) (ERCC5)	1	X69978		+	+	+		+	
exostoses (multiple)-like 3 (EXTL3)	1	AF001690		+	+	+		+	
F11	1	X77744				+			

F1-ATPase beta subunit (F-1 beta)	2	X03559									
Fanconi anaemia group A	2	Z83095									
Fanconi anemia, complementation group A (FANCA)	1	X99226	+	+	+	+					
far upstream element (FUSE) binding protein 1 (FUBP1)	2	U05040	+		+					+	
farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltransferase, geranyltransferase) (FDPS)	1	J05262	+	+	+	+				+	
farnesyl-diphosphate farnesyltransferase 1 (FDFT1)	2	X69141	+	+	+	+	+	+	+		
farnesyltransferase, CAAX box, beta (FNTB)	2	L00635		+	+						
Fas ligand (gene and promoter region)	1	AF044583									
Fas-ligand associated factor 1	1	U70667									
fatty-acid-Coenzyme A ligase, long-chain 1 (FACL1)	4	D10040	+	+	+	+	+	+	+		
Fc fragment of IgA, receptor for (FCAR)	1	X54150									
Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide (FCER1G)	1	M33195	+	+	+	+				+	
Fc fragment of IgE, low affinity II, receptor for (CD23A) (FCER2)	2	X04772	+	+							
Fc fragment of IgG, low affinity IIa, receptor for (CD32)	6	M31932	+	+	+	+	+	+	+		
Fc fragment of IgG, low affinity IIa, receptor for (CD32) (FCGR2A)	1	X62572	+	+	+	+	+	+	+		
Fc fragment of IgG, low affinity IIIa, receptor for (CD16) (FCGR3A)	34	X07934	+	+	+	+				+	
Fc fragment of IgG, receptor, transporter, alpha (FCGRT)	3	U12255		+	+	+	+	+	+		high in many libraries
fc-igr	1	Z13983									
Fc-gamma-receptorIIIB (FCGR3B)	2	M90746									
feline sarcoma (Snyder-Theilen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fps) oncogene homolog(FES) c-fes/fps)	3	X06292									
female sterile homeotic-related gene 1 (mouse homolog) (FSRG1)	2	X96670	+	+	+	+				+	
ferritin L-chain	9	Y09188									
ferritin, heavy polypeptide 1 (FTH1)	4	M11146	+	+	+	+	+	+	+		
ferritin alpha pseudogene	1	Y09232									
fetal Alzheimer antigen (FALZ)	2	U05237		+							
fetal Ig heavy chain variable region	1	M34024									
fibrinogen (FBL)	1	X56597	+	+	+	+	+	+	+		
fibrinogen-like protein 2 (T49)	3	Z36531				+					

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)